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Cluster headache (CH) is one of the trigeminal autonomic cephalalgias (TACs), a group of primary 
headaches which share prominent cranial parasympathetic autonomic features. CH is diagnosed by 
applying its definition of the International Classification of Headache Disorders (ICHD-3 beta).1 CH 
attacks most often are very severe, unilateral and (usually) in the distribution of the first branch of the 
trigeminal nerve. The attacks are accompanied by ipsilateral cranial parasympathetic autonomic 
features, an ipsilateral partial Horner’s syndrome, a sensation of auricular fullness and/or a sense of 
restlessness or agitation. Untreated attacks usually last for 15-180 minutes (min) and occur from one 
every other day to eight per day during the episodes when the disorder is active. Headache attacks 
either occur in one series/cluster period of less than 1 year, or in at least two series/cluster periods of 7 
days to 1 year separated by a headache-free period of at least 1 month (i.e. Episodic cluster headache 
(ECH)), or in one series/cluster period of more than 1 year or in at least two series/cluster periods 
separated by a headache-free period of less than 1 month (i.e. Chronic cluster headache (CCH)). CH 
can be primary or secondary when it occurs for the first time closely related to another disorder which 
causes headache.1          
 ECH and CCH are reported in at least 80% and 4 to 20% of CH patients, respectively. In the 
long term, more than 50% of patients will keep the subtype that is present at the time of diagnosis. The 
lifetime prevalence of CH  is 124 per 100,000 and the 1-year prevalence is 53 per 100,000 in 
population-based studies. 1-Person year incidence ranges from 2.07 (in 1989-1990) to 9.8 per 100,000 
(in 1979-1981). A male to female ratio of 4.3:1 has been reported. The mean age of onset is between 
29.6 and 35.7 years. CH has a considerable impact on daily living in three quarters of patients,2 
reflected in the name ‘suicide headache’. Active suicidal ideation indeed was found in 5.9% in CCH 
and 6.3% in ECH patients, and even 55% of CH patients have suicidal thoughts during lifetime.3 
Obviously, the enormous impact of CH makes the search for effective treatments of utmost 
importance. In this search, understanding CH pathophysiology can provide a basis. And in the other 
way, effective treatments can expand the knowledge of CH pathophysiology.   
 
Cluster headache pathophysiology  
Although headaches that we recognise as and mention CH today have been described since the 17th 
century,4 extensive study of the pathophysiology and successful treatment had to wait until the second 
half of the 20th century. In the causation of CH, a centrally driven change in cranial blood vessel 
diameter is considered to play a role. Pain afferents from the trigeminovascular system traverse the 
ophthalmic nerve and synapse in the trigeminocervical complex. The second-order neurons project to 
the thalamus and thalamocortical projections lead to pain awareness. Trigeminal-autonomic reflex 
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activation of the efferent parasympathetic fibres arising in the superior salivatory nucleus of the facial 
nerve causes (further) blood vessel dilatation. Dilatation of the carotid artery can result in a third-order 
sympathetic nerve lesion with a partial Horner’s syndrome. Parasympathetic activation also leads to 
conjunctival injection, lacrimation, rhinorrhoea and nasal congestion.5 Parasympathetic outflow is also 
directly activated by the hypothalamus. Moreover, the posterior hypothalamic grey matter region 
triggers the pain and controls the (typical) circadian rhythm.6  
 
Oxygen treatment in the past 60 years and its position 
CH treatment comprises of acute/attack treatment and short-term and long-term preventive/ 
prophylactic treatment. While preventive treatment (not further discussed here) is aimed to reduce the 
frequency and intensity of CH attacks, the goal of acute treatment is to abort a CH attack within a few 
min. Nowadays, this can be achieved in most patients by injecting 6 mg of Sumatriptan 
subcutaneously or inhaling 100% oxygen. Nasal Sumatriptan, nasal(/oral) Zolmitriptan, nasal 
Lidocaïne, oral/rectal Ergotamine tartrate and nasal/intravenous(/intramuscular) Dihydroergotamine 
are alternative, but inferior acute treatments, due to a slower effect, unfavourable pharmacologic 
profile or impractical route of administration.7    
 Oxygen was actually one of the first successful options for acute treatment. In his 1956 
publication on ‘Histaminic cephalgia’, Bayard T. Horton, a CH investigator of the first hour,8 stated 
that breathing of 100% oxygen can alleviate an attack considerably when the attack is mild and 
oxygen is used immediately.9 Stimulated by a letter to the editor on this topic by Janks,10 Kudrow took 
an interest in oxygen treatment for CH and conducted a trial in 1981, which was positive.11 Today, 
inhalation of 100% oxygen via a non-rebreathing mask at a flow rate of at least 7 litre/minute (L/min) 
is still recommended as an acute treatment,6 although 12 L/min has also been proven to be effective.12 
However, not all patients are able to use oxygen effectively, and it is this ineffectiveness which 
necessitates further research into pathophysiology and treatment effects, in order to find a treatment 
regime which is 100% effective (and has negotiable side effects). Here, I will first present a brief 
overview of the known degrees and modes of effectiveness of inhalation of 100% oxygen at different 
flow rates and pressures.  
 
Oxygen response rates at flow rates of 6-8 L/min 
A number of studies have investigated the acute treatment success achieved by inhalation of 100% 
pure oxygen at normal (i.e. approximately 7 L/min) flow rates.  
In the first part of Kudrow’s study fifty-two CH patients were treated with 100% oxygen via a 
facial mask at a flow rate of 7 L/min for 15 min, starting at the onset of each of ten CH attacks. 
Prophylactic medication was not withheld in twenty-eight patients. ‘Treatment success’ was defined as 
‘complete or almost complete cessation of head pain within 15 min for at least seven of ten attacks’. 
Seventy-five percent of patients successfully treated their CH attacks. In the second part of the study (a 
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crossover trial), the effectiveness of oxygen inhalation was compared to that of sublingual ergotamine 
tartrate administration. An additional fifty patients were treated with 100% oxygen via a facial mask at 
a flow rate of 7 L/min for 15 min starting at the onset of each of ten CH attacks, and sublingual 
ergotamine tartrate or vice versa. Prophylactic medication was withheld. Eighty-two percent of the 
oxygen users successfully treated their CH attacks.11  
In Fogan’s double-blind crossover study, treatments of 100% oxygen and compressed room 
air, both supplied via a non-rebreathing face mask at a flow rate of 6 L/min for up to 15 min, were 
compared. Nineteen CH patients were treated with each treatment/gas for zero to nine (oxygen) or ten 
(air) CH attacks. ‘CH pain relief’ was scored ‘0 for no relief, 1 for slight relief, 2 for substantial relief 
and 3 for complete relief’. The ‘relief score’ was an average of the scores. The average relief score 
with oxygen was 1.93 and with air was 0.77. The difference between the average relief scores was 
statistically significant (p < 0.01). As a continuation of the Kudrow study, this study ruled out the 
possible effects of pressurised gas flow itself, the breathing mask and the attention on the person's own 
breathing.13  
In Heckl’s study, ten patients (eight with CH and two with Chronic paroxysmal hemicrania 
(CPH)) were treated with oxygen via an oxygen mask at a flow rate of 7 L/min at the onset of a 
headache attack. All six ECH patients already experienced relief at treatment onset. Mean pain 
reduction was 60-80%. A primary chronic cluster headache (PCCH) patient had only a temporary 
mean pain reduction of 60%, with a reduction in attack duration of 67% to circa 20 min. A secondary 
chronic cluster headache (SCCH) patient had a pain reduction of most 60-70%, without a reduction in 
attack duration.14  
In a study conducted by Gallagher et al. abortive treatments of analgesics (most commonly 
‘combination-type medications containing barbiturates or narcotics’) and/or 100% oxygen (supplied 
via a face mask at a flow rate of 8 L/min for 10-15 min) were compared. All sixty patients were 
offered both treatments. ‘Significant (headache) relief’ (no definition given) was reported in thirty-
nine of fifty-one (i.e. 76%) patients, who first chose oxygen inhalation therapy compared to ten of 
forty-eight (i.e. 21%) patients, who first chose analgesics. However, only 31% of patients preferred to 
continue using oxygen inhalation, compared to 65% of patients who chose to continue using 
analgesics. The efficacy of oxygen treatment did not outweigh the unpractical use and the occurrence 
of  rebound CH.15 
 
Higher oxygen flow rates of 12-15 L/min 
Seven L/min has become the standard and minimal oxygen flow rate since Kudrow’s study.11 When I 
started my studies on CH and oxygen in 2008, there was only one small study with only three CH 
patients, who were resistant to standard oxygen flow rates of 7-10 L/min, and who inhaled oxygen at 
flow rates of 14-15 L/min. ‘Alleviation’, ‘70-100% relief’ and ‘full headache relief’ were achieved 
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multiple times using these higher oxygen flow rates. The author suggested that flow rates up to 15 
L/min should have been used before CH patients are considered unresponsive to oxygen treatment.16  
 More recently, a trial was published with high flow oxygen, in which 12 L/min was found to 
be an effective treatment. In Cohen’s double-blind crossover trial 100% oxygen and air, both supplied 
via a non-rebreathing face mask at a flow rate of 12 L/min for 15 min, were compared. Of the seventy-
six ECH and CCH patients who completed the study, seventy-three CH patients treated two CH 
attacks each with each treatment/gas and were included in the primary analysis. A pain free state (or a 
state of ‘adequate relief’ (not defined)) after 15 min of inhalation was achieved in 116 out of 150 (i.e. 
78%) oxygen-treated and 29 out of 148 (i.e. 20%) air-treated CH attacks. The difference was 
statistically significant (p < 0.001).12   
 
Mechanisms of action of normobaric oxygen 
The mechanisms underlying the antinociceptive effect of oxygen are not well understood. Initially a 
primary vascular target was presumed. Sakai et al. suggested at first that inhalation of 100% oxygen 
during a CH attack reduces the cephalic flow and thereby relieves pain. The in vitro evidence for 
oxygen directly causing vasoconstriction of cerebral blood vessels was discussed.17 Further 
endorsement of a direct or indirect vasoconstrictor effect of 100% oxygen came from a reduction in 
pulsation amplitude of (terminal) branches of the internal and external carotid vasculature, particularly 
on the symptomatic side, during 10 min of breathing of 100% oxygen in nitroglycerin-induced CH 
attacks.18 Moreover, other studies, applying Xenon, visualised a reduction in cerebral blood flow due 
to oxygen inhalation in spontaneous19, 20, 21 and nitroglycerin- or alcohol-induced CH attacks.21 During 
the conduction phase of our studies on CH and oxygen evidence was published on an indirect 
vasoconstrictive effect of 100% oxygen, which inhibited a subpopulation of efferent neurons 
projecting from the superior salivatory nucleus (i.e. the aforementioned origin of neurons for the 
cranial parasympathetic vasodilator pathway), by maximally 33% at 20 min.22    
 Most pain reduction, simultaneously with a reduction in autonomic symptoms, was found in 
patients with an abnormally high reduction of cerebral blood flow induced by oxygen inhalation 
during CH attacks. However, some pain relief was also found in patients with a normal cerebral blood 
flow response, suggesting other factors than vasoconstriction causing pain relief as well as a relation 
between pain intensity and autonomic symptoms.19 Schuh-Hofer et al. demonstrated that hyperoxia 
significantly inhibited rat dural protein plasma extravasation and therefore counteracted neurogenic 
inflammation.23  
 
Factors determining normobaric oxygen response 
At the start of my research, I specifically assumed that factors determining oxygen response could 
contribute to our knowledge of CH pathophysiology. At that time, it was not known which 
characteristics predicted acute treatment response in CH patients completely. Table 1 shows the 
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factors that had been associated with an unfavourable response to oxygen. Schürks et al. identified 
restlessness (OR 0.09, p = 0.019) as a negative predictor of oxygen response. It was hypothesized that 
restlessness causes intolerance of the oxygen face mask in some.24 Restlessness during a CH attack 
was reported by 67.9% of patients.25 
Kudrow found significantly better (p < 0.05) effects of oxygen inhalation in ECH patients 
under 50 years of age (‘treatment success’ 92.9%) than in CCH patients over 49 years of age 
(‘treatment success’ 57.1%). There was no significant response difference between ‘young’ (i.e. under 
50 years of age) and ‘old’ (i.e. over 49 years of age) CH patients. Neither was there a significant 
response difference between ECH and CCH patients in all age groups.11 Likewise, Schürks et al. did 
not identify age and ECH (%) as statistically significant negative predictors of oxygen response.24  
Kudrow and Schürks et al. both found no significant response difference between male and 
female patients.11, 24, 25 However, Rozen et al. found an oxygen treatment response in only 59.1% of 
women, versus 87% of men. This difference was significant (p = 0.01).26  
In another study, Rozen noted that a history of smoking was reported by 75% of women, 
versus 61% of men.16 Schürks et al. did not identify current smoking (%) as a statistically significant 
negative predictor of oxygen response.24 There were statistically significantly more male current 
smokers than female current smokers.25 
Rozen et al. found significantly more vomiting (46.9% versus 17.4%, p = 0.003) and more 
nausea (62.5% versus 43.5%, p = 0.09) in women.26 Schürks et al. identified nausea/vomiting as a 
negative predictor of oxygen response (OR 0.41, p = 0.029).24 Nausea and vomiting were reported by 
27.8% during CH attacks.25  
Kudrow noted that in some cases, unresponsive to either oxygen or ergotamine, the acute CH 
attack treatment had been started late.11 Schürks et al. stated it was less obvious whether the timing of 















Table 1. Factors associated with an unfavourable response to oxygen in CH attacks 
Factors                                                                 p value                                                           
 
Restlessness 24    0.019 a 
CCH and > 49 years of age 11 < 0.05 b 
Females 11, 24, 25, 26  0.01 c – ‘no significance’ c 
Nausea and vomiting 24, 26    0.029 a 
a Oxygen responders (defined by the criterion: ‘compared to untreated CH attacks, CH pain must have been 
reduced in at least three CH attacks by at least 50% within 15 min after oxygen application and despite the used 
flow rate’) were compared to non-responders (who should have used therapeutic flow rates).24  
b ECH patients < 50 years of age were compared to CCH patients > 49 years of age.11  
c Females were compared to males.25, 26 
 
Hyperbaric oxygen 
The rather successful use of oxygen led to experiments with hyperbaric oxygen (HBO). Porta et al. 
stated that a high blood oxygen saturation of  98% during min is required for treatment success, which 
can be induced by HBO inhalation. After the initial case report by Weiss, Porta et al. first confirmed 
that HBO inhalation could be effective for individual CH attacks.27 HBO consists of 100% oxygen at a 
pressure more than 1 atmosphere. Two studies investigated the acute treatment effect achieved by 
inhalation of  HBO.  
In the crossover study conducted by Porta et al., abortive treatments of ‘normobaric oxygen 
inhalation’ (at a flow rate of 7 L/min for 15 min) and HBO inhalation (administered in a hyperbaric 
chamber with 100% oxygen with compression up to 2 atmosphere absolute (ATA)) were compared. In 
contrast to five patients who were ‘partially refractory’ and three patients who were ‘totally refractory’ 
to normobaric oxygen inhalation, all fourteen patients achieved ‘complete relief’ a few min after 
starting HBO treatment.27  
A double-blind study by Di Sabato et al. compared the acute treatment effect of HBO 
(administered in a hyperbaric chamber during 30 min with a pressure up to 2.5 ATA, in seven ECH 
patients) and of a placebo procedure (normal air administered in a hyperbaric chamber during 30 min 
at a pressure of 1.0 ATA, in six ECH patients) both to the mean of the duration of the last three CH 
attacks occurring before the test. HBO interrupted the CH attack in 86% of patients, whereas placebo 
did not change the duration of CH attacks in 100% of patients (so one can expect there was no 
interruption).28 However, the difference was not statistically significant (p = 0.08).29  
 
As expected, Di Sabato et al. realised that HBO as an acute treatment is not practical, because of the 
short duration of CH attacks and the costs of HBO treatment.28 Pascual et al. suggested that HBO 
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could have prophylactic effects.30 Five studies investigated the prophylactic treatment effect achieved 
by inhalation of HBO. 
In the study by Di Sabato et al. described above, of the six patients (i.e. 86%) in which HBO 
interrupted the current CH attack, three patients did not have CH attacks for 4-6 days and another three 
patients did not have CH attacks during the follow-up period of 2 months. The CH attack pattern 
remained unchanged in the patients on placebo.28  
Pascual et al. studied the frequency and duration of CH attacks during HBO treatment (ten 
sessions administered in a hyperbaric chamber for 70 min per session at a pressure of 2.5 ATA), 
compared to the last (minimum) 2 weeks before treatment start. The four CCH patients continued 
using preventive treatment (Lithium). One patient did not have any CH attacks until 31 days after his 8 
day treatment. In contrast, another patient did not experience any effect in frequency (and duration).30 
Nilsson Remahl et al. conducted a double-blind crossover study in which HBO treatment 
(composed of 100% oxygen) and hyperbaric normoxic placebo treatment (composed of 10% oxygen), 
both supplied in a hyperbaric chamber by a mask for 70 min in two sessions 24 hours apart at 2.5 
ATA, were compared. Fourteen CH patients breathed HBO, sixteen CH patients breathed hyperbaric 
normoxic placebo. ‘A headache index’ (HI) (sum of (number of headache attacks times their degree of 
severity)) was calculated for 1 week prior to as well as for 1 week following each separate treatment. 
A treatment was considered effective if the HI decreased by > 50%. HBO treatment was effective in 
five of fourteen (i.e. 36%) patients and hyperbaric normoxic placebo treatment was effective in six of 
sixteen (i.e. 38%) patients.31 There was no significant (p = 0.92) difference in treatment effectiveness 
between HBO and hyperbaric normoxic placebo treatment.29 One ECH patient who responded to HBO 
was free of CH attacks for 6.5 months. However, two ECH patients who responded to hyperbaric 
normoxic placebo treatment had a remission period (free of CH attacks) for even more than 1 year. 
The study only found a true preventing effect of (100%) oxygen while the patient was under 
hyperbaric conditions.31  
Di Sabato et al. placed seven ECH patients in a hyperbaric chamber during 30 min with 
pressures up to 2.5 ATA. A disappearance or at least a 50% diminution ‘of the CH’ (unknown 
frequency, duration or severity) was observed during 3 days after exposure.32 In another study by Di 
Sabato et al. ten CCH patients were placed in a hyperbaric chamber during fiteen sessions of 30 min 
with pressure up to 2.5 ‘atm abs’ while breathing 100% oxygen administered through a facial mask. 
There was a decrease in the weekly number of attacks during the treatment period (i.e. 30 days). The 
‘clinical index’ (not defined) remained at ‘significantly’ lowered numbers during the first 2 weeks of a 
4-week follow-up period after HBO treatment.33       
The authors mentioned several mechanisms that could explain the effect of HBO. It induces 
vasoconstriction, reduces cerebral hypoxia by increasing oxygen diffusion, acts against oedema of the 
blood vessel wall and interstitium and stimulates the serotonin synthesis in the central nervous 
system.28 In vitro a normal 5-Hydroxytryptamine (5-HT) turnover was found after HBO.33 
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Furthermore, HBO could act against the sterile inflammation produced by release of neuropeptides 
from the trigeminal neuron.32 Finally, HBO has some nonspecific actions such as an influence in the 
prostaglandin cascade.30  
 
Cold air 
Mc Leod et al. investigated the interesting hypothesis that cooling rather than the oxygen 
concentration plays the main role in relieving a CH attack as cold temperature causes vasoconstriction. 
Eight CH patients treated ten CH attacks using a device which delivered room air cooled to 5°C via a 
non-rebreathing face mask at a flow rate of 6 L/min for 15 min or until the headache was aborted. Of 
these eight CH patients, six treated the next five CH attacks using 100% oxygen (no details of 
administration were provided). The level of relief was scored ‘0 for no or minimal relief, 1 for slight 
relief, 2 for substantial relief and 3 for complete relief’. ‘Significant relief’ combined categories 2 and 
3. ‘Significant relief’ was achieved in 85% (p < 0.0005) using the cold room air device and in 83% (p 
< 0.0005) using 100% oxygen. The main relief score for the sixty-eight observations in which cold 
room air provided ‘significant relief’ was 2.69 and for the twenty-five observations in which 100% 
oxygen provided ‘significant relief’  was 2.72. The difference between the main relief scores was not 
statistically significant. So, contrary to Fogan’s and Cohen’s results, cold room air can be effective in 
the acute treatment of CH.34   
 
To summarize, 100% oxygen supplied via a facial mask at a flow rate of 7 L/min given at pain 
onset for 15 min, provides successful headache relief in 75-82%. Patients who have no response to 
100% oxygen at a flow rate of 7 L/min should be exposed to flow rates of 12 and possibly even 14-15 
L/min, before they are considered refractory. Restlessness, an age > 49 years in CCH, (female gender) 
and nausea and vomiting are proven factors predicting a negative oxygen response.  
HBO of 2.0–2.5 ATA can terminate CH attacks in a few to 30 min in 86% to probably 100%. 
HBO can terminate CH attacks also in those considered refractory to normobaric oxygen. HBO cannot 
prevent subsequent CH attacks.  
Cold (5°C) room air supplied via a face mask at a flow rate of 6 L/min for 15 min was as 
effective in relieving pain as 100% oxygen.  
 
Scope of this thesis 
 
When I started my studies in 2008, it was not possible to find clues that provided further insight into 
CH pathophysiology, based upon the data on proven factors predicting the oxygen response in CH 
attacks in particular. It led me to believe that it would be worthwhile to set up a systematic search for 
characteristics that would predict the effect of oxygen in CH.  
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 I referred shortly to the history of oxygen application for CH in the past 60 years. As is true 
for the rebound phenomenon, which had been noted by Kudrow in 1981 already,11 I increasingly 
realised more things could be learned from the past. Being interested in the origin of applying oxygen 
for CH, which provides a perspective for our studies, I did a more extensive historical review of CH 
and oxygen therapy (chapter 2).  
 I carried out a retrospective (chapter 3) and subsequently a prospective (chapter 4) cross-
sectional correlation study. Although described in more detail in the prospective study, in both studies 
I used the same classification in five groups of response to oxygen, which enabled a comparison.  
 In my retrospective study, six patients spontaneously reported an increase in CH attack 
frequency when using oxygen as acute treatment. Because this phenomenon implies an important 
limitation in the use of oxygen, in my prospective study I specifically asked for a change in CH attack 
frequency after start of oxygen therapy. During the course of my prospective study, 7% of the patients 
reported the phenomenon. As Kudrow described a rebound phenomenon in even 25% of his patients 
using oxygen for CH,11 I decided not to wait until the final patient inclusion in my prospective study, 
and I studied the phenomenon more closely in my patient series present at that time. To study the 
rebound phenomenon, first I had to define it. This definition and the results of the study will be 
presented in chapter 5.   
 Apart from studying clinical characteristics, during the course of our studies I became 
interested in clinical neurophysiology as a means for further elucidation of pathophysiological 
mechanisms in CH. To investigate the (direct or indirect) effect of oxygen on medullary interneurons, 
I intended to study the nociception specific blink reflex before and during a CH attack, as well as 
before and during oxygen treatment. This study had unexpected, serendipitous results, that are 
described in chapter 6. As the remaining data from this study, notably the effect of oxygen on the 
nociception specific blink reflex may be useful in further research, I described these data in an 
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Overview. Oxygen has been a generally accepted treatment method for cluster headache attacks ever 
since Kudrow (1981) conducted a controlled trial showing that oxygen was equally or even more 
effective than ergotamine injections.  
Purpose. The aim of the present study was to provide a historical perspective of oxygen treatment in 
cluster headache and to find the origin of this treatment. Oxygen for cluster headache was first 
described by Horton in 1952 and for migraine patients in 1940 by Alvarez. At the time, neither of the 
authors provided any reason why they chose for this treatment method. The vasoconstrictive effect of 
oxygen was not described by Horton until 1961.  
Conclusion. We suggest that these authors originally adhered to the vasoconstrictive theory of vascular 
headache that was prevalent in the early 20th century until Wolff demonstrated the contrary in the late 
1930s. The early literature describes an analogy between angina pectoris and migraine, as being both 
due to vasoconstriction. As oxygen was described as a treatment for angina pectoris, this may be the 
reason why oxygen was tried for migraine and cluster headache at a time when they were not 
























Oxygen has been used to treat cluster headache (CH) attacks since Horton first described it in 1952.1 
The mechanism by which oxygen relieves CH attacks is still unclear, as is the pathophysiology of CH 
itself. In this article we will provide a historical perspective of oxygen treatment in CH and figure out 
why we started treating our CH patients with oxygen in the first place. 
 
History of cluster headache 
One of the earliest descriptions of a ‘cluster headache-like syndrome’ dates back to the 17th century.2 
The Dutch physician Nicolaes Tulp (1593-1674) described the headache history of a Dutch man, 
which seemed to fit a diagnosis of CH, although autonomic symptoms were hardly described. Several 
cases describing symptoms that nowadays would be recognized as CH have been published since 
then.3, 4, 5  
 In 1926 the London neurologist Wilfred Harris (1869-1960) gave the first complete 
description of CH, which he named migrainous neuralgia or ciliary (migrainous) neuralgia (if the 
symptoms were mostly located near the eye).6 He noticed a clear difference in clinical characteristics 
between migrainous neuralgia, migraine and trigeminal neuralgia. He described the unilaterality, 
frequency and autonomic features that we now know are typical for CH. He also recognized that 
Horner’s syndrome could occur and he described the so-called ‘cluster phenomenon’.7 Harris treated 
his patients with alcohol injections, at first in or around the supraorbital and infraorbital nerve and 
later in the Gasserian ganglion.8 Later, he noticed the positive effect of subcutaneous injections of 
ergotamine that had become available previously.9 
 In 1939, Bayard Horton (1895-1980) described cluster attack features and a specific treatment 
method using histamine desensitization in a paper called ‘A new syndrome of vascular headache: 
results of treatment with histamine’.10 The association with histamine was possibly related to one of 
the current pathogenic allergy theories, in which migraine was compared to asthma and urticaria. 
Horton speculated that CH was caused by an 'anaphylactoid reaction' to endogenous histamine.11, 12 He 
was probably not aware that Harris in 1926 already described the syndrome we now know as CH. 
 Only in 1952 did Horton detail the pain and its associated symptoms, and the syndrome then 
became well known.1 Twelve years before the publication of his 1939 article, he had noticed patients 
with erythromelalgia of the feet. He noticed the extreme grades of vasodilatation that were associated 
with their complaints of burning distress. In CH patients he noticed an increase in surface temperature 
of the painful areas, roughly corresponding to the branches of the external carotid artery. Hence the 
term ‘erythromelalgia of the head’ was proposed. Later, he noticed the effect of histamine in 
provoking an attack and as he thought that there was an important pathogenic role for the vasodilator 
histamine, he called the disease ‘histaminic cephalgia’. 
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 The term ‘cluster headache’ was introduced by Kunkle et al. in 1952, but ‘Horton’s headache’ 
and ‘histaminic cephalgia’ were more frequently used names at first.13 Horton treated his patients with 
oxygen and ergot preparations but mostly by histamine desensitization.  
 In 1961, Horton referred to one of his earlier unpublished papers (1938) entitled: ‘Migraine: 
treatment with histamine’.14 This paper was published under the name ‘A new syndrome of vascular 
headache: results of treatment with histamine’ in 1939 and turned out to be his first discussion of 
CH.10 This shows that migraine and CH were considered similar clinical entities of vascular origin 
before the clinical descriptions of Horton himself and Harris became known.  
 
Horton and oxygen treatment 
Nowadays oxygen is frequently used as an acute treatment for CH attacks.15, 16 As mentioned above, it 
is still not clear why oxygen aborts CH attacks so well. Recent studies show that activation of the 
trigeminovascular system, along with the autonomic reflex arc, are important in the pathophysiology 
of CH.17 Akerman showed that treatment with 100% oxygen in rats was able to inhibit neuronal firing 
in the trigeminal cervical complex and to attenuate the blood flow changes in response to stimulation 
of the facial/greater superficial petrosal nerve efferents. Oxygen treatment had no effect on activation 
of trigeminal afferents in response to stimulation of dural structures. It seems that oxygen acts on the 
parasympathetic pathways to exert its abortive effects, rather than directly on trigeminal afferents to 
the dural vasculature.18 More study on the subject is still required to gain more insight into the 
pathophysiology and potential treatment methods of CH. 
 What is the origin of the use of oxygen as a treatment for CH? Working at the Mayo clinic 
(Rochester, Minnesota, USA) in 1940, Alvarez described his usage of oxygen in the treatment of 
headache.19 He used a nasal mask to deliver oxygen at a flow rate between 6 and 8 litre/minute 
(L/min). He believed that it was effective for the treatment of typical migraine, and that it gave some 
relief in a group of patients he called ‘Probably not migraine or else migraine with complications’ and 
in a group called  ‘Headache, not migrainous’. In the ‘Typical migraine’ group, 88% of the patients 
noticed relief to some extent, 42% had complete relief and 36% much relief. In the ‘Probably not 
migraine or else migraine with complications’ group only 33% and in the ‘Headache, not migrainous’ 
group only 40% noticed any relief. Histaminic cephalgia, or any other description of CH, was not yet 
mentioned separately, but it seems likely that CH patients may have been included in the ‘Typical 
migraine’ and ‘Probably not migraine’ groups.  
 The first time that oxygen therapy was recommended as a possible treatment method for CH 
attacks was in Horton’s 1952 paper.1 In 1955, in the Bulletin of the Tufts, Horton described the 
successful treatment with oxygen in a population of 1176 patients with histaminic cephalgia.20 
However, this was not a systematic study, as it was solely based on his experience in the clinic. He 
usually recommended oxygen usage in combination with an intravenous injection of 
dihydroergotamine. Oxygen without dihydroergotamine was found effective in less severe CH attacks, 
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which he graded 1 and 2, but of little value in severe attacks, graded 3 and 4. Furthermore, he noticed 
that oxygen was most effective when the oxygen treatment was started promptly at the onset of an 
attack. The reason why Horton started using oxygen as a treatment is not clear from his early papers. 
He may have followed up on Alvarez, who treated migraine with oxygen, not describing why he did 
so either. However, Horton stated that the pain in episodes of histaminic cephalgia was caused by 
vasodilatation of extracranial vessels and he noted that the intravenous administration of 1:500,000 
solution of epinephrine could also be used to abort attacks. He also noted that epinephrine constricts 
the extracranial vessels, which may have been a clue for his ideas on the pathophysiological origin of 
CH. Whether he was really aware of the vasoconstrictive effects of oxygen, and whether this is why he 
tried to use oxygen in his clinic in the first place, is not clear. Of course, it is also possible that the 
effective use of oxygen was discovered by coincidence.  
 If we assume that the vasoconstrictive effect of oxygen was known, it would seem reasonable 
to treat both migraine and CH with oxygen, as Horton at first described them as variations of the same 
disease. In his 1959 paper ‘Management of vascular headache’, Horton made a distinction between 
migraine and histaminic cephalgia.21 In migraine he distinguished three phases but in histaminic 
cephalgia only two. In migraine, the first phase was supposed to be due to vasoconstriction, not giving 
rise to pain but rather to scotomata and other cortical manifestations. This phase does not occur in 
histaminic cephalgia. The vasodilating second phase was thought to explain the associated pain. It 
would occur more promptly in histaminic cephalgia than in migraine. The third phase was thought to 
be due to oedema, which was also believed to cause pain. This is short lasting in histaminic cephalgia 
but may persist for hours in cases of migraine, explaining the difference in symptom duration (Table 
1).   
 In this paper,21 Horton also described the treatment of both migraine and histaminic cephalgia. 
He mentioned the effectiveness of vasoconstricting agents in migraine. Oxygen, however, was not 
listed among them. In the same article, oxygen was mentioned as an acute treatment for histaminic 
cephalgia, but again without any reasoning why this was done. Not until 1961 in the Maryland State 
Medical Journal was oxygen described by Horton as a vasoconstricting agent.14 In that article, he also 
referred to treating other vascular headaches with oxygen, without mentioning the results of this 
treatment.  
 In conclusion, we can say that there is no clear documentation of why Horton started using 
oxygen therapy as an acute treatment for CH patients and why Alvarez used it in all headache patients. 







Table 1. Pathophysiologic mechanism for ‘histaminic cephalgia’ and migraine according to Horton 
(1959) 21 
 Vasoconstriction Vasodilatation Oedema 
Migraine + + + (long lasting) 
Histaminic cephalgia - + + (short lasting) 
Associated symptom Cortical symptoms (e.g. scotomas)  Pain Pain 
 
 
The use of oxygen before Horton 
There was a period in which sympathicotonic (with pale face) as well as sympathicolytic (with red 
face) types of migraine were distinguished in textbooks. This resulted from the discussion in the 1850s 
and 1860s following the discovery of the vasomotor nerves,22 although the angiospastic concept of 
migraine was discussed earlier (e.g. by Parry 23). These ideas on the pathophysiological mechanisms 
underlying migraine (sympathicotonic and sympathicolytic) existed next to each other for several 
decades, although Latham tried to combine these ideas, suggesting vasoconstriction in the aura phase 
followed by vasodilatation in the headache phase (1873).24 On one side there was Edward Woakes, 
who introduced ergot for its vasoconstrictive effect in the treatment of migraine (1868),25 and on the 
other side there was a period in the early 20th century in which ergotamine was thought to block the 
sympathetic nerve effects and was therefore used as the treatment for sympathicotonic conditions, 
including migraine. It would appear later that this was a matter of dosage, lower dosages being 
vasoconstrictive (as in the case of Woakes) instead of vasodilatating (in the early 20th century 
applications).26 In his 1935 review of migraine in Bumke’s and Foerster’s Handbuch der Neurologie, 
Hugo Richter (1886-1945) stated that from all evidence available at that time, the vasoconstrictive 
model of migraine was the most plausible.27 
 In the 1930s, John Graham and Harold Wolff studied the external carotid arteries by 
measuring the amplitude of pulsations following ergotamine injections, which showed a simultaneous 
decrease in amplitude and decline in migrainous headache. A relationship with cerebrospinal fluid 
pulsations (reflecting intracranial artery extension) was not observed. They concluded that the 
headache-ending effect was most likely caused by narrowing of the dilated arteries, which had caused 
pain by being overstretched.28 They thereby refuted the sympathicotonic theories of the 1920s and 
concluded that ergotamine had a vasoconstrictive effect. As this study was published in 1938, Horton 
and Alvarez may have been unaware of this mechanism when they started their research and may have 
adhered to the vasoconstrictive theory of migraine (and CH). The 1939 paper by Horton, however, had 
already described that the pathogenesis of the pain most likely lies in the phenomenon of 
vasodilatation.  
 In June 1930, the results of an experimental study in cats by Harold Wolff and William 
Lennox (1884-1960) were published.29 They conducted several experiments to determine the effect of 
variations in the oxygen and carbon dioxide content of the blood on the pial vessels. They concluded 
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that changing the oxygen concentration had a small but noticeable effect on the diameter of the pial 
vessels. An increase in oxygen concentration let to vasoconstriction, while a decrease in oxygen 
concentration let to vasodilatation. 
 It could be suggested that the use of oxygen was eventually based on this study, but the effects 
described by Wolff and Lennox were small and observed in pial vessels. Moreover, Horton did not 
mention the vasoconstrictive effect of oxygen until 1961.   
 As mentioned before, it is possible that Alvarez (and Horton) adhered to the vasoconstrictive 
theories of headache at the start of their research.  
 
 In the early 20th century, oxygen was frequently used as a treatment for angina pectoris, a 
condition known to be associated with vasoconstriction.30 The effect of oxygen had been noted in 
1900 by Steele.31 Taking into account the well-known use of oxygen in angina pectoris, it is possible 
that Alvarez tried to use oxygen in migraine to treat the supposed hypoxia caused by vasoconstriction. 
This theory is supported by writings of Hans Curschmann (1875-1950) in 1926, cited by Richter.27 
Curschmann noted that people with migraine often tended to also have angina pectoris complaints. 
Moreover, they tended to have complaints of cold hands and feet, possibly caused by vascular spasm, 
which might also underly the migraine. This strengthens the idea that there was a theory about a 
relationship between angina pectoris and migraine. Therefore, it seems reasonable that the treatment 
for angina pectoris was also tried in migraine (and thereby CH) patients.  
 On a side note, it is interesting to note that Curschmann already described that smokers in 
particular were more prone to developing angina pectoris. This did not become common knowledge 
until the second part of the 20th century. In 1964, The Reports of the Surgeon General on Smoking and 
Health reported growing evidence of an increased risk of cardiovascular disease in smokers.32 One of 
the earliest studies on this subject was done by English et al. He found that the incidence of coronary 
disease in male patients at the Mayo Clinic was about three times greater in cigarette smokers than in 
non-smokers in the 40-59-year age range.33 Furthermore, Russek published a study in 1950, stating 
that 100% oxygen given via a face mask led to a more pronounced and longer duration of the ECG 
manifestations of myocardial ischemia and failed to prevent the onset or influence the duration of 
anginal pain. He therefore believed that oxygen should be contra-indicated for angina pectoris without 
hypoxaemia.34   
 
The use of oxygen after Horton 
In the years that followed Horton’s publications, several studies reported the use of oxygen in the 
treatment of CH. Sjaastad mentioned a study, published in 1953, in which attacks provoked by 
nitroglycerin or histamine were successfully aborted by treatment with 100% oxygen.35 In 1958, 
Friedman and Mikropoulos described that ergotamine appeared to be more effective than oxygen.36 
Nelson (1970) described oxygen to be fairly effective when given early and of little use when started 
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at the peak of an attack.37 In 1976, Graham stated that patients had occasionally obtained relief of 
acute attacks by breathing 100% oxygen for 15 minutes (min).38 The first systematic study on the 
effect of oxygen therapy in the acute treatment of CH attacks was done by Kudrow in 1981.15 He took 
an interest in oxygen therapy after a letter published in the JAMA (1978) by optometrist JF Janks, who 
described in detail his personal experience with oxygen inhalation for acute cluster attacks.39 In 
Kudrow’s study, the effect of self-administrated oxygen, using a mask and at a flow rate of 7 L/min 
for 15 min, was compared with sublingual ergotamine administration. The results showed that oxygen 
administration at 7 L/min for 15 min and sublingual ergotamine administration were both effective in 
aborting CH attacks. Oxygen aborted more than seven out of ten attacks in 82% of the patients, 
ergotamine in 70%. Moreover, the response to oxygen was faster, with an average response time of 6 
min. After 6 min only 28.2% of the ergotamine group attacks were aborted. The peak response time 
for sublingual ergotamine was between 10 and 12 min. When the side-effects and contra-indications 
were also taken into account, oxygen seemed to be the best choice for the treatment of a CH attack. 
However, Kudrow also described a rebound effect in oxygen users: a shorter time until the next attack 
after oxygen usage. This was found in 25% of the patients.15 Not until after Kudrow’s study was 
published, did oxygen therapy as an acute CH treatment seem to be on the rise. Results like these, 
however, were not found in following studies.   
 In his book on CH, Kudrow (1980) mentioned an earlier study on oxygen treatment that was 
also described in his 1981 article, in which fifty-two patients were treated with 100% oxygen for 15 
min. He noted that 75% responded significantly. The worst responders were chronic cluster headache 
(CCH) patients over 49 years of age.40 In a recent study, however, responders to oxygen seemed to be 
slightly older (p = 0.11) and percentages of episodic cluster headache (ECH) patients were equally 
distributed between the responder and non-responder group.41 
 Kudrow further described a study by Sakai and Meyer, who demonstrated that 100% oxygen, 
administered during an attack, promptly reduced cerebral blood flow and pain. It was suggested that 
there is a hyperreactivity of the cerebral blood vessels to oxygen in CH patients.42 
 In 1981 treatment with oxygen at 8 L/min was compared with the patients usual oral 
medication, such as ergot derivatives or analgesic tablets.43 All but one patient noticed faster relieve 
when treated with oxygen compared with oral medication, and all twelve patients responded to oxygen 
treatment. A crossover study by Fogan (1985) between oxygen at 6 L/min and room air showed a 
highly statistically significant difference in pain relief scores. Fifty-six percent of patients experienced 
relieve in over 80% of attacks while using oxygen, compared with 7% using room air.44 Nowadays, 
oxygen still is usually delivered at a flow rate of 7 L/min, as was done in the early study by Kudrow. 
A recent study was conducted with a higher oxygen flow rate, 12 L/min, which also appeared to be 





Table 2. Important data in the history of cluster headache in relation to oxygen 
1900 Steele 31 Oxygen as a treatment for angina pectoris 
1926 Curschmann 27 Co-morbidity of angina pectoris and migraine 
1926 Harris 6 First complete description of cluster headache (migrainous ciliary neuralgia) 
1930 Wolff 29 Effects of oxygen on cranial blood vessels 
1938 Graham 28 Effect of ergotamine injections most likely caused by vasoconstriction of the    
carotid arteries 
1939 Horton 10 First description of histaminic cephalgia 
1940 Alvarez 19 First description of oxygen as a treatment for headache. Good results in 
typical migraine 
1952 Horton 1 First description of oxygen as a treatment method for histaminic cephalgia 
1955 Horton 20 Review paper about oxygen treatment in 1176 patients with histaminic 
cephalgia 
1981 Kudrow 15 First systematic study on oxygen treatment for cluster headache 
Oxygen seemed equally or more effective than ergotamine 
1985 Fogan 44 Crossover study showed that oxygen was more effective than room air 
2009 Cohen 16 Oxygen at 12 litre/minute was proven more effective than room air 
 
 
Hyperbaric oxygen treatment 
Hyperbaric oxygen (HBO) in the treatment of CH has also been tried. Sjaastad mentioned a case report 
by Weiss et al. (1989),45 who described the successful treatment of two attacks in a patient refractory 
to all other treatments. Unfortunately, the timing of the events was poorly described, and the 
possibility of spontaneous recovery, without an influence of HBO, could not be excluded.35  
 Following this case report several studies were conducted to explore the abortive and 
prophylactic effect of HBO in CH. Porta et al. (1991) conducted a crossover study between HBO 
treatment and normobaric oxygen treatment at a flow rate of 7 L/min for 15 min. Eight out of fourteen 
patients were ‘partially refractory’ or ‘totally refractory’ to normobaric oxygen. All fourteen patients 
achieved ‘complete relief’ within a few min after starting HBO treatment.46 
 Di Sabato et al. (1993) conducted a double-blind study comparing HBO with placebo. HBO 
resulted in an interruption of the current attack in six out of seven patients. Of the six patients in which 
HBO resulted in an interruption of the attack, three had no more attacks for a period lasting from 4 to 
6 days, and the other three had no attacks during the entire follow-up period of 2 months. In the 
patients receiving placebo treatment the occurrence of successive attacks remained unmodified.47 
 Pascual et al. (1995) studied the effect of five to twenty sessions of HBO therapy on both the 
duration and frequency of CH attacks in four people with CCH. Two patients improved dramatically 
while on HBO treatment. This positive treatment effect remained for 2 and 31 days, respectively, after 
treatment. One patient noticed only a lower frequency of attacks and one patient noticed no effect at 
all.48 A double-blind placebo crossover study by Nilsson Remahl et al. (2002) described a positive 
effect of both hyperbaric placebo and HBO treatment in six out of sixteen and five out of fourteen 
patients, respectively. The effect was mainly prophylactic and was thought to be caused by the 
hyperbaric condition itself, or by a marked placebo effect.49  
 A Cochrane review (2008) concluded that there is insufficient evidence to establish the effects 
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of HBO as a treatment for an acute CH attack or as prophylaxis.50 Because of high costs and poor 
availability, the use of HBO for the abortive treatment of CH is not advised. 
 
Oxygen and Migraine  
As mentioned above, Alvarez described the successful treatment of migraine with oxygen in 1940.19 
Currently, oxygen treatment for migraine attacks is applied only sporadically. A Cochrane review in 
2008 concluded that there was some evidence that HBO treatment was effective for the termination of 
acute migraine in an unselected population.50 No evidence was found for a prophylactic effect of 
HBO. Given the costs and poor availability of HBO therapy, it was concluded that more research 
should be done on patients unresponsive to standard therapy. Few adequate studies on migraine and 
normobaric oxygen therapy, as conducted by Alvarez, were found. Two small studies comparing 
normobaric oxygen with HBO found normobaric oxygen to be ineffective in the treatment of 
migraine.51, 52 Another study (1999), conducted for treatment of acute migraine headache, compared 
nitrous oxide with 100% oxygen.53 No analgesic effects of oxygen were found in this study in a small 
group (n = 12). However, the flow rate at which oxygen was applied was not provided, which makes 
these results much less valuable. It is not clear where oxygen got lost as a treatment for migraine 
between 1940 (Alvarez) and today. It was not mentioned as a possible treatment method for migraine 
in a large review on the subject in 1985.12 
 In 1961, Horton also described treating vascular headaches other than CH with oxygen. The 
results of this treatment, however, were not reported.14 It may be postulated that oxygen treatment 
might not cover the long duration of a migraine attack. Moreover, the use of acute medication in an 
occasional migraine attack might not cause any problems, but when using it to treat CH attacks, 
potentially occurring multiple times per day, this might give rise to adverse effects. As already 
described by Alvarez, oxygen therefore might be more useful in patients with daily attacks than in 
those with longer and less frequent attacks. An interesting note by Alvarez supporting this idea is that 
in some migraine patients the headache started to recur about an hour after they stopped oxygen 
treatment.19 Furthermore, some of the patients had to continue treatment for an hour or two before the 
headache disappeared, which could of course cause much practical discomfort.  
 
Conclusions 
It seems that oxygen was first used in a period when the vasoconstriction theory of migraine or 
vascular headache reigned. An association with angina pectoris was probably made. Later it turned out 
that the situation was the opposite: in CH there is not vasoconstriction but vasodilatation, and the 
oxygen probably does not control hypoxia. Moreover, oxygen is not effective in vasoconstriction 
(without clear hypoxaemia) and in the case of angina pectoris might even cause more vasoconstriction. 
Even though it was based on what later appeared to be wrong assumptions, an effective treatment was 
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Most cluster headache patients respond to oxygen therapy, but approximately 20% does not. The aim 
of the present study was to assess which factors differ between cluster headache patients who respond 
to oxygen therapy and those who do not. We included patients from the headache clinic of Atrium 
Medical Centre Heerlen (n = 53) and patients who responded to a cluster headache web-site (n = 62). 
Participants completed a questionnaire with questions on cluster headache and factors that might be of 
significance with respect to the response to oxygen. Non-responders had less often smoked in the past 
(p = 0.014), had longer cluster headache attacks (p = 0.049), and more often reported interictal 
headache (p = 0.02) than responders. Logistic regression analysis showed these variables to be 
independent risk factors for not responding to oxygen and a clinical prediction model is provided. The 
area under the receiver operating characteristic curve was 0.75.  We conclude that cluster headache 
patients who smoked in the past, had shorter attacks and were pain-free interictally respond best to 


























The clinical syndrome of cluster headache (CH) is a well defined type of primary headache for which 
the International Headache Society has composed a set of diagnostic criteria in the ‘Second Edition of 
International Classification of Headache Disorders (ICHD-II)’.1 One of the first successful acute 
treatments for CH was oxygen. In his 1956 publication on ‘histaminic cephalgia’, Horton stated that 
immediate use of 100% oxygen will alleviate a mild attack considerably.2 Stimulated by a letter to the 
editor,3 Kudrow took an interest in oxygen treatment for CH and conducted a trial in 1981.4 Until 
recently, inhalation of 100% oxygen via a non-rebreathing mask at a flow rate of at least 7 litre/minute 
(L/min) for 20 minutes (min) was still recommended as one of the acute treatments.5 However, 18-
25% of patients do not experience successful or significant headache relief with 100% oxygen at a 
flow rate of 7-8 L/min given at pain onset for 15 min.4, 6 Moreover, several disadvantages are 
associated with oxygen use, including the inconvenient equipment, the fire hazard (especially since 
two thirds to almost 80% of CH patients currently smoke 7) and the risk of psychological dependence 
with fear of leaving the home.8 Therefore, it may be useful to know in advance which patients are 
unlikely to respond. Although some data can be derived from a few studies,4, 9, 10, 11 resulting in a 
variety of factors influencing the chance of an unfavourable response, this question has not been 
studied adequately. 
 In the present study our objective is to provide a clinical predictive model for oxygen response 
in CH patients. Which patient characteristics determine clinical response to oxygen in the acute 
treatment of CH?  
 
Methods 
We recruited CH patients from the headache clinic of the Atrium Medical Centre Heerlen (Atrium 




CH patients from the headache clinic of the Atrium MC were contacted to inform them about the 
study and to ask whether they were interested in participation. We also included patients who 
responded to a call for study participants on a CH web-site. 
 Of the 155 persons to whom questionnaires were sent 140 responded. The questionnaires were 
checked to verify the diagnosis of CH according to the ICHD-II criteria for CH.1 Patients were 
included if they had used oxygen for the first time less than 10 years ago and if they fulfilled the 
ICHD-II criteria for CH. The only criterion of the ICHD-II criteria the participants did not have to 
fulfil was a duration of the attack to be maximum of 3 hours (h). Van Vliet et al. stated that the upper 
limit of a CH attack of 3 h may be too strict.12 Therefore we also included patients who exceeded the 
upper limit of 3 h if the remaining symptoms were typical for CH. The upper limit of the maximal 
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duration of the attacks was 24 h to make a clear difference with hemicrania continua. Exclusion 
criteria were uncertainty about the diagnosis, the use of oxygen less than four times and an age under 
18 years.  
 We included 115 patients. Written or verbal informed consent was obtained from all 
participating patients. The Local Ethics Committee of the Atrium MC approved this study. The study 
was registered in the Dutch Trial Register (NTR 1539). The selection of patients is shown in Figure 1.  
 
 
Figure 1.  Patient flow chart 
a Patients were excluded because they did not meet the ICHD-II criteria or they had not used oxygen at least 
three times 
Cluster headache patients Atrium 
Medical Centre Heerlen with oxygen 
therapy started after 1998 (n = 84) 
20 patients excluded because of absent 
address or phone number 
64 patients approached to participate,  
63 agreed to answer a questionnaire  
155 questionnaires sent  
140 questionnaires returned 
Responders to the cluster headache  
web-site (n = 92) 
 
 
25 patients excluded a 
 
 




The participants completed a questionnaire consisting of items on patient and headache characteristics 
such as age, co-morbidities, smoking habits, alcohol use, duration and frequency of the attacks without 
medication effects and autonomic features. We especially paid attention to treatment and treatment 
response. We specifically asked to what extent the pain was relieved by using oxygen (with multiple 
choice answers: complete/much/little/none). If there was any doubt about the answers we contacted 
the participant by phone or e-mail to elucidate the answers. Moreover, we studied the medical files of 
the participants treated in the Atrium MC to see if the answers were matching. We contacted patients 
by phone to elucidate any inconsistencies.   
 The response to oxygen therapy was classified into five distinct groups as shown in Table 1. 
Clear responders were defined as patients who felt a reduction of pain on at least three occasions by at 
least 50% (complete or much relief) within 15 min after the start of oxygen inhalation. In the initial 
analysis we compared the clear responders with the clear non-responders plus the moderate responders 
(group A versus group B + C). We omitted group D from the initial analysis as the reaction to oxygen 
could have been mistaken for the natural course of the CH attack. Group E was left out because we 
believe this effect is not really beneficial. We also performed sub-analyses comparing the clear 
responders with the clear non-responders (group A versus group B), and comparing group A + E 
versus group B + C. 
 
 
Table 1.  Classification responders to oxygen 
Group Definition n  
A Clear responders: A reduction of the pain on at least three occasions by at least 50% (complete or much 
relief) within 15 min after the start of oxygen inhalation 
70 
B Clear non-responders: No or little effect of oxygen inhalation 19 
C Moderate responders: Some relief of oxygen but not fulfilling definition A 12 
D Responders to oxygen but reduction of the pain after more than 15 min  8 
E Responders fulfilling definition A,  except for an increase in attack frequency after using oxygen 6 
      
 
Statistics 
We used descriptive statistics to summarise our variables including mean, standard deviation (SD), 
median, inter quartile ranges (IQR), frequencies and percentages. The percentages of dichotomous 
variables were compared using Chi-square tests. In case of low cell count (< 5 observations) we used 
Fisher’s exact test. Non-normally distributes variables were analysed using the Mann-Whitney U test. 
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The continuous and normally distributed variables were compared using the Independent t test. All 
tests were two-tailed. The variables that showed significance in the single variable analysis were 
evaluated in the logistic regression analysis. We evaluated the predictive ability by determining the 
area under the receiver operating characteristic (ROC) curve. All analyses were performed using 
‘SPSS for Windows’ version 16. The threshold of significance is p < 0.05 in all analyses.   
 
Results 
A total of 115 patients were included, of whom eighty-seven men (75.7%), giving a male-to-female 
ratio of 3:1. Mean current age was 47.9 years (SD 12.0) and mean age at onset of the CH symptoms 
was 37.0 (SD 14.4). The majority of the participants had episodic cluster headache (ECH) (73.4%). 
Eighty-nine of the 115 patients remembered the past oxygen flow rate, with a mean of 7.6 L/min (total 
range 2-15 L/min). Seventy-eight of these eighty-nine patients used a flow rate of more than 6 L/min, 
making the use of an oxygen face mask necessary. 
 
Baseline characteristics 
Only a few patient characteristics differ between the patients recruited from the Atrium MC and the 
patients recruited via the web-site (Table 2). One easily explicable difference is the number of 
diagnoses made by a neurologist, obviously because of the way the participants were recruited. All 
patients recruited from the headache clinic of Atrium MC were diagnosed by a neurologist, whereas 
only 54.1% of the patients recruited via the web-site were diagnosed by a neurologist. The remaining 
twenty-nine patients were diagnosed by a general practitioner or another physician. Two less obvious 
differences are the smoking habits and the use of alcohol. In the Atrium MC cohort significantly more 
patients currently smoke. In the web-site cohort significantly more patients are currently using alcohol 
and used alcohol in the past.  
 Because of the retrospective character of this study, we split the group of patients into one 
cohort with the use of oxygen for the first time less than 5 years ago and a cohort using oxygen for the 
first time 5-10 years ago and compared these cohorts. The rationale for this division was that we 
assumed a smaller risk of recall bias when the cohorts did not differ significantly. The only significant 
difference was the appearance of interictal headache, with the most recent cohort experiencing more 
interictal headache (58.3%  versus 81.4%).  
  Based on these results we believe it was acceptable to lump together the cohorts Atrium MC, 
web-site, cohort 1999-2003 and cohort 2004-2009 and split the total group again in responders and 







Table 2.  Comparison characteristics cohort Atrium Medical Centre Heerlen to cohort web-site 
 a Chi-square test, continuity correction, b Independent samples t test, c Mann-Whitney U test, d Pearson Chi-




Patient and headache characteristics of the responders (group A) and non-responders (group B + C) 
are shown in Tables 3 and 4. A significant difference with respect to patient characteristics between 
responders and non-responders is smoking in the past. There are more smokers in the responders 
group compared to the non-responders. The percentages of consumers of alcohol do not differ, 
however, there is a difference in the number of alcoholic drinks consumed in responders who use 
alcohol compared with non-responders who use alcohol. This difference is also not statistically 
significant.  
  









 Cohort Atrium MC  
(n = 53) 
Cohort web-site 
(n = 62) 
Significance 
(p value) 
Men, n (%) 37 (69.8) 50 (80.4) 0.26 a 
Age at onset cluster headache, mean (SD) 37.8 (13.5) 36.3 (15.1) 0.57 b 
Diagnosis by neurologist, n (%) 53 (100.0) 33 (54.1) <  0.001 a 
Current smoking,  n (%) 







Current consumers of alcohol, n (%)  







Average attack duration (min) 80.00 (38-120) 90.00 (45-158) 0.44 c 
No interictal headache, n (%) 35 (66.0) 40 (65.6) 1.00 a 
Episodic cluster headache, n (%) 35 (66.0) 50 (80.6) 0.12 a 
Age at start oxygen therapy,  median (IQR) 42.00 (37-52) 47.00 (33-52) 0.78 b 
Years between onset of cluster headache and start 
of oxygen therapy,  median (IQR) 
3.00 (0.25-8) 5.00 (2-12) 0.09 c 
Responders, n (%) 33  (62.3) 37 (59.7) 0.91 d 
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Table 3.  Comparison patient characteristics responders and non-responders  
  a Chi-square test, continuity correction, b Independent samples t test, c Mann-Whitney U test, d Fisher’s exact 



















(n = 70) 
Non-responders 
(n = 31) 
Significance 
(p value) 
Men, n (%) 50 (71.4) 24 (77.4) 0.70 a 
Current age, mean (SD) 
    Number of participants currently older than 49, n (%) 
Age at onset CH, mean (SD) 













Diagnosis by neurologist, n (%) 49 (71.0) 25 (80.6) 0.44 a 
Current BMI, median (IQR) 







Current smoking,  n (%) 
Past smoking,  n (%) 










Current consumers of alcohol, n (%)  49 (70.0) 18 (58.1) 0.35 a 
Consumers of alcohol in the past, n (%)  53 (79.1) 21 (72.4) 0.65 a 
History of sleep apnoea, n (%) 
History of other headache disorder(s), n (%) 
History of  trauma capitis, n (%)   
5 (7.1) 
20 ( 28.6) 







Positive family history, n (%) 4 (5.7) 3 (9.7) 0.67 d 
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Table 4.  Comparison headache characteristics responders and non-responders  
a Chi-square test, continuity correction, b Independent samples t test, c Mann-Whitney U test, d Fisher’s exact 
probability test two-sided,  e Pearson Chi-square 
 
 
The attacks of CH last longer in non-responders, with a significant difference in the maximum attack 
duration. In Table 4 and Figure 2 the attack duration without medication effects is shown. In 
responders 18.6% and in non-responders 45.2% exceeded the upper limit of 180 min in the attacks 
which the patients themselves experienced as extremely long. In average attacks only 16.8 % exceeded 
this limit.  
 









(n = 70) 
Non-responders 
(n = 31) 
Significance 
(p value) 
Attack duration without medication (min) 
   Average duration, median (IQR) 
   Minimal duration, median (IQR) 
   Maximal duration, median (IQR) 
















No interictal headache, n (%) 52 (75.4) 15 (48.4) 0.02 a 
Episodic cluster headache, n (%) 54 (77.1) 23 (74.2) 0.95 a 
Autonomic features 
   Conjunctival injection, n (%)  
   Lacrimation, n (%) 
   Nasal congestion, n (%) 
   Rhinorrhea, n (%) 
   Ptosis, n (%) 























   Nausea/vomiting, n (%) 
   Photo-/phonophobia, n (%) 



























Figure 2.  Attack duration in minutes (median) 
The coloured boxes represent the attack duration in 50% of the participants, the vertical line is the near total 
spreading. The dots and asterisks are the extreme values. We omitted the three most extreme measures from this 
figure to enhance the clarity. Two of the omitted values were maximal durations of the attacks in responders 
(960 and 1,440 min), one was a maximal duration of the attack in a non-responder (1,440 min)  
 
 
Another significant difference is the amount of participants who reported to experience interictal pain. 
Of all responders, 75.4% does not experience headache between the CH attacks. Only 48.4% of the 
non-responders are pain free interictally. Non-responders more often feel nauseous or restless, but this 
difference did not reach statistical significance.  
 We also asked ECH sufferers how long a cluster period lasts on average, minimally and 
maximally. In contrast with the attack duration, cluster periods lasted longer in responders compared 
to non-responders. This difference is not statistically significant. No differences were found in attack 
frequency, duration of remission period or frequency of cluster periods. In chronic cluster headache 
(CCH) patients there was no difference in cluster attack frequency in responders compared to non-
responders. 
 Other than the patient and headache characteristics, the questionnaire also contained items on 
the oxygen, other acute and prophylactic treatments as described above; this is summarized in Table 5. 
Responders had a higher age when starting with oxygen (p = 0.18). There was no difference in the 
number of years between the onset of the CH symptoms and the start of oxygen therapy; the patients 
reported a median of 4 years in responders and a median of 3 years in non-responders. Most patients 
started oxygen therapy immediately after the onset of an attack. Non-responders to oxygen reported 
significantly more relief from triptan use. Responders more often use verapamil (84.1 % compared to 
66.7 % in non-responders, p = 0.09). Other prophylactic treatments which were used were prednisone 
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(n = 12), methysergide (n = 6), lithium (n = 3) and ergotamine (n = 1). Groups using these other 
prophylactic treatments were too small for statistical analysis.  
 
 
Table 5. Comparison cluster headache therapy responders and non-responders 
a Chi-square test, continuity correction, b Independent samples t test, c Mann-Whitney U test, d Fisher’s exact 




Next to the initial analysis described above, we made a sub-analysis. In sub-analysis part 1 we 
compared group A (n = 70) with group B (n = 19), so the clear responders versus the clear non-
responders. In sub-analysis part 2 we compared group A + E (n = 76) with group B + C  (n = 31), so 
the clear responders plus the patients with an increase in attack frequency using oxygen versus the 
clear non-responders plus the moderate responders. In sub-analysis part 1 the only two variables which 
reached significance are shown in Table 6. The difference in interictal pain was also seen in the initial 
analysis. Significantly more non-responders reported nausea and vomiting (50% compared to 20% of 
the responders), a difference we did not find in our initial analysis.  
 








(n = 70) 
Non-responders 
(n = 31) 
Significance 
(p value) 
Age at start oxygen therapy,  median (IQR) 45.0 (12.5) 41.6 (9.5) 0.18 a 
Years between onset of cluster headache symptoms          
and start of oxygen therapy,  median (IQR) 
4.00 (1-9) 3.00 (0-12) 0.74 b 
Oxygen dose > 10 L/min, n (%) 3 (5.3) 3 (11.1) 0.38 d 
Minutes until start of oxygen therapy after onset of  
cluster headache symptoms, median (IQR) 
1.00 (1-5) 1.00 (1-5) 0.77 b 
Triptan users, n (%) 
   Good response to triptans (much or total 







Verapamil users, n (%) 
   Good response to verapamil (much or total  










Table 6.  Significant differences in sub-analysis part 1  
a Non-responders here consisting of only clear non-responders (group B), leaving group C out of the analysis, 
 b Chi-square test, continuity correction, c Fisher’s exact probability test two-sided 
 
 
When comparing group A + E versus group B + C in sub-analysis part 2 we did not find any other 
significant values or differences than we found in our initial analysis.  
 
Multivariate analysis 
Three variables  that were significant in the initial univariate analysis are smoking in the past, interictal 
headache and maximal duration of the CH attack (especially attacks longer than 180 min). We 
performed logistic regression analysis to test if these variables are independent risk factors for 
responding or non-responding to oxygen.   
 Table 7 shows that all the variables contribute significantly to this model, even if we adjust for 
the other variables in the model, so these variables are independent risk factors for responding or non-
responding to oxygen. The odds ratios are also presented in the table. The presence of every one of the 
three variables, smoking in the past, no interictal headache and a maximal attack duration of 180 min 
or less, gives patients approximately a three to four times higher odds of being a responder than being 
a non-responder.  
 
 
Table 7.  Multivariable predictors for oxygen responders in cluster headache patients  
 
       
We evaluated the predictive ability of our set of variables for responding to oxygen by determining the 
area under the ROC curve, shown in Figure 3. The area under the ROC curve was 0.75, indicating a 
fair discrimination of the final model.                        
 
       
 Responders    
(n = 70) 
Non-respondersa    
(n = 19) 
Significance 
(p value) 
No interictal headache, n (%) 52 (75.4) 8 (42.1) 0.01 b 
Nausea/vomiting, n (%) 14 (20.0) 9 (50.0) 0.02 c 
 Odds ratio 95% CI Significance 
Smoking in the past,  n (%) 3.99 1.24-12.80 0.020 
No interictal headache, n (%) 3.26 1.24-8.57 0.016 















Figure 3.  Receiver operating characteristic curve 
Area under ROC Curve is 0.75 
 
 
Finally, we studied the relationship between interictal pain and severity of CH. We found that 
interictal pain is an independent predictor of oxygen response instead of being the consequence of  the 
severity of CH. Biserial correlation coefficients were assessed. The correlation coefficient of interictal 
pain and attack frequency was 0.08 at a significance level of  0.95; the correlation coefficient of 
interictal pain and severity of  a CH attack was 0.04 at a significance level of  0.99. Therefore, no 
correlation between interictal pain and severity of CH could be established.   
 
Discussion 
In this study of 115 CH patients who used oxygen, we identified three predictors of poor oxygen 
response, notably no smoking in the past, interictal headache, and a maximal attack duration of more 
than 180 min. The presence of each variable gives patients approximately a three to four times higher 
odds of being a non-responder than being a responder. 
 
Currently, it is not fully known which characteristics predict response to oxygen in CH patients. Table 
8 shows factors that have been associated with an unfavourable response in previous studies.4, 9, 10, 11 In 
a recent study, restlessness (OR 0.09, p = 0.019) and nausea/vomiting (OR 0.41, p = 0.029) were 
identified as negative predictors of oxygen response. It was hypothesized that the oxygen face mask is 
not tolerated in some restless patients.10 Restlessness and nausea/vomiting during a CH attack were 
reported by 67.9% and 27.8 % of the patients, respectively.9 One study found women having 
significantly more often nausea (62.5% versus 43.5%, p = 0.09) and vomiting (46.9% versus 17.4%, p 
= 0.003) than men. In this study, an oxygen treatment response of only 59.1% in women was found 
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compared to 87% in men. This difference is significant (p = 0.01).11 Other studies did not identify 
gender as a predictor of response to oxygen therapy.4, 9, 10   
 Seventy-five percent of women versus 61% of men reported a smoking history.13 Current 
smoking was not identified as a statistically significant negative predictor of oxygen response.10 There 
were statistically significantly more men than women smoking currently.9  
 One trial found significantly better effects of oxygen inhalation in ECH patients under 50 
years of age compared to CCH patients over 49 years of age (‘treatment successes’ of 92.9% and 
57.1% respectively, p < 0.05). There was no significant response difference between patients under 50 
years of age and patients over 49 years of age, neither was there between ECH and CCH patients of all 
ages.4 Likewise, a more recent study did not identify age and ECH (%) as statistically significant 
negative predictors of oxygen response.10  
 One author noted that in some unresponsive cases acute CH attack treatment had been started 
late.4 Another study group stated it was less obvious whether the timing of acute treatment influences 
treatment success.10  
 
 
Table 8.  Factors associated with an unfavourable response to oxygen in cluster headache attacks from 
previous studies.4, 9, 10, 11 
Factors p value 
Restlessness 10 0.019 
Chronic cluster headache and > 49 years of age 4  < 0.05 
Females 4, 9, 10, 11 0.01 – ‘no significance’ 
Nausea and vomiting 10, 11 0.029 
 
      
Smoking as a predicting factor for oxygen response was mentioned in two previous studies. We also 
could not identify current smoking as a statistically significant negative predictor of oxygen response. 
However, in contrast to the previous finding of women responding less to standard oxygen therapy and 
having a higher past smoking percentage than men,13 we clearly found absence of past smoking to be a 
predictor of poor oxygen response. It is difficult to explain this finding. Smaller changes in cerebral 
gray matter blood flow during inhalation of 100% oxygen in chronic cigarette smokers compared to 
non-smokers suggest decreases in vasoconstrictor capacitance among smokers. In their discussion, the 
authors also mention that chronic cigarette smoking disrupts the normal balance between vasodilator 
prostacyclin and vasoconstrictor thromboxane A2 in favour of vasoconstriction.14 However, increases 
in middle cerebral artery flow velocity and a reduced cerebrovascular resistance caused by 
(current/active) smoking have been found in two other studies.15, 16 In one of these, identical decreases 
in middle cerebral artery flow velocity during hyperoxia in smokers and non-smokers were 
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demonstrated.16 We conclude that the (although conflicting) results at least do not endorse an 
excessive cerebral blood flow reduction in smokers in response to hyperoxia, as suggested by our 
results.    
 In the present study, significantly more responders do not experience interictal headache. 
However, when comparing the 1999-2003 cohort to the 2004-2008 cohort, we found patients reporting 
significantly less interictal headache and having a slightly (not significantly) higher responder 
percentage (69.8%, compared to 55.6%) in the 1999-2003 cohort. Therefore, recall bias could be 
involved..Another explanation could be that a number of patients who experience interictal headache 
are misdiagnosed hemicrania continua patients with fluctuations in headache intensity, and therefore 
respond less to oxygen inhalation. However, approximately three-quarters of the responders and non-
responders have ECH. In non-responding ECH patients, the duration of the cluster period was 1.00-
2.63 months. Therefore, besides an unknown reaction to indomethacin, the diagnosis of hemicrania 
continua is unlikely because of a headache duration of less than 3 months.1 Furthermore, the majority, 
if not all, patients are able to delineate attacks from interictal pain, as experienced in clinical practice. 
Finally, it could be the effect of oxygen itself to stop the CH attack and subsequently prevent the 
occurrence of interictal headache possibly following an ongoing CH attack. We found this effect of 
oxygen to be independent of the severity of CH, measured by attack frequency and severity of a CH 
attack.   
 We included patients who exceeded the upper limit of attack duration of 3 h if the remaining 
symptoms were typical for CH. We found 26.7 % of the responding and non-responding patients 
reporting their longest attacks lasting more than 180 min. Only 16.8% reported their attacks of average 
duration lasting more than 180 min. In one study 12.7 % of  CH patients exceeding the average 3 h 
limit was found.12 In another, only 7.3% of the patients had a CH attack duration of more than 180 
min.9 It is remarkable that two of three patients with maximal attack durations exceeding 8 h were 
responders. These three patients reported an average attack to last only 150-180 min. Therefore, 
oxygen may prevent CH attacks to last extremely long, but variance in effect between attacks in one 
patient is possible. Because of exclusion in the univariate analysis of patients experiencing an increase 
in attack frequency using oxygen, the variance cannot be attributed to rebound CH. Logistic regression 
analysis showed a maximal attack duration of more than 180 min to be a predictor of poor oxygen 
response, independent of the occurrence of interictal headache. .  
 In summary, we conclude that the more typical CH patients, i.e. (past) smokers, having attacks 
lasting less than 180 min without interictal headache, respond best to oxygen inhalation.  
 
An area under the ROC curve of 0.75 indicates that, besides our model, other factors are involved as 
well. Alternative factors to predict poor oxygen response found in previous studies were restlessness, 
nausea/vomiting, female gender and CCH in combination with an age of more than 49 years.4, 9, 10, 11 
Although we also found more non-responders reporting restlessness and nausea/vomiting, this 
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difference did not reach significance in the initial univariate analysis. But when comparing the clear 
responders to the clear non-responders in the first part of the univariate sub-analysis, we also found 
significantly more non-responders reporting nausea and/or vomiting. Stimulation of certain areas of 
the hypothalamus can cause vomiting by unknown but probably direct neural connections with the 
vomiting centre located bilaterally in the medulla. Nausea is caused by excitation of certain portions of 
the vomiting centre or a closely associated area of the medulla.17 The exact triggering site for nausea 
and vomiting in CH attacks is unknown. We were unable to confirm gender as a predictor of oxygen 
response.  
 Unfortunately, we were unable to include enough patients to compare ECH patients under 50 
years of age to CCH patients over 49 years of age, as was done in a previous study.4 In our study, 
responders to oxygen seem to be slightly older (p = 0.11); the percentages of ECH patients in the 
responder and non-responder group were almost equal.   
 In one study it was noted that in some cases unresponsive to oxygen (or ergotamine), the acute 
CH attack treatment had been started late.4 In our study most patients started oxygen use immediately 
after onset of the attack, so we cannot judge the influence of delay on the effect. 
 
We found that the majority of the patients used oxygen at a flow rate of approximately 7 L/min, using 
an oxygen face mask. This is consistent with the Dutch guidelines for CH that have advised (since 
1997) using 6-7 L/min using an oxygen face mask.18 It was based on trials (of Kudrow 4 and Fogan 19), 
showing successful relief using this flow rate. Suggestions to use higher flow rates came in 2004, 
when Rozen reported three patients in whom a flow rate of 14-15 L/min was successful after initial 
failure with 7-10 L/min.13 The suggestion was confirmed on a larger scale by a recent trial in which a 
flow rate of 12 L/min was used.20  
 
A difference we found in the present study is that non-responders to oxygen report significantly more 
relief from triptan use. Because of the retrospective character of this study, patients may have used 
oxygen and triptans together, so one may assume that the effect of triptans is less clear in responders. 
Moreover, the placebo effect of triptans, which is known to be large in headache patients,21, 22could be 
more manifest in non-responders to oxygen.  
 Furthermore, we found oxygen-responders using verapamil more often (p = 0.09). Because of 
the retrospective character, time relationship between start of oxygen treatment and start of 
prophylactic verapamil treatment could not be adequately studied in all patients. However, it may be 
assumed that the majority of the patients in this study started verapamil and oxygen simultaneously, as 
such has been described in the Dutch guidelines for CH since 1997.18 Like clinical practice in migraine 
patients, this finding suggests that CH patients who use prophylactic medication are more responsive 
to acute therapies. However, a pilot study on topiramate prophylaxis and triptan response in migraine 




An interesting finding headache specialists sometimes observe in daily practice was reported by six of 
our participants, who responded well to oxygen but noticed an increase in attack frequency when using 
oxygen to abort an attack. In some of these patients oxygen seemed not to abort the attack but rather to 
postpone it instead. Twenty-five percent of the patients in a previous trial experienced rebound cluster 
attacks.4 The EFNS guideline correctly states oxygen use should be restricted in cases in which 
oxygen delays rather than aborts the attack.24 More research on this subject is obviously necessary.  
 
One of the limitations of the present study is the retrospective character with a risk of recall bias. We 
tried to reduce this risk by comparing patients who used oxygen for the first time less than 5 years ago 
with patients who used oxygen for the first time 5 to 10 years ago. Another limitation is the use of 
questionnaires completed by the patients themselves. However, CH is a revolting pain which patients 
seem to remember accurately. Moreover, we compared given answers to medical files and contacted 
patients to elucidate unclear answers or inconsistencies. Finally, we compared the baseline 
characteristics of our study population to those previously studied and these appeared to be consistent.9 
Therefore, we believe that our data represent accurate findings.  
 Obviously, a larger study population would have allowed us to analyse all our near significant 
variables in the logistic regression analysis.  
 
Conclusion 
No smoking history, interictal headache, and a maximal attack duration of more than 180 min were 
identified as predictors of a poor oxygen response. The presence of each variable gives patients 
approximately a three to four times higher odds of being a non-responder than being a responder 
Although in daily practice oxygen should not be withheld if unfavourable factors are present, the 
information could be discussed with the individual patient when an acute CH treatment is prescribed. 
To analyse all our near significant variables and abort the risk of recall bias, a more refined 
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Response to 100% oxygen as acute treatment for cluster headache is relative low considering certain 
subgroups or predictors. The primary purpose of the present study was to find prospectively which 
factors differ between responders and non-responders to oxygen therapy. The second goal was to find 
whether any of these differences would clarify the mechanism of pain reduction by oxygen and cluster 
headache pathophysiology. 
 Patients diagnosed with cluster headache according to the ICHD-II criteria, who started on 
oxygen therapy (n = 193), were recruited from 51 outpatient clinics and via patient web-sites in The 
Netherlands. Patients had to return two questionnaires around the start of oxygen therapy (n = 120). 
Eventually, 94 patients were included.  
 Clear non- plus moderate responders had ever used pizotifen more often (p = 0.03). Clear non-
responders more often had photophobia or phonophobia during cluster headache attacks (p = 0.047) 
and more often had used triptans in the same active phase as the phase in which they had used oxygen 
for the first time (p = 0.02). Using correction for multiple testing, we could only confirm a statistical 
significant difference in triptan use.  
 We were unable to locate the level of action of oxygen in the thalamus and cortex or confirm 
the sites of its action presently known, solely based on current knowledge of photophobia circuits. 
However, we conclude that particularly the higher frequency of photophobia or phonophobia in clear 
non-responders deserves further study to understand the mechanism of pain reduction by oxygen and 





















Cluster headache (CH) is one of the trigeminal autonomic cephalalgias (TACs). Attacks are 
characterised by severe unilateral pain, mostly located in the first trigeminal division and lasting 15-
180 minutes (min), associated with at least one ipsilateral autonomic feature and/or restlessness or 
agitation.1 Inhalation of 100% oxygen via a non-rebreathing mask with a flow rate of at least 7 
litre/minute (L/min) is one of the acute attack treatments.2 Successful relief inhaling normobaric 100% 
oxygen, administered through a facial mask at a flow rate of respectively 7, 6, and 12 L/min for 15 
min was proven in three trials.3, 4, 5 Percentages of successful treatment were 75% and 82% of CH 
patients using 7 L/min 3 and percentage of pain freedom at 15 min was 78% of oxygen treated CH 
attacks using 12 L/min, the latter being significantly better than high-flow air placebo (p < 0.001).5 
Response to 100% oxygen is more variable when other study types and/or subgroups or predictors are 
considered.3, 6, 7, 8, 9 Most extreme oxygen responses at the lower end were found in non-placebo 
controlled studies in the subgroup of chronic cluster headache (CCH) patients aged older than 49 years 
(percentage of successful treatment of 57%) 3 and for the predictor restlessness (Odds ratio (OR) for 
oxygen response of 0.10).8 Lower oxygen responses can be of clinical significance, because oxygen 
use has several disadvantages, such as a fire hazard and rebound CH, as we demonstrated in a recent 
study.10 To provide a clinical prediction model for oxygen response in CH patients, we performed a 
retrospective cross-sectional correlation study. Variables predicting non-response to oxygen were: no 
smoking history (OR 3.99), interictal headache (OR 3.26) and a maximal attack duration of more than 
180 min (OR 3.84). Particularly in patients with one or more of these characteristics, this information 
could be discussed before oxygen prescription.11    
 At present, little is known about CH pathophysiology and the mechanism of action of oxygen. 
A dysfunction in the interactions between brain areas of the pain matrix might produce a permissive 
state, resulting in disinhibition of the hypothalamo-trigeminal pathway and thus a pain attack. 
Ipsilateral parasympathetic symptoms could be caused either by a direct hypothalamic effect or by 
peripheral stimulation of parasympathetic efferents of the superior salivatory nucleus (SSN).12 Oxygen 
is suspected to produce cerebral vasoconstriction. It can produce cerebral vasoconstriction centrally at 
brain stem level via inhibitory effects on the cranial parasympathetic vasodilator pathway.13 
Furthermore, oxygen can produce cerebral vasoconstriction peripherally at a vascular level via direct 
potentiation of the constrictive effect of catecholamines and 5-hydroxytryptamine (5-HT) on muscle or 
the indirect Pasteur effect,14 or via decrease in the trigeminal released calcitonin gene-related peptide 
(CGRP) concentration.15 However, oxygen induced vasoconstriction is probably not the only factor 
responsible for pain relief.16 Another vasoactive pathophysiological mechanism, in a more or lesser 
way related to vasoconstriction, is the anti-inflammatory role hyperoxia has in neurogenic 
inflammation.17 The variables predicting non-response to oxygen in our retrospective study did not 
learn us more about mechanisms of action of oxygen and, therefore, CH pathophysiology.11    
52 
 
 In order to analyse near significant variables of the retrospective cross-sectional correlation 
study 11 and to abort the risk of recall bias, we have studied the factors which differ between 
responders and non-responders to oxygen therapy in a prospective study design. The second goal of 
this prospective study was to find whether any of these differences would clarify the mechanism of 




We recruited CH patients from 51 outpatient clinics and via advertisements placed on two patient 
web-sites in The Netherlands. Patients were recruited between October 2009 and February 2013. 
 
Study population 
Patients diagnosed with CH according to the ICHD-II criteria 1 (except for the criteria of a maximum 
attack duration of 180 min if untreated 18 and a maximal attack frequency of eight per day (if the 
average attack frequency was eight or less per day)), who started on oxygen therapy, were included. 
Oxygen and its preferred flow rate was prescribed by the patient’s neurologist. Exclusion criteria were: 
age under 18 years, uncertainty about the diagnosis, previous use of oxygen therapy as attack 
treatment for headache and present use of oxygen therapy in less than three CH attacks. The study 
used two questionnaires. The first questionnaire contained questions to verify the ICHD-II diagnosis 
of CH. The combined first and second questionnaires contained questions asking about exclusion 
criteria. All neurologists and neurology registrars in The Netherlands were informed by letters and an 
e-mail about the inclusion criteria and two of the exclusion criteria (age under 18 years and previous 
use of oxygen therapy as attack treatment for headache).    
            
Study procedure 
Following study application, the first questionnaire was sent to the patient. This first questionnaire 
contained questions about smoking, alcohol consumption, other medical diagnoses, family history, 
medication use, CH characteristics and the influence of CH on daily activities. The second 
questionnaire was sent to the patient 1 month after the first questionnaire. This second questionnaire 
contained different questions about oxygen use, effects of oxygen use and medication use. In case 
questionnaires were not returned by the patient, they were sent to the patient again with monthly 
intervals, up to a maximum of three times for the first questionnaire (i.e. 2 months after the first 
sending). If there was any doubt about answers, inconsistency in answers or an unanswered question, 
the patient was contacted by phone or e-mail for elucidation.     
 To enable a comparison with our retrospective cross-sectional correlation study,11 response to 
oxygen was classified in the same five groups, as shown in Table 1. Clear oxygen responders were 
defined as patients, who have experienced a pain reduction of at least 50% within 15 min after the start 
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of oxygen inhalation in at least three CH attacks. In the initial analysis we compared the group of clear 
responders (group A) with the combined group of clear non-responders (group B) and moderate 
responders (group C). In the sub-analysis we compared the group of clear responders (group A) with 
the group of clear non-responders (group B). In both analyses we left the groups oxygen responders 
with response after more than 15 min (group D) and with an increase in attack frequency (group E) out 
of the comparison, because the oxygen responses in both groups are not considered beneficial and 
because there is no clear distinction with the natural course of a CH attack in group D. Furthermore, 
we did not perform a sub-analysis comparing the combined group of the clear responders (group A) 
and oxygen responders with an increase in attack frequency (group E) with the combined group of 
clear non-responders (group B) and moderate responders (group C), because this sub-analysis revealed 
no new significant factors in our retrospective cross-sectional correlation study.11        
 
 
Table 1. Classification of response to oxygen 
Group Name Definition n 
A Clear responders 
 
Pain reduction of at least 50% within 15 min after the 
start of oxygen inhalation (or within 20 min after the start 




B Clear non-responders Little or no effect of oxygen inhalation  19 
C Moderate responders Some relief of oxygen, but not fulfilling definition A, D 
and E 
12 
D Late responders Pain reduction of at least 50%, more than 15 min after 
the start of oxygen inhalation (or at least 50% pain 
reduction within 20 min after the start of at least 16 min 
of oxygen inhalation) 
18 
(4) a 
E Patients with tendency to 
rebound cluster headache 
Pain reduction of at least 50% within 15-20 min after the 
start of oxygen inhalation with an increase in attack 
frequency following oxygen use 
4 
a Values in brackets are the numbers of patients fulfilling the definitions in brackets. These numbers are included 




To summarize values of continuous variables we used means and medians as measures for central 
tendency and standard deviations (SD) and interquartile ranges (IQR) as measures of dispersion 
respectively. To summarize values of categorical variables we used sums (n) and percentages (%).    
To test whether the distribution of continuous variables was normal we used the Kolmogorov-Smirnov 
test in combination with the Q-Q Plot. Values of continuous and normally distributed variables were 
compared using the Independent samples t test. Values of continuous and non-normally distributed 
variables were compared using the Mann-Whitney U Test. Sums and percentages of the (dichotomous) 
categorical variables were compared using the Fisher’s exact test in case of at least one observed 
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and/or expected cell count of five or less and the Chi-square test in case of all cell counts of more than 
five. All tests were two-tailed. The threshold for significance was p < 0.05. In a post-hoc analysis we 
used the Bonferroni correction with a threshold for significance calculated by the formula p < 
(0.05/number of related variables). The number of related variables was set at four for variables 
concerning prophylactic medication, two for variables concerning acute medication and three for 
variables concerning photophobia and/or phonophobia. All analysis were performed using ‘IBM SPSS 
Statistics 21 for Windows’.     
 
Ethics 
The study was approved by the local ethics committee. Written or verbal informed consent was 
obtained from all patients.   
 
Results 
Patient selection and inclusion 
Of the 193 patients who entered the study (of whom 169 (87.6%) following initial screening by the 
patient’s neurologist or neurology registrar), questionnaires were sent to 192. Both questionnaires 
were returned by 120 patients (response rate of 62.5%). Subsequently, a second screening using the 
inclusion and exclusion criteria was performed. Twenty-six patients were excluded and ninety-four 
patients were included. Of these ninety-four patients, ninety-two (97.9%) were known to have been 





















Figure 1. Flow chart of patient inclusion 
 
a  
Patients excluded because of not having returned both questionnaires with unknown reason: n = 54 
Patients excluded because of not having returned both questionnaires with known reason: n = 18: 
 no cluster period or oxygen use: n = 15 
 no correct address and phone number: n = 1 
 no cluster headache: n = 2 
 
b 
Patients excluded because of: 
 unknown number of oxygen treated cluster headache attacks: n = 3 
 less than three oxygen treated cluster headache attacks: n = 4 
 no oxygen treatment at all: n = 7 
 no reliable VAS scores: n = 1 
 oxygen treatment in the past: n = 9 
 uncertainty about diagnosis cluster headache: n = 1 




Of the ninety-four patients who were included, seventy-five (79.8%) were men. Mean current age was 
45.3 (SD 13.0) and median age at onset of CH was 37.0 (IQR 25). Fifty-five (58.5%) patients smoked 
at the time of inclusion and seventy-seven (81.9%) patients smoked in the past. Of the sixty-one 
patients who could be reliably classified using the first questionnaire, forty-two (68.9%) had episodic 
cluster headache (ECH) and nineteen (31.1%) had CCH. Approximately half of patients (54.3%) did 
not experience interictal headache. The median maximal attack duration without medication was 108 
(IQR 120) min in eighty-two patients and of these, seventeen (20.7%) had a maximal attack duration 
of more than 180 min. Three (3.3%) of ninety-one patients had a maximal attack frequency in the 
active phase of more than eight per day (range seventy-seven to eighty-four attacks/week in these three 
Entered patients: n = 193 
Patients to whom questionnaires were  
sent: n = 192 
Patients who have returned both  
questionnaires: n = 120 
Total included patients: n = 94 
Patients excluded because of not having returned 
both questionnaires: n = 72 a 
Patients excluded because of various  
reasons: n = 26 b 
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patients) with an average attack frequency of eight or less per day. Following oxygen prescription, the 
median used oxygen flow rate was 7.0 (IQR 5.0) L/min (range 6.0-25.0 L/min) in ninety-two patients. 
Ninety patients started using oxygen median 5 (IQR 4) min (range 0-60 min) following headache 
onset.       
 
Univariate analysis 
Comparisons of patient characteristics, headache characteristics and therapies between clear 
responders (group A) and clear non- plus moderate responders (group B + C) are shown in Tables 2, 3 
and 4 respectively. There were no statistical significant differences in patient and headache 
characteristics. There was one statistical significant difference in therapies.  
 Relatively more clear responders than clear non- plus moderate responders smoked in the past 
(90.2% versus 71.0%) and this difference approximated statistical significance. There was no 
difference in the median age at which patients started smoking and the median number of pack years 
per smoker. In their current active phase relatively more clear responders than clear non- plus 
moderate responders were able to drink alcoholic beverages (63.4% versus 41.9%), but this difference 
was not statistical significant. There was no difference in the median number of alcoholic beverages, 
which were drunk per week by these patients.      
 There was a trend of clear non- plus moderate responders experiencing untreated attacks of 
longer duration than clear responders. Especially the difference in percentage of patients, who 
experienced maximal attack durations of more than 180 min, approached statistical significance. There 
was no difference in the presence of interictal headache. There seemed a second, small trend of clear 
non- plus moderate responders experiencing a higher attack frequency in active phases than clear 
responders. There was, however, no difference in ever (i.e. before the start of oxygen therapy as attack 
treatment) and current (here following the start of oxygen therapy as attack treatment) use of 
verapamil and ever use of lithium and methysergide (not shown in Table 4). Statistical significant (p = 
0.03) more clear non- plus moderate responders than clear responders had ever used pizotifen (13.8% 
versus 0.0%), but the absolute number of users was small in the group of clear non- plus moderate 
responders. There was relatively more current triptan use by clear non- plus moderate responders than 
clear responders (50% versus 27.5%), however, the difference was not statistical significant.  
Relatively more clear responders than clear non- plus moderate responders had ipsilateral rhinorrhoea 
during attacks (70.0% versus 44.8%) and this difference neared statistical significance. However, other 
related ipsilateral parasympathetic autonomic features such as lacrimation and nasal congestion did not 
differ. Slightly more clear-non plus moderate responders than clear responders experienced photo- or 
phonophobia during attacks (67.7% versus 48.8%), but again there was no statistical significant 
difference.   
 Clear responders and clear non- plus moderate responders used the same median oxygen flow 
rate of 7 L/min with an IQR of 5 (range 6.0-25.0 and 6.5-25.0 respectively), following headache onset 
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after a median of 2 respectively 3 min. Despite absent or moderate responses, 35.5% of clear non- plus 
moderate responders experienced an effect of oxygen in more than half of CH attacks and 63.3% 
classified their response as good (not shown in Table 4).     
 There was no difference in an experienced good response (i.e. much or total relief of pain) to 
cold (for example by use of cold packs).  
  
 
Table 2. Comparison of patient characteristics between clear responders (group A) and clear non- plus 
moderate responders (group B + C) 




 Group  
total n 
 Group  
total n 
Men, n (%) 32 (78.0) 41 26 (83.9) 31 0.77 a 
Current age, mean (SD) 47.4 (13.1) 41 45.9 (11.2) 31 0.61 b 
   Number of participants currently 
   older than 49, n (%)                    
20 (48.8) 41 13 (41.9) 31 0.74 c 
Current BMI, median (IQR) 25.3 (5.9) 41 25.5 (5.6) 30 0.22 d 
Smoking      
   Current smoking, n (%)   29 (70.7) 41 17 (54.8) 31 0.25 c 
   Past smoking, n (%)  37 (90.2) 41 22 (71.0) 31 0.06 a 
      Pack years per smoker, median    
      (IQR) 
20 (18) 37 21 (26) 22 0.85 d 
      Age at start smoking, median (IQR) 16.0 (5.0) 37 16.0 (5.6) 22 0.89 d 
Alcohol consumption      
   Current consumers of alcohol, n (%) 26 (63.4) 41 13 (41.9) 31 0.12 c 
      Current number of alcoholic  
      consumptions/week per user,  
      median (IQR) 
6.5 (7.8) 24 10.0 (7.0) 13 0.51 d 
   Consumers of alcohol in the past, n  
   (%) 
28 (71.8) 39 20 (66.7) 30 0.85 c 
History of      
   Sleep apnoea, n (%) 3 (7.5) 40 3 (10.0) 30 1.00 a 
   Other headache disorder(s), n (%) 19 (46.3) 41 12 (40.0) 30 0.77 c 
   Head trauma, n (%) 11 (27.5) 40 11 (37.9) 29 0.51 c 
Positive family history (1st & 2nd 
degree) for cluster headache, n (%)  
5 (12.2) 41 4 (12.9) 31 1.00 a 













Table 3. Comparison of headache characteristics between clear responders (group A) and clear non- 
plus moderate responders (group B + C) 




 Group  
total n 
 Group  
total n 
Age at onset cluster headache, median 
(IQR) 
37 (25) 40 41 (22) 31 0.63 a 
Strict unilaterality of cluster headache, 
n (%) 
39 (97.5) 40 28 (90.3) 31 0.31 b 
Attack duration without medication in 
min 
     
   Minimal, median (IQR) 30 (25) 37 35 (45) 24 0.38 a 
   Average, median (IQR) 60 (60) 38 60 (106) 26 0.19 a 
   Maximal, median (IQR) 90 (124) 38 165 (140) 27 0.18 a 
      Maximal and more than 180   
      min, n (%) 
5 (13.2) 38 9 (33.3) 27 0.07 b 
No interictal headache, n (%) 25 (61.0) 41 15 (48.4) 31 0.41 c 
Accompanying autonomic features      
   Conjunctival injection, n (%) 31 (77.5) 40 20 (66.7) 30 0.46 c 
   Lacrimation, n (%) 36 (87.8) 41 25 (83.3) 30 0.73 b 
   Nasal congestion, n (%) 26 (63.4) 41 24 (80.0) 30 0.21 c 
   Rhinorrhoea, n (%) 28 (70.0) 40 13 (44.8) 29 0.06 c 
   Miosis, n (%) 20 (58.8) 34 13 (54.2) 24 0.93 c 
   Ptosis, n (%) 33 (80.5) 41 21 (67.7) 31 0.34 c 
Accompanying other features      
   Restlessness, n (%) 37 (90.2) 41 28 (90.3) 31 1.00 b 
   Nausea/vomiting, n (%) 8 (19.5) 41 9 (30.0) 30 0.46 c 
   Photo-/phonophobia, n (%)  20 (48.8) 41 21 (67.7) 31 0.17 c 
Attack frequency per week in active 
phase 
     
   Minimal, median (IQR) 7.0 (7.0) 40 8.8 (9.1) 30 0.90 a 
   Average, median (IQR) 14.0 (21.0) 41 21.0 (15.8) 29 0.29 a 
   Maximal, median (IQR) 21.0 (24.5) 39 28.0 (28.0) 31 0.27 a 
Pain at fixed times, n (%) 21 (51.2) 41 15 (48.4) 31 1.00 c 
Headache during night time, n (%) 37 (90.2) 41 29 (93.5) 31 0.69 b 
First cluster, n (%) 16 (39.0) 41 13 (41.9) 31 1.00 c 
Chronic cluster headache, n (%) 7 (25.0) 28 9 (45.0) 20 0.26 c 
Episodic cluster headache, n (%) 21 (75.0) 28 11 (55.0) 20 0.26 c 
Average cluster duration in weeks, 
median (IQR)    
4.5 (13.1) 20 8.0 (10.0) 11 0.97 a 
Cluster frequency per year, median 
(IQR) 
0.50 (1.69) 22 1.25 (2.11) 12 0.61 a 
Much or serious restriction in activities, 
n (%)     
23 (57.5) 40 19 (61.3) 31 0.94 c 
Much or serious restriction in work, n 
(%)    
18 (45.0) 40 21 (67.7) 31 0.10 c 










Table 4. Comparison of therapies between clear responders (group A) and clear non- plus moderate 
responders (group B + C) 




 Group  
total n 
 Group  
total n 
Therapies before start of oxygen 
therapy 
     
   Current medication use for other  
   disorders, n (%) 
21 (51.2) 41 19 (61.3) 31 0.54 a 
   Ever used therapies for cluster  
   headache 
     
      Exposure to cold, n (%) 24 (58.5) 41 15 (48.4) 31 0.54 a 
         Good response to cold (much or 
         total relief of pain), n (%)  
3 (12.5) 24 1 (6.7) 15 1.00 b 
      Triptan(s), n (%) 23 (57.5) 40 19 (63.3) 30 0.81 a 
         Good response to triptan(s)  
         (much or total relief of pain), n 
         (%)  
19 (86.4) 22 12 (70.6) 17 0.26 b 
      Verapamil, n (%) 24 (58.5) 41 23 (76.7) 30 0.18 a 
         Good response to verapamil 
         (much or total relief of pain), n 
         (%)   
10 (45.5) 22 7 (35.0) 20 0.71 a 
      Pizotifen, n (%) 0 (0.0) 40 4 (13.8) 29 0.03 b 
         Good response to pizotifen (much  
         or total relief of pain), n (%) 
0 (0.0) 0 1 (25.0) 4 - 
Following start of first ever oxygen 
therapy 
     
   Current use of oxygen in L/min,  
   median (IQR)    
7.0 (5.0) 39 7.0 (5.0) 31 0.31 c 
   Time between headache onset and  
   oxygen start in min, median (IQR) 
2 (4) 40 3 (4) 28 0.76 c 
   VAS score before oxygen use, 
   median (IQR)    
9 (2) 41 9 (2) 31 0.78 c 
   Triptan use in same active phase, n 
   (%) 
11 (27.5) 40 15 (50) 30 0.09 a 
   Verapamil use in same active phase,  
   n (%) 
26 (63.4) 41 20 (64.5) 31 1.00 a 
VAS score visual analog scale score of 1-10, with score 10 relating to the worst imaginable pain ever 




In the sub-analysis we compared patient characteristics, headache characteristics and therapies 
between clear responders (group A) and clear non-responders (group B). This sub-analysis could not 
confirm a statistical significant difference in ever pizotifen use; one clear non-responder had used 
pizotifen. Furthermore, the sub-analysis could not reveal a statistical significant difference in one of 
the characteristics (past smoking; maximal attack duration without medication longer than 180 min; 
rhinorrhoea), which difference approximated statistical significance in the initial univariate analysis. 
Significant (p = 0.047) more clear non-responders than clear responders reported photo- or 
phonophobia during headache attacks (78.9% versus 48.8%), as shown in Table 5. Furthermore, the 
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sub-analysis disclosed a statistical significant difference (p = 0.02) in triptan use, with more clear non-
responders than clear responders using a triptan in the same active phase as the phase in which they 
had used oxygen for the first time (63.2% versus 27.5%), also shown in Table 5. We did not find both 
differences in the univariate analysis. Again, both clear responders and clear non-responders used the 
same median oxygen flow rate of 7 L/min with an IQR of 5 and a range of 6.0-25.0 and 6.5-15.0 
respectively. A flow rate of more than 15 L/min was used by one clear responder.        
 
 
Table 5. Sub-analysis. Found significant differences in characteristics and therapies between clear 
responders (group A) and clear non-responders (group B) 
Characteristic / therapy Clear responders Clear non-responders Significance 
(p)  Group  
total n 
 Group  
total n 
Photo-/phonophobia, n (%) 20 (48.8) 41 15 (78.9) 19 0.05  
(0.047) a 
 
Triptan use in same active phase as 
first ever oxygen therapy, following 
start of this first ever oxygen therapy, n 
(%) 
11 (27.5) 40 12 (63.2) 19 0.02 b 




To correct for multiple testing, we used the Bonferroni correction to calculate new thresholds of 
significance for the variables, which differences were statistical significant in the univariate analysis or 
univariate sub-analysis. Thresholds for significance were 0.01 for the variable ‘ever used pizotifen’, 
0.02 for the variable ‘accompanying photo-/phonophobia’ and 0.03 for the variable ‘triptan use in 
same active phase as first ever oxygen therapy, following start of this first ever oxygen therapy’. Using 
this Bonferroni correction, we could only confirm a statistical significant difference in triptan use.     
 
Discussion 
In this prospective cross-sectional correlation study of response to oxygen therapy in ninety-four CH 
patients, we have studied the factors which differ between clear responders and clear non- plus 
moderate responders as well as between clear responders and clear non-responders. Clear non- plus 
moderate responders had ever used pizotifen more often. Clear non-responders more often had 
accompanying photo- or phonophobia during headache attacks and more often had used a triptan in 
the same active phase as the phase in which they had used oxygen for the first time ever. Following 
correction for multiple testing, this study only found a statistical significant difference between clear 
responders and clear non-responders in triptan use in the active phase in which they had used oxygen 
for the first time ever.   
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 In the present study clear non- plus moderate responders had ever used pizotifen significantly 
more often. Pizotifen can be used as preventive treatment of CH and is recommended by the Dutch 
practice guidelines of chronic recurrent headache without neurological abnormalities as one of the 
second line preventive treatments for ECH and as third choice preventive treatment for CCH.19 The 
percentage and absolute number of ever users of pizotifen in the group of clear non- plus moderate 
responders were small (13.8 % and four respectively) and the difference was not statistical significant 
using correction for multiple testing. Based on these marginal notes, we do not believe that past use of 
the serotonin and histamine inhibitor pizotifen will be associated with a current response to oxygen, 
not to mention a causal relationship.  
 Second, in this study clear non-responders significantly more often had accompanying photo- 
or phonophobia during headache attacks than clear responders (78.9% versus 48.8%), when not 
corrected for multiple testing. None of the clear non-responders fulfilled the ICHD-II criteria for 
migraine without aura 1 and therefore we do not assume a misdiagnosis of migraine with cranial 
autonomic symptoms (CAS) in these patients.20 Migrainous symptoms during headache, such as 
photo- and phonophobia, were self-reported by up to 91% and 89% of CH patients (with a diagnosis 
according to the IHS criteria of 1988) respectively.21 In another study, based on the study of several 
cohorts and patients seen in practice, 65% of CH patients had photo- or phonophobia with attacks.22 In 
all TAC groups photo- and/or phonophobia was often lateralized clinically (54% in CH up to 67% in 
chronic paroxysmal hemicrania) compared to migraine (8%), a difference which was statistical 
significant (p < 0.0001) when comparing episodic primary TACs with episodic migraine only.23 We 
did not ask for lateralisation of photo- and phonophobia. Despite clinical experience, at least during 
cluster periods there was no quantitative difference between symptomatic and asymptomatic sides in 
light- and sound-induced discomfort thresholds.21 This lack of quantitative lateralisation of photo- and 
phonophobia could suggest a mechanism cluster periods and migraine have in common. As there are, 
to our knowledge, no quantitative measurements of photo- and phonophobia during CH attacks, 
clinical lateralisation is not confirmed and therefore cannot contribute to our knowledge of the exact 
level of action of oxygen. The pathophysiology of photophobia, in particular, has been investigated in 
recent years. Interestingly, the two identified circuits that mediate photophobia both share parts with 
the trigemino-autonomic reflex in CH. The first photophobia circuit overlaps at the levels of the SSN, 
pterygopalatine ganglion, vasculature (ocular), trigeminal nerve and ganglion, trigeminal caudal 
nucleus, thalamus, and cortex. The second circuit overlaps at the levels of the thalamus and cortex. 
Furthermore, altered activity of the CGRP receptor causes an increase in light aversion.24 The 
photophobia circuits contain locations at which oxygen is presently known to exert its action in CH: 
the SSN and vasculature (also in relation to CGRP). Non-response to oxygen and presence of photo- 
and phonophobia could be two expressions of a higher nociceptive sensitivity. In our opinion, it would 
be incorrect to locate, solely based on theoretical grounds, the level of action of oxygen also in the 
thalamus and cortex.  
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 Third, in this study clear non-responders significantly more often used a triptan in the same 
active phase as the phase in which they had used oxygen for the first time ever, even when corrected 
for multiple testing. This seems logical, as alternative attack treatments will be prescribed in case of 
non-response to oxygen.  
 In this prospective study, we could not confirm, at a statistical significant level, the results of 
our retrospective cross-sectional correlation study, in which the variables ‘no smoking history’, 
‘interictal headache’ and ‘a maximal attack duration of more than 180 min’ predicted non-response to 
oxygen.11 However, compared to clear responders, again clear non- plus moderate responders in this 
prospective study (comparable to the group ‘non-responders’ in the univariate analysis of our 
retrospective study 11) had smoked in the past less often and had had a maximal attack duration of 
more than 180 min more often. Differences in both variables approximated statistical significance in 
this prospective study. Possibly, a larger study population would have led to significant differences in 
this present study as well.  
 Comparable to our retrospective study,11 we left the group oxygen responders with an increase 
in attack frequency (group E) out of the analysis, because this oxygen response is not considered 
beneficial. Patients in group E did not completely fulfil our definition of the rebound effect, which was 
defined as a more rapid than usual (for the individual patient) recurrent CH attack after complete relief 
following oxygen therapy, or an increase in the number of attacks per 24 hours (h) while using oxygen 
therapy as acute attack treatment.10 In the present study, we have asked only for an increase in attack 
frequency while using oxygen and just a few patients have been contacted to further elucidate the 
rebound phenomenon.11 An increase in attack frequency while using oxygen was reported by four 
clear non- plus moderate responders as well. As lack of a good oxygen response probably will lead to 
discontinuation of its use in these patients, this will probably not get attention in daily practice, but 
still deserves further scientific study.   
 Although we previously ruled out a misdiagnosis of migraine with CAS in non-responders, 
who had accompanying photo- and phonophobia during headache attacks, it is of interest to mention 
that the opposite may be applicable, as a recent case report again described the effectiveness of 100% 
oxygen as attack treatment in a migraine patient with lateralised CAS.25 This seems in agreement with 
the effects of oxygen on the parasympathetic SSN in rats.13 In our study, however, we could not find a 
statistical significant difference in the presence of parasympathetic autonomic symptoms between 
clear responders and clear non- (plus moderate) responders. Interestingly, migraine patients with a 
smoking history (past and current smoking) of at least 1 serried year were found to have associated 
autonomic symptoms (not necessarily lateralised) significantly more often than migraine patients 
without this smoking history.26 Ever smoking increases the concentration of nicotinic acetylcholine 
receptors (nACHRs) in the brain stem, which could hypothetically lead to more prominent autonomic 
symptoms, via vasoactive intestinal polypeptide (VIP) modulation of the receptors.26 Although not 
63 
 
hypothesised in our retrospective study, in which we found absence of past smoking to be a predictor 
of non-response to oxygen,11 these nACHRs could be a focus in future research in oxygen therapy.  
 One of the weaknesses of this prospective study is the lack of control of the way of oxygen 
delivery and breathing techniques used. For example, hyperventilation may cause hyperoxia and 
hypocapnia, both of which induce cerebral vasoconstriction. As all of the ninety-two patients with 
known oxygen flow rates used at least 6 L/min of continuous flow oxygen, of which 96.7% used at 
least 7 L/min, most patients should have used an oxygen face mask. However, there are different types 
of face mask, with and without non-rebreathing system and with various degrees of fitting to the face. 
The type of oxygen mask in combination with breathing technique used is probably one of the factors 
that determines oxygen efficacy, as in a recent pilot study all four CCH patients treated with demand 
valve oxygen with hyperventilation became pain free within 20 min of oxygen use, in contrast to two 
of three patients treated with continuous flow oxygen.27 Further study is necessary, but it may be 
assumed that the type of oxygen delivery system for continuous flow oxygen and the breathing pattern 
could have been confounding factors in this study.  
 Another weakness of the present study is the use of questionnaires. To reduce the number of 
unintentional false answers, we contacted patients by phone to elucidate answers and we left a few 
questions, which had been interpreted in different ways by different patients, out of statistical analysis.    
  
Conclusion 
Clear non- plus moderate responders to oxygen had ever used pizotifen more often. Clear non-
responders to oxygen more often had photo- or phonophobia during headache and more often had used 
triptans in the same active phase as the phase, in which they had used oxygen for the first time. Using 
correction for multiple testing, we could only confirm a statistical significant difference in triptan use.  
 In this study, we were unable to locate the level of action of oxygen in the thalamus and cortex 
or confirm the sites of its action presently known, solely based on current knowledge of photophobia 
circuits. 
 We believe that particularly the higher frequency of photo- or phonophobia in clear non-
responders to oxygen deserves further study to understand the mechanism of pain reduction by oxygen 
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Background. Rapid recurrence of a new cluster headache attack following oxygen treatment was 
named the ‘rebound effect’ by Kudrow (1981). It has never been studied properly. To study this effect, 
we defined it as a more rapid than usual (for the individual patient) recurrent cluster headache attack 
after complete relief following oxygen therapy, or an increase in the number of attacks per 24 hours 
while using oxygen therapy as acute attack treatment. We reviewed the literature and searched our 
cluster headache study databases. 
Case series. In our eight patients with rebound cluster headache, the effect was experienced following 
87.5% of oxygen treated attacks. Duration until the next cluster headache attack was on average 894 
minutes shorter and frequency was on average 1.6 cluster headache attacks per day higher than 
without oxygen therapy. 
Conclusion. Although the 1981 trial reported a prevalence of 25%, rebound cluster headache 
following oxygen therapy is rarely reported nowadays. This may be due to better techniques in oxygen 
application, the use of higher oxygen flow rates or underreporting. The few literature data and data on 
our eight patients did not provide clues about the mechanism of the rebound effect. Further study, 























Oxygen has been used to treat cluster headache (CH) attacks since 1952.1 Not much is known about its 
mechanism of action and why it provides a successful or significant headache relief in 75-82% of the 
patients using a flow rate of 6-8 litre/minute (L/min).2 Therefore, we carried out a retrospective cross-
sectional correlation study,2 in which we assessed the characteristics that differentiate between CH 
patients who respond to oxygen and those who do not.2 Currently, this subject is being investigated 
further in a prospective study. 
 One of the observations from these studies was that some patients reported a complete 
response to oxygen within 15 minutes (min), but noticed rapid recurrence of a new attack, giving the 
impression that oxygen only postpones the attack. Such attacks return sooner than attacks not treated 
at all. The phenomenon was described in Kudrow’s 1981 oxygen trial and called ‘rebound headache’.3 
Given that the rebound effect of oxygen therapy in CH patients has never been studied adequately, we 
studied the phenomenon by doing a literature search and describing the patients we observed. We 
therefore defined the rebound effect as a more rapid than usual (for the individual patient) recurrent 
CH attack after complete relief following oxygen therapy, or an increase in the number of attacks per 
24 hours (h) while using oxygen therapy as acute attack treatment. 
 
Case series 
We describe four of 115 (3.5%) patients from our retrospective study,2 three of forty-three (7.0%) 
patients from our current prospective study and one outpatient, all of whom reported a complete relief 
of a CH attack following oxygen therapy, followed by a more rapid recurrence of CH attacks or an 
increase in the attack frequency. All patients used oxygen only as acute CH attack treatment. One 
hundred percent oxygen was applied using a non-rebreathing face mask. Rebound CH was reported 
spontaneously in the retrospective study. In our current prospective study, we specifically asked about 
a change in attack frequency after start of oxygen therapy. Patients 4 and 8 (Tables 1 and 2) 
spontaneously reported a more rapid recurrent CH attack, although attack frequency and time between 
the initial and rebound CH attack were not reported. The outpatient said that ‘In my opinion, oxygen 
seems to postpone about 50% of the CH attacks, finally leading to a shorter period between the attacks 
which increase in both duration and severity’. Patient and headache characteristics and effectiveness of 
oxygen therapy are summarized in Tables 1 and 2. Patients could clearly make a distinction between a 
CH attack and interictal headache. On average, rebound CH was experienced in 87.5% of oxygen 
treated CH attacks (range 50–100%); the mean duration until the next CH attack was 39 min (range 0–
120) when using oxygen instead of 933 min (range 165–1440) without using oxygen; the mean 
frequency was 4.1 CH attacks/day (range 2-8) when using oxygen instead of 2.5 CH attacks/day 





A PubMed search did not provide additional information about the rebound effect, except that most of 
those referring to the phenomenon quoted Kudrow.3 Searching the books The Headaches 4 and Cluster 
Headache Syndrome 5 did not result in additional references.  
 Kudrow was the first to report the rebound effect in 1981.3 Twenty-five percent of the patients, 
who initially responded well to 100% oxygen administered through a face mask at a flow rate of 7 
L/min for 15 min, reported rebound CH.3 Mathew experienced that a number of patients responding to 
oxygen reported having recurrent headache within a short time, for which repeated oxygen 
administration was required.6 Torelli and Manzoni described the rebound effect as a ‘reappearance of 
pain after 1-2 hours of oxygen inhalation’.7 It is not clear for what reason they chose this time limit.  
 Using our definition, we found seven patients in our combined study group of 158 patients 
(4.4%) who reported the rebound phenomenon, which is much less than the 25% reported by 
Kudrow.3 Possibly, the phenomenon occurs more rarely because of better techniques in applying 
oxygen or because of the tendency to increase the oxygen flow rate. Another explanation may be that 
patients are rarely interviewed about the phenomenon, as might have been the case in our retrospective 
study. 
 Recurrence of CH attacks has been reported in long-term 8 as well as short-term 9  treatment 
with subcutaneous sumatriptan. In the latter, sumatriptan provided ‘relief’ (in one patient) or 
‘complete relief’ (in five patients) within 5 min following subcutaneous administration, but the CH 
attack frequency increased to 150-1100% of its original frequency. The increased attack frequency 
occurred already after 48 h in one patient and after the second dose in another. The attack frequency 
also showed a linear relationship with the number of sumatriptan injections per 24 h. Owing to the 
high number of CH attacks, sumatriptan became quickly overused. Rossi et al. state that the increased 
CH attack frequency suggests a drug-induced event, probably because of the short-lasting effect of 
subcutaneous sumatriptan.9  The rebound effect of oxygen therapy was also experienced immediately 
by three of our patients, and therefore seems to occur as early as in sumatriptan use. Six of our eight 
patients had used triptans at some point, and none of them experienced rebound CH following their 
use. It is not known whether patients experiencing rebound following use of subcutaneous sumatriptan 
are more prone to rebound following oxygen therapy.  
 Taken together, these preliminary data on the rebound effect following sumatriptan and 
oxygen use in CH patients suggest an effect of specific substances with a short half-life. Because of 
the immediate development of rebound CH after the first use of oxygen therapy in three patients, 
rebound CH is not (only) the result of medication overuse or tachyphylaxis, which would be more 
likely after intake over longer periods.   
 As mentioned earlier, we hypothesize that oxygen flow rates may play a part in the 
effectiveness of oxygen therapy, as four out of the six patients with known oxygen flow rates who 
experienced rebound CH used an oxygen flow rate of 7.0 L/min or less. The effectiveness of use of 
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high oxygen flow rates (12-15 L/min) was recently reported by Rozen 10 and Cohen et al.11 Cohen et 
al.’s trial did not report a rebound effect; the investigators 11 asked the patients to report the time 
between achievement of a pain free state and the next attack, but only few datapoints were obtained, 
for which reason they did not study it further (personal communication by P. Goadsby, 25 August, 
2010). Further research on this subject is obviously necessary.  
 
Conclusion  
Rebound CH following oxygen therapy has rarely been reported in the literature since it was 
mentioned to occur in 25% of the patients in Kudrow’s 1981 trial.3 The phenomenon may have 
occurred more rarely since, because of better techniques in applying oxygen or because of the 
tendency to increase the oxygen flow rate. Another explanation may be underreporting. To identify 
patients with rebound CH following oxygen therapy, we defined this rebound effect as a more rapid 
than usual (for the individual patient) recurrent CH attack after complete relief following oxygen 
therapy, or an increase in the number of attacks per 24 h while using oxygen therapy as acute attack 
treatment. We believe rebound CH following oxygen therapy deserves more attention and should be 
asked about when treating CH patients with oxygen. Given that little is still known about the origin 
and the development of the rebound effect, more prospective research on this subject is obviously 
necessary, in particular on a possible relationship between oxygen flow rates and rebound CH.
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   Prospective 
study 
  Outpatient 
Patient 1 2 3 4 5 6 7 8 
Gender, age (yrs) M, 39 F, 47 M, 48 M, 24 F, 26 M, 32 M, 23 M, 61 
Age at onset of CH (yrs) 34 30 42 18 25 25 22 52 
Type of CH  E E C C C E E E 
Duration of cluster period* 15 weeks 3 weeks Not known Not known 1.5 yrs 4 weeks 8 weeks 13 weeks 
Interictal headache + + + + - + + - 















use with O2 is 
not clear) 
 




























Verapamil Verapamil  
History of other headache 
disorders 






CH: cluster headache, E: episodic, C: chronic, yrs: years, M: male, F: female, O2: oxygen, TTH: tension type headache, MO: migraine 
without aura 
*  ‘Duration of cluster period’ is the mean duration of past cluster periods of patients 1 and 2 and current duration of the cluster period in 
patients 5, 6, 7 and 8.  
† Type of headache disorder unknown. 
‡ Chronic headache; no medication overuse headache.
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   Prospective 
study 
  Outpatient 
Patient  1 2 3 4 5 6 7 8 
Average number of CH attacks/day 
without O2 therapy 
7 1 1 2 4 1 0.5 - 1 3 




2 6 * 4‡ 
 
3-4‡ 2-3 3 
Average duration of CH attacks without 
O2 therapy (min) 
45 450† 83 60 23 120 120 180 
Average duration until complete relief of 
CH after start O2 therapy (min) 
7.0 10.0 20.0 1.5 5.0 15.0 12.0 10.0 
Average duration until new CH attack 
without O2 therapy (h) 
2.75 24 Not known * 3 24 24 * 
Average duration until new CH attack 
after initial attack for which O2 was used 
(h) 
0.50 Immediately  Not known * 0.38 0.75 2.0 0.25 
Use of O2 therapy 5 yrs 3 yrs Not known Not known 4 weeks 8 weeks 10 weeks 7 yrs 















O2 flow rate (L/min) 6.0 Not known 7.0 Not known 7.0 7.0 12.0 12.0 
Time between first use of O2 therapy and 
developing rebound CH 
Immediately 2.5 yrs 9 weeks 10-15 
times O2 
therapy 
Immediately 1 week 9 weeks Immediately 





CH: cluster headache, O2: oxygen, yrs: years. 
* Patients 4 and 8 spontaneously reported a rapid recurrent CH attack after using oxygen therapy for the initial CH attack. Attack 
frequency and time between initial and rebound CH attack were not reported. 
† Patients did not necessarily have to fulfill the criteria of a maximum attack duration of 3 h, as Van Vliet et al. state that this upper limit 
of a CH attack may be too strict.12  
‡ The total number of CH attacks in a day on which a patient used oxygen. The frequency of oxygen therapy can be less, because oxygen 
is not used during every CH attack. Patient 6 used triptans to treat some of the CH attacks.  
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Nociception specific supraorbital nerve stimulation may 
prevent cluster headache attacks: serendipity in a blink 
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Background. In cluster headache, neuromodulation is offered when patients are refractory to 
pharmacological prophylaxis. Non-invasive peripheral neuromodulatory approaches are of interest. 
We will focus on these and particularly on nociception specific, transcutaneous supraorbital nerve 
stimulation. 
Methods. In a study using the nociception specific blink reflex, we made a serendipitous discovery, 
notably the potential prophylactic effect of bilateral, time contingent, nociception specific, 
transcutaneous stimulation of the supraorbital nerve.  
Results. We report on a case series of seven cluster headache patients, in whom attacks seemed to 
disappear during repeated stimulation of the supraorbital nerves. Three patients stopped experiencing 
attacks since study participation. 
Conclusions. Bilateral, time contingent, nociception specific, transcutaneous supraorbital nerve 
stimulation may have a prophylactic effect in episodic and chronic cluster headache. Given its limited 
side effects and its non-invasive nature further studies to investigate this potential peripheral 



























When cluster headache (CH) patients are refractory to or do not tolerate pharmacological prophylaxis, 
peripheral nerve blocks  may be effective, but attacks may recur within weeks.1 The next line of 
treatment comprises neuromodulation and peripheral as well as central approaches are available. Deep 
brain stimulation of the posterior hypothalamus,2 however, may bring on even fatal side effects. Less 
invasive methods are being studied 3 and occipital nerve stimulation is considered the first-line 
neuromodulatory approach in refractory chronic cluster headache (CCH), although randomized 
controlled trials are still awaited for.4, 5 Because even peripheral invasive neuromodulatory approaches  
carry a certain risk of device- and surgery-related side effects, non-invasive peripheral 
neuromodulatory approaches are of particular interest.4 
 Study of the blink reflex is of interest in CH. A concentric planar stimulating electrode with a 
central cathode and external anode ring selectively stimulates superficial nociceptive A-delta fibres of 
the supraorbital nerve in the nociception specific blink reflex.6 In order to further unravel CH 
pathophysiology, we are investigating the effect of oxygen on medullary interneurons. The study uses 
a repeated measures design, in which the nociception specific blink reflex is measured every 2 hours 
(h) before a spontaneous attack, shortly after onset of an attack and 12-15 minutes (min) after start of 
oxygen treatment. At present, eight patients have enrolled and none of them experienced a 




Patients diagnosed by their neurologist with active CH according to the International Classification of 
Headache Disorders, second edition (ICHD-II) criteria 7 were included. Patients were excluded in the 
case of  secondary CH, other headache diagnoses or painful conditions, pregnancy or lactation, 
intolerability of the oxygen face mask and incapacitation to understand and sign for informed consent. 
Chronic obstructive pulmonary disease and previous thermolesion of the sphenopalatine ganglion 
were among the relative exclusion criteria. Patients were not allowed to use nitroglycerin, 
subcutaneous sumatriptan and alcohol in the preceding 2.5, 12 and 24 h respectively and other triptans 
in the preceding 6 days. Dosages of prophylactic medication were not allowed to be changed in the 
preceding 2 weeks.  
 Eligible patients were scheduled for study participation when the chance of occurrence of a 
spontaneous CH attack was expected to be ‘moderate’ to ‘high’ on that single day in the afternoon or 
evening (and one night), based on the individual patient’s  attack frequency and pattern during 







Time contingent, nociception specific blink reflex 
The supraorbital nerves were electrically and separately stimulated with a 200 pulse per second (pps) 
train of three 0.5 ms pulses by the special concentric planar stimulating electrode with central cathode 
and external anode ring,6 placed on the skin 10 mm cranial of the supraorbital notch on both the 
affected and non-affected side. The current intensity was adjusted with increasing 0.3 mA steps, 
delivered at unpredictable intervals, until 2.1 mA (once 2.4 mA), until 1.2 times the intensity of 
acquired stable R2 responses or until the patient’s tolerance limit was reached. Four well-displayed 
nociception specific blink reflexes were obtained for each side (using the stimulation sequence two at 
the affected side – four at the non-affected side – two at the affected side), with different intervals of at 
least 15 seconds to minimize habituation. To exclude diurnal variance, the nociception specific blink 
reflex without oxygen treatment was elicited every 2 h before the expected occurrence of a 
spontaneous attack. As a control, the nociception specific blink reflex was measured once outside an 
attack during 4 min of inhalation of 100% oxygen with a flow rate of 12 litre/min (L/min) using a non-
rebreathing face mask.  
 
Questionnaires 
Before study participation, patients filled in a questionnaire to double-check the diagnosis and 
preceding medication use.  
 At variable times following study participation, we contacted the patients to inquire 
retrospectively more specifically about medication use and attack frequency and pattern in the week 
before and following study participation. A diary was kept by two patients in the week before and 
three patients in the week following study participation.  
 
Ethics 
All patients gave written informed consent for participation in the original study, which was approved 
by the local ethics committee.  
 
Results 
At present, eight of targeted twenty CH patients have participated in the study. Despite a double-check 
of the neurologist’s ICHD-II diagnosis of CH,7 we questioned the diagnosis of one patient during 
follow-up. We therefore excluded this patient and present the characteristics of seven patients (Table 
1; Figures 1-2). 
 Despite questioning on exclusion criteria and instructions on medication intake beforehand, 
four patients satisfied at least one exclusion criterion at time of study participation. We chose for 
continued study participation with complete mention of the satisfied exclusion criteria. All patients 




 The pinprick-like pain of the nociception specific stimulation was tolerated by all patients, 
although in one patient (no. 2) a low current of 0.9 mA had to be used to retain tolerability. Patients 
underwent a median of six stimulation sequences and, except for one patient, who underwent seven 
stimulation sequences, the first, third and higher numbered sequences were given at intervals of 2 h. 
None of the patients experienced a spontaneous attack during the clinical study time of median 8.4 h. 
 The chance of occurrence of an attack during study time could be considered ‘high’ in patients 
no. 3-5 (Figure 2). However, patient no. 5 had a dose increase of verapamil 2 days before study 
participation.  
 The fact that patients no. 2, 3 and 7 completely stopped experiencing CH attacks since study 
participation was unexpected and of even more interest. Patients no. 2 and 3 were studied while they 
were 6 and 8.5 months in their first cluster and their sustained attack freedom lasted for at least 133 
and 128 days (i.e. time until retrospective inquiring) respectively. Patient no. 7 had CCH and was 
retrospectively questioned only 13 days following study participation. He was experiencing his longest 
time of attack freedom since onset of CCH 5 years before. In contrast to these striking frequency 
decreases, one CCH patient (no. 4) described an increase in attack frequency in the week following 
study participation. This increase, however, was not sustained, as this patient experienced 6 days of 
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   CCH: chronic cluster headache; CH: cluster headache; ECH: episodic cluster headache; first: first cluster; ADHD: attention deficit hyperactivity disorder;  
   TIA: transient ischemic attack; CEA: carotid endarterectomy; DM: diabetes mellitus; COPD: chronic obstructive pulmonary disease; M: man; sc: subcutaneous;  
   od: once daily; b.i.d.: twice daily;  t.i.d.: three times a day; q.d.s.: four times a day; tab: tablet   
   a All retrospective answers presented in this table were given by the patients at given number of days following study participation 
   b The patient has not taken sumatriptan tablets in the 6 days before study participation, according to the study protocol 
   c The patient uses oxygen at a flow rate of 12 L/min during 15 min as CH attack treatment 





























Figure 2. Estimated number of days/week in which the patient experienced a cluster headache attack 









In this study on CH pathophysiology, we may have found a serendipitous discovery that is of 
importance for future prophylactic treatment studies. All our seven CH patients did not experience any 
attack during study participation using 2-hourly, nociception specific, transcutaneous stimulation 
(NSTS) sequences on the bilateral supraorbital nerves to elicit nociception specific blink reflexes. 
Furthermore, three of seven CH patients have not experienced any attack following study 
participation.  
 
Non-invasive supraorbital nerve stimulation 
The supraorbital nerve can easily be stimulated in a non-invasive way, transcutaneously. In a recent 
double-blind trial (PREMICE) in migraine patients, bilateral, daily transcutaneous stimulation of the 
supraorbital and supratrochlear nerves was proven effective. No adverse or side effects were reported.8 
A prophylactic effect of punctual transcutaneous electrical nerve stimulation in migraine patients, after 
more than 6 months, was shown in 1988, although methodological concerns may be raised in that 
study.9 
 NSTS as possible prophylactic therapy offers advantages over invasive stimulation and 
pharmacological therapy. First, side effects are few. It is known to produce a pinprick-like pain at 
intensities of more than 0.6 mA.6 Furthermore, there is a possible counter effect of an increase in CH 
attack frequency, as experienced by patient no. 4. A second advantage of NSTS is the non-
invasiveness of the procedure. It gets around the known side effects of invasive peripheral 
neuromodulatory approaches, which include electrode migration, local infections and depletion of the 
implantable battery.4 Furthermore, as there are no fixed electrodes, stimulation can be easily applied 
on both sides and for a certain period of time, preventing the problem of side shift and allowing 
episodic cluster headache (ECH) patients to be treated by neuromodulation, respectively.  
 
Neurostimulation and cluster headache pathophysiology 
At present, little is known about CH pathophysiology and mechanism of action of neurostimulation. 
Peripheral nerve stimulation is traditionally thought to modulate the intrinsic electrical, afferent 
impulses travelling to the brainstem and higher. The ‘gate-control theory’ of Melzack and Wall deals 
with the influence of a competition between nociceptive and innocuous signals on second-order 
neurons,10, 11 the latter signals transmitted by A-beta fibres. One may question the applicability of this 
theory to NSTS of the supraorbital nerve, in which nociception specific stimulation of trigeminal A-
delta afferents seems to suppress the transmission of the other nociceptive (i.e. headache) signal on a 
segmental level. Furthermore, mediation in the analgesic effect of descending pain inhibitory 
pathways through stimulation of ascending tracts by peripheral nerve stimulation has been suggested.11 
In addition to a central influence, Reed and colleagues speculated on a possible relationship with the 




complex.12 In that way, direct stimulation of the terminal branches of the trigeminal nerve in particular 
could play an additional role.  
 It is obvious that our findings need to be interpreted carefully and that further studies are 
required. There are several limitations in our present case series, including the absence of a control 
group; some violations to the study protocol; the heterogeneity in clinical study time, stimulation 
characteristics, group of patients and data collection; and the small sample size. 
 In conclusion, bilateral, time contingent, nociception specific, transcutaneous supraorbital 
nerve stimulation could have a prophylactic effect in ECH and CCH. The suggested effect emerged as 
serendipity in a study using the nociception specific blink reflex to investigate the effect of oxygen 
treatment on medullary interneurons in CH. Given its limited side effects and its non-invasive nature, 
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Chapter 7  
 
 
High-flow oxygen therapy in cluster headache patients has 
no significant effect on nociception specific blink reflex 
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Background. The exact pathophysiology of cluster headache is unclear. We examined the influence of 
interneurons on the trigemino-facial reflex arch and the effect of oxygen, by using the nociception 
specific blink reflex parameters.  
Findings. There is no significant effect of oxygen, immediately and over time, on the nociception 
specific blink reflex parameters in ten male patients during the active phase of cluster headache, 
outside attacks. Also, there is no significant difference between the symptomatic and asymptomatic 
side. None of the subjects experienced a cluster headache attack during study participation. We 
therefore present the collected data as reference values of nociception specific trigeminal stimulation 
and the effect of oxygen on nociception specific blink reflex parameters.  
Conclusion. The nociception specific blink reflex seems not a suitable instrument for exploring the 





























The exact pathophysiology of cluster headache (CH) is unclear. Previous studies have shown that 
100% oxygen therapy is a notable CH attack reliever.1 Exactly how oxygen exerts its pain reducing 
effect in patients with CH is uncertain, but it is shown to directly or indirectly cause vasoconstriction.  
Indirect vasoconstriction can be the result of a possible action on the parasympathetic outflow from 
the superior salivatory nucleus (SSN), as is shown in rats.2  
 The blink reflex (BR) is a brainstem reflex, elicited through stimulation of the supraorbital 
nerve, derived from the first branch of the trigeminal nerve, resulting in a bilateral blink reaction of the 
eyelids through the facial nerve. The BR is composed of an early pontine response (R1), and a late 
medullary response (R2).3 R1 is oligosynaptic, ipsilateral and not clinically visible, whereas R2 is 
polysynaptic, bilateral and clinically observable.4 A nociception specific blink reflex (nBR) can be 
elicited by transcutaneously selectively stimulating superficial nociceptive A-delta fibers of the 
supraorbital nerve with a concentric planar stimulating electrode. The response consists of only a 
bilateral R2. Using the nBR, the function of the afferent trigeminal and efferent facial nerves and their 
central connections can be assessed.3  
 We wanted to examine the influence of interneurons on the trigemino-facial reflex arch and 
the effect of high-flow (12 litre/minute (L/min)) oxygen by using the nBR and its parameters. 
However, none of the subjects experienced a CH attack during study participation, despite the fact that 
all of the subjects were in a cluster period at the time. This was possibly due to a preventive effect of 
nociception specific trigeminal stimulation on CH attacks.5 We therefore present the data as reference 
values of the nBR parameters in patients in a cluster period outside a CH attack and the effect of high-
flow oxygen inhalation.  
 
Methods  
Information concerning study population, in- and exclusion, equipment and questionnaires was 
already described in a previous publication.5 The study was approved by the local ethics committee. 
All patients gave written informed consent. The study terminated early because none of the patients 
experienced a CH attack during clinical study time. One patient was excluded because the diagnosis of 
CH was questioned following study participation. CH patients were not compared to healthy controls; 
the baseline measurement was considered a control. 
 We elicited nBRs in eleven patients using Synergy EMG equipment (Natus Neurology). For 
stimulation we used a concentric planar electrode with central cathode and external anode ring (K2 
concentric ring stimulating electrode, 1.5 mm; Inomed, Emmendingen, Germany). Disposable 
silver/silver chloride electrodes were placed over the orbicularis oculi muscles, just lateral of the mid-
pupillary line (active) and near the lateral canthus (reference). The ground electrode was placed on the 
chin. The supraorbital nerve was stimulated 10 mm cranial of the supraorbital notch with a 200 pulse 
per second (pps) train of three 0.5 ms pulses. The current intensity was increased stepwise by 0.3 mA, 
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with regard to the tolerance limit of the patient, up to 20% above the level that acquired stable R2 
responses to assure supramaximal stimulation, with a maximum of 2.1 mA (once 2.4 mA). The stimuli 
were delivered at unpredictable intervals of at least 15 seconds to minimize habituation. Both the 
symptomatic and the asymptomatic side were stimulated until we had obtained four blink reflexes on 
each side (here referred to as one measurement). In each subject, the R2 responses were elicited at at 
least the five time points: before oxygen inhalation, during oxygen inhalation and every 2 hours (h) 
thereafter up until 6 h after oxygen inhalation. It was originally planned to continue until a 
spontaneous CH attack occurred, but this did not happen.  
 We analyzed the measurements before, during and 6 h after oxygen inhalation. All responses 
were evaluated by two researchers (DH and MH). For each stimulation site and time we calculated the 
shortest latency, amplitude, duration and area of the R2 response using Synergy Reader version 
20.1.0.100 (Natus Neurology). 
 
Statistical analysis 
We performed the analyses using IBM SPSS statistics version 21. Variables were tested for normal 
distribution (Shapiro-Wilk). We calculated mean with standard deviation (SD) or median with 
interquartile range (IQR) as appropriate. Differences of mean were tested with a paired samples t-test. 
Differences of median were tested using Wilcoxon signed-rank test. Significance levels were adjusted 
for multiple testing by Bonferroni correction (p < 0.0025).  
 
Results 
Ten CH patients were included. All CH patients were men. Mean age was 45.7 (range 24-69). Mean 
BMI was 24.0 (range 20.5 – 36.0). Three patients had episodic cluster headache (ECH), five patients 
had chronic cluster headache (CCH) and two patients were in their first cluster. Six patients 
experienced attacks on the left side, four on the right. Eight patients were current smokers.  
 Table 1 shows the nBR parameters of the symptomatic and asymptomatic side after both 
ipsilateral and contralateral stimulation, and before and after oxygen inhalation (n = 10). There is no 
significant difference in the nBR parameters before and during oxygen inhalation. There were also no 
differences in baseline parameters when the symptomatic side was compared to the asymptomatic 
side. We then studied the difference between the measurements before oxygen inhalation and 6 h after 
oxygen inhalation (n = 9; the measurement in one subject was rejected because it was impossible to 
elicit R2 responses after 6 h). This difference was not significant either and we considered  the values 






Table 1. Nociception specific blink reflex variables at baseline and during high flow oxygen 
inhalation (12 L/min) 
Nociception specific blink reflex 
variable 
Baseline  During high flow oxygen 
inhalation  
 
  mean (SD) * mean (SD) * p value 
R2 latency,  
symptomatic side (ms) 
      
ipsilateral stimulation 44.95 (5.65) 47.09 (6.29) 0.225 
contralateral stimulation 48.75 (6.53) 50.56 (6.03) 0.392 
Shortest R2 latency,  
symptomatic side (ms) 
      
ipsilateral stimulation 39.05 (6.55) 43.37 (6.19) 0.025 
contralateral stimulation 44.12 (6.69) 44.65 (4.16) 0.789 
R2 amplitude,  
symptomatic side (mV) 
      
ipsilateral stimulation 0.27 (0.10) 0.25 (0.08) 0.387 
contralateral stimulation 0.19 (0.07) 0.17 (0.07) 0.235 
R2 duration,  
symptomatic side (ms) 
      
ipsilateral stimulation 52.63 (14.39) 50.36 (13.65) 0.263 
contralateral stimulation 47.74 (19.17) 45.74 (14.27) 0.381 
R2 area,  
symptomatic side (mVms) 
      
ipsilateral stimulation 2.28 (1.03) 2.04 (0.94) 0.202 
contralateral stimulation 1.57 (0.78) 1.25 (0.47) 0.132 
    
R2 latency,  
asymptomatic side (ms) 
      
ipsilateral stimulation 47.62 (10.60) 46.01 (8.96) 0.223 
contralateral stimulation 49.93 (9.44) 48.85 (7.51) 0.418 
Shortest R2 latency, 
asymptomatic side (ms) 
     
ipsilateral stimulation 42.92 (10.73) 40.18 (9.40) 0.086 
contralateral stimulation 44.17 (10.21) 42.58 (8.51) 0.484 
R2 amplitude,  
asymptomatic side (mV) 
      
ipsilateral stimulation 0.32 (0.15) 0.27 (0.11) 0.100 
contralateral stimulation 0.19 (0.09) 0.16 (0.09) 0.174 
R2 duration,  
asymptomatic side (ms) 
      
ipsilateral stimulation 49.29 (19.30) 53.80 (16.54) 0.216 
contralateral stimulation 47.97 (18.11) 49.50 (16.53) 0.394 
R2 area,  
asymptomatic side (mVms) 
      
ipsilateral stimulation 2.40 (1.13) 2.26 (0.86) 0.544 
contralateral stimulation 1.61 (0.82) 1.32 (0.64) 0.068 








In this study on the pathophysiology of CH using 2-hourly transcutaneous stimulation sequences on 
the supraorbital nerves to elicit the nBR, none of the included patients did experience a CH attack 
during study participation. This may be an important serendipitous discovery for future prophylactic 
treatment studies, which we have discussed before.5  
 Based on the nBR parameters there is no significant effect of oxygen, immediately and over 
time. There is also no significant difference between the symptomatic and asymptomatic side of the 
nBR parameters during the active phase of CH, but outside CH attacks. The stringent correction for 
multiple testing poses a risk for false negative results. Using no correction, however, none of the 
results (except for the ‘ipsilateral shortest R2 latency symptomatic side during oxygen administration’ 
and ‘contralateral area asymptomatic side after 6 h’) would have been significant. 
 It would be interesting to observe what will happen at brainstem level during CH attacks in 
humans. However, if noninvasive nociception specific supraorbital nerve stimulation (SNS) indeed is 
confirmed to act in a prophylactic way in CH, it may be difficult to measure nBR parameters during a 
CH attack. 
 The nBR was first studied in healthy subjects using a custom built concentric planar 
stimulating electrode allowing only the nociception specific A-delta fibers to be stimulated.3 The nBR 
was further characterized in 104 healthy volunteers without any history of headache. Mean R2 onset 
latencies were 44.7 ms ipsilateral and 45.4 ms contralateral.6 We are the first to present nBR reference 
values in CH patients and the effect of oxygen on the nBR parameters. Consequently, it is not possible 
to make an accurate comparison with other nBR studies. 
 Our results of the nBR in CH and those from the literature raise some concerns about the 
applicability of the BR in CH. We searched the literature for BR R2 parameters and found conflicting 
results with studies indicating no difference between CH patients and healthy controls,7 a decreased 
excitability in CH patients based on a lower R2 amplitude,8 or an increased excitability based on an 
increased R2 duration and amplitude.9 
 If we combine these variable findings with our own results of the nBR, we feel that the nBR 
may not be a suitable instrument for exploring the pathophysiology of CH, although a previous BR 
study suggested otherwise.10 We have to emphasize that most studies measured conventional non-
nociceptive BRs, nevertheless without consistent results. We studied a fairly small homogeneous 
group of ten male CH patients. It is desirable to study a larger population with both male and female 
patients comparing CH patients in the active versus the remission phase. Also, the addition of healthy 
controls is necessary to compare values between groups in further studies.  
 
We conclude that the nBR is not different between symptomatic and asymptomatic sides in patients 
during the active phase of CH, outside of CH attacks, and that there is no measurable effect of oxygen 
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inhalation. Considering our observations with respect to the possible prophylactic action of SNS,5 it is 
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The studies compiled in this thesis focus on the acute treatment of cluster headache (CH)  with oxygen 
and predictors for its efficacy.  
 
Chapter 2 comprises of a historical review of oxygen therapy in headache and particularly in CH.1   
 In the early 20th century, oxygen was frequently used to treat angina pectoris, which was 
known to be associated with vasoconstriction.2 Possibly because migraine, which was not yet 
separated from CH, was also believed to be caused by vasoconstriction,3 oxygen was tried for 
headache treatment likewise. During the late 1930s, an opposite view regarding the pathophysiology 
of ‘migrainous headaches’ and the oxygen effect arose: in ‘migrainous headaches’ there is no 
vasoconstriction, but vasodilatation, and oxygen probably does not control hypoxia, but probably 
causes vasoconstriction. The latter was already concluded in 1930.4 
 The first description of oxygen treatment in headache in 1940 did not specifically deal with 
CH.5 The first recommendation of oxygen treatment for CH was in 1952, when Horton described the 
pain and associated symptoms of CH.6 The reason why Horton started using oxygen as a headache 
treatment is not clear from his early papers. As late as in 1961 was oxygen described by Horton as a 
vasoconstricting agent.7  
 The efficacy of (normobaric) oxygen at flow rates of 6, 7 and 12 litre/minute (L/min) as acute 
CH treatment was confirmed in three clinical trials,8, 9, 10 the first of which was published 29 years 
after the first recommendation.9 From that time, oxygen was established as acute CH treatment. 
 Next to normobaric oxygen treatment, the abortive and prophylactic effects of hyperbaric 
oxygen (HBO) treatment in CH have also been explored in several studies, but no firm evidence of its 
efficacy was found.11  
  With  (normobaric) oxygen an effective, acute CH treatment was found, the exact mechanism 
of which is still unclear. Only recently, it was suggested that treatment with 100% oxygen in rats acted 
on the parasympathetic pathways to exert its abortive effects on evoked trigeminovascular activation 
and autonomic pathway activation during CH attacks, rather than directly on trigeminal afferents to the 
dural vasculature (i.e. a direct vasoconstriction).12  
 
In Chapter 3 I describe a retrospective cross-sectional correlation study on the predictive factors for 
efficacy of oxygen in CH.13  
 Hundred-fifteen adult CH patients,14 who had used oxygen for the first time less than 10 years 
before and at least four times, were included and assessed by means of a questionnaire (see Appendix 
A).   
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 Using the Bonferroni correction for multiple testing, there were no statistically significant 
differences in the initial univariate analysis of diverse factors comparing the clear (oxygen) responders 
with the clear non-responders plus the moderate responders.13  
 A multivariate analysis on the significant variables of the initial univariate analysis, when the 
Bonferroni correction was not applied, showed that ‘smoking in the past’, a ‘maximal duration of the 
CH attack of 180 minutes (min) or less’ and ‘no interictal headache’ were independent factors 
determining oxygen response. The presence of every one of these three variables gave patients an 
approximately three to four times higher odds of being a responder than being a non-responder.13  
 
In Chapter 4 I describe a prospective cross-sectional correlation multi-centre study on the predictive 
factors for efficacy of oxygen in CH.15  
 The study used two questionnaires (see Appendix B and C). Ninety-four adult CH patients,14 
who took oxygen therapy for the first time and who subsequently used it in at least three CH attacks, 
were included. To enable a comparison with the retrospective study,13  response to oxygen was 
classified in a nearly similar way.15   
 Using the Bonferroni correction for multiple testing, only a statistically significant difference 
in triptan use was found. Clear non-responders compared to clear responders more often used triptans 
in the cluster period in which they had used oxygen for the first time ever as well.15 
 Concerning a significant difference in photo- and phonophobia, found in the univariate sub-
analysis when the Bonferroni correction was not applied, I place our results in the perspective of the 
finding that the photophobia circuits contain locations at which oxygen is presently known to exert its 
action in CH: the superior salivatory nucleus and vasculature.15  
 
In Chapter 5 I describe the 'rebound effect of oxygen',16 which was defined for study purposes as ‘a 
for the individual patient more rapid than usual recurrent CH attack after complete relief following 
oxygen therapy, or an increase in the number of attacks per 24 hours (h) while using oxygen therapy 
as acute attack treatment’.16  
 Eight patients fulfilling our definition (four from the retrospective study,13 three from the then 
still ongoing prospective study 15 and one CH patient not included in either of the two studies) were 
reported. The report of the defined rebound effect by only 4.4% of the combined study group 16 is 
much less than found in literature lacking a clear definition of the rebound phenomenon.9  
 In the eight studied patients, rebound CH was not experienced after all their attacks, but on 
average in 87.5% of oxygen treated CH attacks. The mean duration until the next CH attack was 39 
min when using oxygen versus 933 min without. The mean frequency was 4.1 CH attacks/day when 
using oxygen versus 2.5 CH attacks/day without.16    
 Similar to the factors predicting oxygen response, the rebound effect deserves clinical 




In Chapter 6 I describe our study of the diagnostic nociception specific blink reflex to investigate the 
(direct or indirect) effect of oxygen on medullary interneurons in CH patients.17  
 The superficial nociceptive A-delta fibres of both supraorbital nerves were selectively 
stimulated,18 up to a median of six series.17   
 We encountered unexpected therapeutic and prophylactic effects of the stimulation. These 
serendipitous results manifested during the study of the first seven CH patients, who were all in their 
cluster period or had chronic cluster headache (CCH). None of these seven patients experienced a 
spontaneous CH attack during the clinical study time of median 8.4 h. Furthermore, three patients, who 
had active CH for at least 6 months, experienced a CH attack freedom of at least 13 days following 
study participation.17  
 
In Chapter 7 I describe, as reference values for future studies, the collected nociception specific blink 
reflex R2 parameters of  the study of ten male CH patients outside a CH attack, but in a cluster period 
or having CCH, and the effect of high-flow oxygen inhalation on these parameters.19  
 There were no significant differences in the nociception specific blink reflex R2 parameters 
before versus during and before versus 6 h following oxygen inhalation (n = 10 and 9 respectively), 






The various studies of this thesis, added to those in the literature, suggested several targets for (further) 
studies. In addition to the discussion of the previous studies, I will briefly discuss current studies and 
literature on some of these different targets as a basis for further research.  
 
Oxygen flow rates, techniques of oxygen application, breathing patterns and gas 
temperatures and pressures 
The beneficial effect of oxygen compared to sublingual ergotamine tartrate and placebo has been 
shown at flow rates of 7 and 12 L/min, respectively.9, 10 The difference in effect between 7 L/min and 
12 L/min, however, has never been investigated in a controlled study. Our current ongoing CLuster 
headache ATtacks OXYgen Treatment (CLATOXYT) trial (trial ID NTR3801) has the primary 
objective to study whether there is a difference in treatment effect between these two oxygen flow 
rates in the acute treatment of CH attacks. This study in newly diagnosed or oxygen naïve adult CH 
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patients, uses a double-blind crossover design, two questionnaires and a diary. At present, 
approximately 90% of the targeted total number of patients has been included. 
 We recently reviewed the efficacy of the standard non-rebreathing masks with normobaric 
room temperature oxygen in relieving pain in CH.20  
 Regarding the fraction of inspired oxygen, interfaces like tusk mask variants are at least 
similar to the standard non-rebreathing masks, and demand valve oxygen is even superior.20 Currently, 
only demand valve oxygen (in combination with initial hyperventilation) has been investigated in a 
pilot study as a new oxygen delivery system for the acute treatment of CH. The number of four 
participants was too small to draw any firm conclusions,21 although the positive trend suggests 
requirement of further study in larger patient groups.   
 Although hyperventilation may result in an increase in partial pressure of oxygen, hypocapnia 
and vasoconstriction,20 the effect of hyperventilation on pain reduction during a CH attack has not 
been extensively studied. Whether hyperventilation is superior to normal breathing with regard to CH 
pain reduction is unknown and might require further study.  
 In a study investigating an expected superior role of inhaled gas temperature over oxygen 
concentration, it was shown that inhalation of room air of 5 °C at a flow rate of 6 L/min for at least 15 
min provided significant relief in 85% of eighty treated CH attacks, a result similar to 100% oxygen 
(with no details provided on its prescription).22 In a pilot study, intranasal cooling to approximately 2 
°C by evaporation of by perfluorohexane cooled oxygen at a ‘low’ flow rate for a maximum of 20 min 
provided a complete or partial pain and symptom relief immediately following treatment in 40% and 
50% of twenty treated migraine attacks, respectively.23 In conclusion, cryotherapy applied as cooled 
gas (room air or 100% oxygen) could have a yet underestimated therapeutic effect in neurovascular 
headaches. Especially, room air and not per se 100% oxygen could possibly be an effective acute 
treatment in CH, if cooled.22 This could be a target for further studies. 
 The effects of 100% oxygen at pressures above one atmosphere (hyperbaric oxygen) have 
been studied in CH. The current evidence is insufficient to confirm its acute11 or prophylactic effects.24 
A hyperbaric pressurized air mixture can be delivered by continuous positive airway pressure among 
others. A prophylactic effect of continuous positive airway pressure was described in a number of CH 
cases associated with (predominantly obstructive) sleep apnoea syndrome.25, 26, 27, 28, 29, 30, 31 Therefore, 
the effect of air, not only cooled as mentioned before, but also higher pressurized, could be a target for 
future studies.    
 
Calcitonin gene-related peptide, the nicotinic acetylcholine receptor and the 
photophobia circuits 
The endogenous neuropeptide calcitonin gene-related peptide (CGRP) binds in a competitive 
antagonistic way with exogenous nicotine to the nicotinic acetylcholine receptor and blocks its 
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activation by presynaptically released acetylcholine. It is assumed to improve the signal-to-noise ratio 
in the synapse.32  
 CGRP has been linked to photophobia and thought to modulate nociception by enhancing 
transmission. CGRP receptors are found in the ventroposteromedial thalamus. The posterior thalamus 
is one of the levels of interaction between trigeminal pain modulating systems and photophobia.33 The 
(degree of inhibitory) action of CGRP on the nicotinic acetylcholine receptor at the synapses in 
photophobia circuits could be a focus for further research.  
 In addition to the neuromodulatory actions, CGRP has neurovascular actions. It can induce 
facial and meningeal vasodilation, following stimulation of the trigeminal nucleus caudalis. Following 
this trigeminal nucleus caudalis stimulation, trigeminal CGRP release is assumed to be indirectly 
decreased by blockage of the nicotinic acetylcholine receptor.34 As dural vessels do not contain 
functional cholinergic nicotinic acetylcholine receptors, the regulation of nicotinic acetylcholine 
receptors present in the sphenopalatine ganglion of the facial nerve,35 and its interaction with CGRP at 
its local synapses could be a further focus for research, apart from a potential upregulation of the 
nicotinic acetylcholine receptors in smokers in the brain stem.15  
 
Bilateral, time contingent, nociception specific, transcutaneous supraorbital nerve 
stimulation 
Focussing on supraorbital nerve stimulation, there are anecdotal case reports that describe the efficacy 
in CCH of invasive supraorbital nerve stimulation, alone and in combinations with supratrochlear 
and/or infraorbital and/or occipital nerve stimulation.36, 37, 38  
 The supraorbital nerve can easily be stimulated in a non-invasive way, transcutaneously, 
which offers advantages over invasive stimulation, as described in Chapter 6.17 It is obvious that 
further studies are necessary, not only on the mechanism of action of peripheral neurostimulation, but 
also on the potential prophylactic effect of bilateral, time contingent, nociceptive specific, 
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De studies, die in dit proefschrift zijn gebundeld, zijn gericht op de acute behandeling van 
clusterhoofdpijn (CH) met zuurstof en op de voorspellers van de werkzaamheid hiervan. 
 
Hoofdstuk 2 omvat een historisch overzicht van zuurstoftherapie bij hoofdpijn en in het bijzonder bij 
CH.1 
 In het begin van de 20e eeuw, werd zuurstof vaak gebruikt voor de behandeling van angina 
pectoris, waarvan de associatie met vaatvernauwing bekend was.2 Aangezien migraine, dat nog niet 
gescheiden was van CH, wellicht ook verondersteld werd te worden veroorzaakt door vasoconstrictie,3 
werd zuurstof eveneens uitgeprobeerd als hoofdpijn behandeling. In de late jaren dertig ontstond een 
tegenovergesteld standpunt ten aanzien van de pathofysiologie van 'migraineuze hoofdpijn’ en het 
effect van zuurstof: bij 'migraineuze hoofdpijn' is er geen vasoconstrictie, maar vasodilatatie, en 
zuurstof controleert waarschijnlijk geen hypoxie, maar veroorzaakt waarschijnlijk vasoconstrictie. Dit 
laatste werd reeds geconcludeerd in 1930.4 
 De eerste beschrijving van zuurstoftherapie bij hoofdpijn in 1940 handelde niet specifiek over 
CH.5 De eerste aanbeveling voor zuurstoftherapie voor CH was in 1952, toen Horton de pijn en de 
bijbehorende symptomen van CH beschreef.6 De reden waarom Horton begon met zuurstof als 
hoofdpijnbehandeling wordt niet duidelijk uit zijn vroege publicaties. Pas in 1961 werd zuurstof door 
Horton beschreven als vasoconstrictief.7 
 De werkzaamheid van (normobare) zuurstof met stroomsnelheden van 6, 7 en 12 liter/minuut 
(L/min.) als acute CH behandeling werd bevestigd in drie “clinical trials”,8, 9, 10 waarvan de eerste 29 
jaar na de eerste aanbeveling werd gepubliceerd.9 Vanaf dat moment, was zuurstof gevestigd als acute 
CH behandeling. 
 Naast normobare zuurstoftherapie, werden ook de abortieve en profylactische effecten van 
hyperbare zuurstoftherapie (HBO) bij CH onderzocht in een aantal studies, echter er werd geen hard 
bewijs voor de werkzaamheid hiervan gevonden.11 
 Met (normobare) zuurstof was een effectieve, acute CH behandeling gevonden, waarvan het 
exacte mechanisme nog steeds onduidelijk is. Pas recent werd gesuggereerd dat behandeling met 
100% zuurstof bij ratten werkt op parasympatische “pathways”, om daar zijn abortieve effecten op 
opgewekte trigeminovasculaire activatie en autonome “pathway” activatie tijdens CH aanvallen uit te 
oefenen, in plaats van rechtstreeks op trigeminale afferenten naar durale vaten (dat wil zeggen een 
directe vaatvernauwing).12 
 
In Hoofdstuk 3 beschrijf ik een retrospectieve cross-sectionele correlatiestudie naar de voorspellende 
factoren voor de werkzaamheid van zuurstof bij CH.13 
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 Honderdvijftien volwassen CH patiënten,14 die zuurstof voor het eerst minder dan 10 jaar 
ervoor en tenminste vier keer hadden gebruikt, werden geïncludeerd en in kaart gebracht met behulp 
van een vragenlijst (zie Bijlage A). 
 Gebruik makend van de Bonferroni-correctie voor “multiple testing”, waren er geen statistisch 
significante verschillen in de initiële univariate analyse van diverse factoren, die de “clear (oxygen) 
responders” met de “clear non-responders” én de “moderate responders” vergeleek.13 
 Een multivariate analyse van de significante variabelen van de initiële univariate analyse, 
wanneer de Bonferroni-correctie niet werd toegepast, liet zien dat 'roken in het verleden', een 
'maximale duur van de CH aanval van 180 minuten (min.) of minder' en 'geen interictale hoofdpijn' 
onafhankelijk factoren waren, die de respons op zuurstof bepaalden. De aanwezigheid van elk van 
deze drie variabelen gaf patiënten een ongeveer drie tot vier maal hogere kans een “responder” dan 
een “non-responder” te zijn.13 
 
In Hoofdstuk 4 beschrijf ik een prospectieve cross-sectionele correlatie multicenter studie naar de 
voorspellende factoren voor de werkzaamheid van zuurstof bij CH.15 
 De studie maakte gebruik van twee vragenlijsten (zie Bijlage B en C). Vierennegentig 
volwassen CH patiënten,14 die voor het eerst zuurstoftherapie kregen en dit vervolgens gebruikten bij 
tenminste drie CH aanvallen, werden geïncludeerd. Om een vergelijking met de retrospectieve studie 
mogelijk te maken,13 werd de respons op zuurstof op nagenoeg dezelfde wijze geclassificeerd.15 
 Gebruik makend van de Bonferroni-correctie voor “multiple testing”, werd alleen een 
statistisch significant verschil in triptaan gebruik gevonden. In vergelijking met “clear responders” 
gebruikten “clear non-responders” veel vaker triptanen in de clusterperiode, waarin ze eveneens 
zuurstof voor de eerste keer ooit gebruikten.15 
 Betreffende een significant verschil in foto- en fonofobie, gevonden in de univariate sub-
analyse wanneer de Bonferroni-correctie niet werd toegepast, plaats ik onze resultaten in het 
perspectief van de vaststelling dat de fotofobie circuits lokalisaties bevatten, waarvan thans bekend is 
dat zuurstof er zijn werking uitoefent bij CH: de “superior salivatory nucleus” en de vasculatuur.15 
 
In Hoofdstuk 5 beschrijf ik het ‘rebound effect van zuurstof ',16 dat voor studiedoeleinden 
gedefinieerd was als ‘een voor de individuele patiënt sneller dan normaal recidiverende CH aanval na 
volledige verlichting door zuurstoftherapie, of een toename van het aantal aanvallen per 24 uur (u.), 
terwijl zuurstoftherapie als acute aanvalsbehandeling gebruikt wordt'.16 
 Acht patiënten, die aan onze definitie beantwoordden (vier uit de retrospectieve studie, 13 drie 
uit de toen nog lopende prospectieve studie15 en een CH patiënt, die niet in een van de twee studies 
geïncludeerd was), werden beschreven. De rapportage van het gedefinieerde “rebound effect” door 
slechts 4,4% van de gecombineerde studiegroep16 is veel minder dan  gevonden in de literatuur, waar 
een duidelijke definitie van het “rebound” fenomeen ontbrak.9 
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 De acht onderzochte patiënten ervoeren “rebound” CH niet na al hun aanvallen, maar bij 
gemiddeld 87,5% van de met zuurstof behandelde CH aanvallen. De gemiddelde duur tot de volgende 
CH aanval was 39 min. bij het gebruik van zuurstof versus 933 min. zonder. De gemiddelde frequentie 
was 4,1 CH aanvallen/dag bij het gebruik van zuurstof versus 2,5 CH aanvallen/dag zonder.16 
 Net als bij de factoren die de zuurstofrespons voorspellen, verdient het “rebound effect” 
klinische aandacht in de dagelijkse praktijk.16 
 
In Hoofdstuk 6 beschrijf ik onze studie van de diagnostische nociceptief specifieke blink reflex, om 
het (directe of indirecte) effect van zuurstof op medullaire interneuronen bij CH patiënten te 
onderzoeken.17 
 De superficiële, nociceptieve A-delta vezels van beide nn supraorbitales werden selectief 
gestimuleerd,18 tot een gemiddelde van zes series.17 
 We kwamen onverwachte therapeutische en profylactische effecten van de stimulatie tegen. 
Deze serendiepe resultaten manifesteerden zich tijdens de studie van de eerste zeven CH patiënten, die 
allemaal in hun clusterperiode waren of chronische clusterhoofdpijn (CCH) hadden. Geen van deze 
zeven patiënten ervoer een spontane CH aanval tijdens de klinische studietijd met een mediaan van 8,4 
u. Bovendien ervoeren drie patiënten, die actieve CH hadden sinds tenminste 6 maanden, een CH 
aanvalsvrijheid van tenminste 13 dagen na studieparticipatie.17 
 
In Hoofdstuk 7 beschrijf ik, als referentiewaarden voor toekomstige studies, de verzamelde 
nociceptief specifieke blink reflex R2 parameters van de studie van tien mannelijke CH patiënten 
buiten een CH aanval, maar in een clusterperiode of met CCH, en het effect van inhalatie van zuurstof 
met een hoge stroomsnelheid op deze parameters.19 
 Er waren geen significante verschillen in de nociceptief specifieke blink reflex R2 parameters 
voor versus tijdens en voor versus 6 u. na zuurstofinhalatie (n = 10 en 9 respectievelijk), en voor 






De verschillende studies van dit proefschrift, toegevoegd aan die in de literatuur, suggereren 
verschillende doelen voor (verdere) studies. In aanvulling op de bespreking van de voorgaande 
studies, zal ik kort ingaan op de huidige studies en literatuur van een aantal van deze verschillende 





Zuurstofstroomsnelheden, technieken van zuurstoftoediening, ademhalingspatronen en 
gastemperaturen en -drukken 
Het gunstigere effect van zuurstof ten opzichte van sublinguaal ergotamine tartraat en placebo is 
aangetoond bij stroomsnelheden van 7 en 12 L/min., respectievelijk.9, 10 Het verschil in werkzaamheid 
tussen 7 L/min. en 12 L/min. is echter nooit onderzocht in een gecontroleerde studie. Onze huidige, 
lopende “CLuster headache ATtacks OXYgen Treatment (CLATOXYT) trial” (trial ID NTR3801) 
heeft het primaire doel om te onderzoeken of er een verschil in behandelingseffect bestaat tussen deze 
twee zuurstofstroomsnelheden bij de acute behandeling van CH aanvallen. Deze studie bij nieuw 
gediagnosticeerde of zuurstof naïeve volwassen CH patiënten, maakt gebruik van een dubbelblind 
“crossover design”, twee vragenlijsten en een dagboek. Op dit moment is ongeveer 90% van het 
beoogde, totale aantal patiënten geïncludeerd. 
 We hebben onlangs de werkzaamheid van de standaard “non-rebreathing” maskers, met 
normobare zuurstof op kamertemperatuur, bij het verlichten van pijn bij CH, herbekeken.20 
 Betreffende de fractie van ingeademde zuurstof, zijn “interfaces” zoals “tusk masker” 
varianten tenminste gelijk aan de standaard “non-rebreathing” maskers, en is “demand valve oxygen” 
zelfs superieur.20 Momenteel is alleen “demand valve oxygen” (in combinatie met een initiële 
hyperventilatie) onderzocht in een pilot studie als nieuw zuurstoftoedieningssysteem bij de acute 
behandeling van CH. Het aantal van vier deelnemers was te klein om harde conclusies te trekken, 
hoewel de positieve trend de noodzaak tot verder onderzoek in grotere patiëntengroepen suggereert.21 
 Hoewel hyperventilatie kan resulteren in een toename van de partiële zuurstofdruk, 
hypocapnie en vasoconstrictie,20 is het effect van hyperventilatie op pijnverlichting tijdens een CH 
aanval niet uitgebreid onderzocht. Of hyperventilatie superieur is aan een normale ademhaling met 
betrekking tot pijnvermindering bij CH is onbekend en zou verder onderzoek kunnen vereisen. 
 In een studie, waarin een verwachte superieure rol van de temperatuur van geïnhaleerd gas 
boven de zuurstofconcentratie werd onderzocht, werd aangetoond dat de inhalatie van kamerlucht van 
5 °C met een stroomsnelheid van 6 L/min. gedurende tenminste 15 min. een significante verlichting 
gaf bij 85% van de tachtig behandelde CH aanvallen, een resultaat vergelijkbaar met 100% zuurstof 
(waarvan geen details werden verstrekt over de toediening).22 In een pilot studie gaf intranasale 
afkoeling tot ongeveer 2 °C, door verdamping van door perfluorhexaan gekoeld zuurstof, bij een 'lage' 
stroomsnelheid gedurende een maximum van 20 min. een volledige of partiële pijn- en 
symptoomverlichting onmiddellijk na de behandeling bij 40% en 50% van twintig behandelde 
migraine aanvallen, respectievelijk.23 Concluderend kan cryotherapie, toegediend als gekoeld gas 
(kamerlucht of 100% zuurstof), een nog onderschat therapeutisch effect bij neurovasculaire hoofdpijn 
hebben. Vooral kamerlucht, en niet per sé 100% zuurstof,  kan mogelijk een effectieve acute 
behandeling bij CH zijn, als gekoeld.22 Dit zou een doel kunnen zijn voor verdere studies. 
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 De effecten van 100% zuurstof met een druk boven één atmosfeer (hyperbare zuurstof) zijn 
bestudeerd bij CH. Het huidige bewijs is onvoldoende om acute11 of profylactische effecten ervan te 
bevestigen.24 Een hyperbaar perslucht mengsel kan onder andere geleverd worden door “continuous 
positive airway pressure”. Een profylactisch effect van “continuous positive airway pressure” werd 
beschreven in een aantal CH casussen geassocieerd met (voornamelijk obstructief) slaapapneu 
syndroom.25, 26, 27, 28, 29, 30, 31 Derhalve zou het effect van lucht, niet alleen gekoeld zoals eerder vermeld, 
maar ook met hogere drukken een doel kunnen zijn voor toekomstige studies. 
 
 
“Calcitonin gene-related peptide”, de nicotinerge acetylcholine receptor en de fotofobie 
circuits 
Het endogene neuropeptide “calcitonin gene-related peptide” (CGRP) bindt op een competitieve, 
antagonistische wijze met exogeen nicotine aan de nicotinerge acetylcholinereceptor en blokkeert de 
activering ervan door presynaptisch vrijgemaakt acetylcholine. Het wordt verondersteld de signaal-
ruisverhouding in de synaps te verbeteren.32 
 CGRP is gelinkt aan fotofobie en wordt verondersteld nociceptie te moduleren door de 
transmissie te vergroten. CGRP-receptoren worden gevonden in de ventroposteriomediale thalamus. 
De posterieure thalamus is een van de niveaus van interactie tussen trigeminale pijn modulerende 
systemen en fotofobie.33 De (mate van inhibitoire) werking van CGRP op de nicotinerge 
acetylcholinereceptor in de synapsen in fotofobie circuits zou een focus voor verder onderzoek kunnen 
zijn. 
 Naast de neuromodulatoire werkingen heeft CGRP ook neurovasculaire werkingen. Het kan 
faciale en meningeale vasodilatatie induceren na stimulatie van de trigeminale nucleus caudalis. 
Volgend op deze trigeminale nucleus caudalis stimulatie, wordt verondersteld dat trigeminale CGRP-
vrijmaking indirect wordt verminderd door blokkering van de nicotinerge acetylcholinereceptor.34 
Omdat durale vaten geen functionele, cholinerge, nicotinerge acetylcholinereceptoren bevatten, zou de 
regulatie van nicotinerge acetylcholinereceptoren aanwezig in het ganglion sfenopalatinum van de n 
facialis,35 en de interactie ervan met CGRP ter hoogte van de lokale synapsen, een focus kunnen zijn 
voor verder onderzoek, nog afgezien van een mogelijke opregulatie van de nicotinerge 
acetylcholinereceptoren bij rokers in de hersenstam.15 
 
Bilaterale, tijdcontingente, nociceptief specifieke, transcutane supraorbitale 
zenuwstimulatie 
Gericht op supraorbitale zenuwstimulatie zijn er anekdotische “case reports”, die bij CCH de 
werkzaamheid beschrijven van invasieve supraorbitale zenuwstimulatie, alleen en in combinatie met 
supratrochleaire en/of infraorbitale en/of occipitale zenuwstimulatie.36, 37, 38 
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 De n supraorbitalis kan gemakkelijk worden gestimuleerd op een niet-invasieve wijze, 
transcutaan, wat voordelen biedt ten opzichte van invasieve stimulatie, zoals beschreven in hoofdstuk 
6.17 Het is duidelijk dat verdere studies nodig zijn, niet alleen naar het werkingsmechanisme van 
perifere neurostimulatie, maar ook naar het mogelijke, profylactische effect van bilaterale, 
tijdcontingente, nociceptief specifieke, transcutane supraorbitale zenuwstimulatie bij episodische 
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Informatiebrief: Onderzoek naar clusterhoofdpijn en zuurstoftherapie 
 
 
Heerlen, januari 2009 
 
 
Geachte heer, geachte mevrouw,  
 
Wij zijn in het Atrium Medisch Centrum Heerlen een nieuw onderzoek begonnen naar het effect van 
zuurstoftherapie bij clusterhoofdpijn. We zouden hiervoor uw aandacht willen vragen omdat u als 
clusterhoofdpijnpatiënt deel zou kunnen nemen aan dit onderzoek. Hieronder volgt een korte 
toelichting over het onderzoek.  
 
Zoals u wellicht weet is clusterhoofdpijn een aanvalsgewijze, hevige, borende, eenzijdige hoofdpijn 
waarbij ook verschijnselen aan het oog en/of neus, en bewegingsdrang kunnen optreden. De 
behandeling van een aanval van clusterhoofdpijn kan naast het geven van medicijnen ook bestaan uit 
het toedienen van zuurstof tijdens de aanval. Niet alle patiënten worden echter evenveel geholpen met 
zuurstof. Het is niet bekend welke patiënten wel en welke patiënten niet reageren op zuurstof.  
 
Dit onderzoek heeft als doel te bekijken of er verschillen zijn tussen de groep met 
clusterhoofdpijnpatiënten die wel op zuurstoftherapie reageert en de groep clusterhoofdpijnpatiënten 
die niet op zuurstoftherapie reageert. Verschillen tussen deze twee groepen zouden bijvoorbeeld 
kunnen zijn de leeftijd, het gewicht van de patiënten of bijvoorbeeld het optreden van 
bewegingsdrang. Met behulp van deze gegevens proberen we de oorzaak van het ontstaan van 
clusterhoofdpijn beter te begrijpen en zouden we in de toekomst kunnen bepalen bij wie er wel en bij 
wie er geen zuurstoftherapie geprobeerd wordt.  
 
Wij hopen daarom dat u mee zou willen werken aan dit onderzoek. Dit houdt voor u enkel in dat u de 
bijgevoegde vragenlijst invult en retourneert met de bijgevoegde enveloppe. Hiervoor is geen 
postzegel nodig. Omdat wij de gegevens van dit onderzoek zo snel mogelijk in de praktijk willen 
toepassen zouden wij het op prijs stellen als u de vragenlijst voor 1 april 2009 zou kunnen retourneren.  
 
Voor vragen kunt u contact opnemen met de research assistente Tiny Simons-Sporken (tel: 045-
5766713 of sein 46-6704), of u kunt zich door laten verbinden via het algemene telefoonnummer van 
het ziekenhuis (045 -576 66 66) met de onderzoekers; semi-arts A. Backx (sein 46-7673) of neuroloog 
in opleiding D. Haane (sein 46-6718).  
 
De vragenlijst wordt vertrouwelijk behandeld en anoniem verwerkt.  
 
We willen u bedanken voor uw tijd en voor uw bijdrage aan het onderzoek.  
 
 
Met vriendelijke groet,  
 
Dr. P. Koehler, neuroloog 
Drs. D. Haane, neuroloog in opleiding 
A. Backx, semi-arts neurologie 
 
















Wij willen u vragen het onderstaande naar waarheid in te vullen zodat u toestemming geeft voor het 






heb de bijgevoegde informatiebrief over het onderzoek naar clusterhoofdpijn en zuurstoftherapie 
gelezen en begrepen. Door het zetten van mijn handtekening ga ik akkoord met de verwerking van de 
































Vragenlijst clusterhoofdpijn en zuurstoftherapie:  
 
Deze vragenlijst bestaat uit vier soorten vragen. Bij de meerkeuze vragen kunt u één rondje 
(0) aankruisen met het juiste antwoord, soms kunt u op de stippellijn uw antwoord nog 
aanvullen. Bij de vragen waar ‘Ja/Nee’ achter staat kunt u omcirkelen wat voor u van 
toepassing is. Ook bij de vragen waar ‘helemaal/veel/weinig/niets’ staat kunt u invullen wat 
voor u van toepassing is. Bij de open vragen moet u in uw eigen woorden een korte 
omschrijving geven.  
 
 I: Algemene gegevens: 
1. Wat was uw leeftijd bij ontstaan van de klachten van clusterhoofdpijn?. . . . . . . . . . . . .  
2. Wat was uw leeftijd bij het stellen van de diagnose clusterhoofdpijn?. . . . . . . . . . . . . .  
3. Door wie is de diagnose clusterhoofdpijn gesteld? Huisarts/Neuroloog.                                                                                       
4. Wat is uw lengte en gewicht nu? 
Lengte:………….. Gewicht: ………. 
 
5. En wat waren uw lengte en gewicht bij ontstaan van de hoofdpijn?   
Lengte:…………... Gewicht: ………… 
 
6. Wat is uw beroep? ……………………….. 
 
7. Rookt u, of heeft u gerookt in het verleden?   
Ja/Nee (Indien nee ga verder naar vraag 11) 
 
8. Hoeveel sigaretten per dag rookt u nu per dag? ……………. 
 
9. Hoelang rookt u al? ……………… 
 
10. Hoeveel sigaretten heeft u in het verleden per dag gerookt en voor hoelang?                 
. . . . . . . . . . . . sigaretten per dag, gedurende . . . . . . . . . . . jaar                                       
. . . . . . . . . . . . sigaretten per dag, gedurende . . . . . . . . . . . jaar                                       
. . . . . . . . . . . . sigaretten per dag, gedurende . . . . . . . . . . . jaar 
 
11. Gebruikt u alcohol, of heeft u in het verleden alcohol gebruikt?  
Ja/Nee (Indien nee ga verder naar vraag 13) 
 
12. Hoe vaak per week drinkt u alcohol bevattende dranken? ……………….. 
 
13. Op een typische dag dat u alcohol gebruikt, hoeveel drankjes zijn dat dan?………. 
 
14. Hoeveel glazen alcohol heeft u in het verleden per week gebruikt? …………. 
 
15. Heeft u in het verleden te maken gehad met onderstaande ziekten/aandoeningen?  
a. Slaapapneu syndroom?   Ja/Nee 
b. Andere vormen van hoofdpijn? Ja/Nee 




16. Gebruikt u medicijnen voor andere ziekten/aandoeningen dan clusterhoofdpijn? 
………………………………..   ………………………….. 
………………………………..   ………………………….. 
………………………………..   ………………………….. 
 
17. Komt er bij u in de familie clusterhoofdpijn voor? ……………                        
 II: Clusterhoofdpijn specifieke gegevens:  
Hieronder volgt eerst algemene informatie over clusterhoofdpijn en wat er precies bedoeld 
wordt met een clusterhoofdpijnaanval, een clusterperiode en de piekfase.  
 
De clusterhoofdpijnaanval:  
Deze vragenlijst gaat over het voorkomen van clusterhoofdpijn. Deze hoofdpijn kan 
voorkomen in aanvallen. Een aanval wil zeggen dat de hoofdpijn vrij plotseling begint, 
toeneemt tot een hoogtepunt, enkele minuten/uren of dagen achtereen aanhoudt, en 
vervolgens weer duidelijk afneemt. De aanvallen zijn dus vrij scherp begrensd. Tussen de 
















De clusterperiode:  
Aanvallen van hoofdpijn kunnen in clusterperiodes voorkomen. Een clusterperiode is een 
periode van enige weken tot enkele maanden, waarin de aanvallen van hoofdpijn zeer 
frequent voorkomen (soms meerdere malen per dag). Tussen de clusterperiodes zit een 
aanvalsvrije periode van weken, maanden of zelfs jaren (zie plaatje 3: 1 verticale streep is een 
clusterhoofdpijnaanval, de groepen aanvallen is een clusterperiode). Als dit het geval is, 





Echter, in een klein percentage van de gevallen is er sprake van chronische clusterhoofdpijn. 
Hierbij treden de aanvallen vrijwel dagelijks of wekelijks op, zonder duidelijke, lange 
aanvalsvrije perioden (zie plaatje 4).  
 
De piekfase van een clusterperiode:  
De frequentie van aanvallen tijdens een clusterperiode kan verschillen (zie plaatje 5). In de 
aanloopfase zijn er meestal relatief weinig aanvallen. Vaak wordt de aanloopfase gevolgd 
door een periode met zeer frequente aanvallen (de piekfase). Deze aanvallen duren vaak 
langer dan de aanvallen in de aanloopfase. Aan het eind van een clusterperiode nemen de 













18. Hoe zou u de hoofdpijn tijdens een aanval omschrijven? 
o borend of kloppend 
o stekend, alsof er messen in het hoofd worden gestoken  
o het gevoel alsof het oog eruit gedrukt wordt 
o anders, nl…………………………………………………………………….. 
 
19. Bent u pijnvrij in de periode tussen de aanvallen (plaatje 1) of heeft u tussen de 
hoofdpijnaanvallen minder hoofdpijn (plaatje 2)?  
o Pijnvrij (plaatje 1) 
o Minder hoofdpijn (plaatje 2) 
 
20. Hoe lang duurt een aanval (plaatje 1-2) gemiddeld als u geen medicijnen gebruikt? (graag 
1 antwoord geven) 
o korter dan 15 minuten, namelijk…………………minuten 
o 15 minuten tot 3 uur, namelijk…………………minuten 
o langer dan 3 uur, namelijk …………………uur 
o weet niet 
 
21. Hoe lang duurt een aanval minimaal als u geen medicijnen gebruikt? (graag 1 antwoord  
geven) 
o korter dan 15 minuten, namelijk…………………minuten 
o 15 minuten tot 3 uur, namelijk …………………minuten 
o langer dan 3 uur, namelijk ………………….uur 
o weet niet 
 
22. Hoe lang duurt een aanval maximaal als u geen medicijnen gebruikt? (graag 1 antwoord 
geven) 
o korter dan 15 minuten, namelijk…………………minuten 
o 15 minuten tot 3 uur, namelijk …………………minuten 
o langer dan 3 uur, namelijk…………………..uur 
o weet niet 
 
 
23. Komen de aanvallen van hoofdpijn bij u in clusterperiodes met daartussen periodes van 
weken, maanden of jaren waarin u aanvalsvrij bent (zie plaatje 3)? 
o Ja. Ga verder met de vragen 24 t/m 33 op bladzijde X.  
o Nee (dit betekent dat u geen aanvalsvrije periodes hebt, zie plaatje 4). Ga verder met 
de vragen 34 t/m 38 op bladzijde Y.  
o Vroeger wel, maar nu niet meer (dit wil zeggen dat u nu geen aanvalsvrije perioden 
meer hebt, zie plaatje 4). Ga verder met de vragen 34 t/m 38 op bladzijde Y. 
o Vroeger niet, maar nu wel (dit betekent dat u momenteel tussen de clusterperiodes wel 
aanvalsvrije periodes hebt, zie plaatje 3). Ga verder met de vragen 24 t/m 33 op 






Vraag 24 t/m 33 zijn bedoeld voor mensen die wel aanvalsvrije perioden hebben. 
 
24. Hoe vaak heeft u gemiddeld aanvallen van clusterhoofdpijn in de piekfase (zie plaatje 5)? 
o ………. keer per dag  
o ………. keer per week 
 
25. Hoe vaak heeft u minimaal last van aanvallen van clusterhoofdpijn in de piekfase? 
o ………. keer per dag  
o ………. keer per week 
 
26. Hoe vaak heeft u maximaal last van aanvallen van clusterhoofdpijn in de piekfase? 
o  ………. keer per dag  
o  ………. keer per week 
 
27. Hoe lang duurt een clusterperiode (plaatje 3) gemiddeld? (graag 1 antwoord geven) 
o  ………. weken 
o  ………. maanden 
o  ………. jaren 
 
28. Hoe lang duurt een clusterperiode minimaal? (graag 1 antwoord geven) 
o ……….  weken  
o ……….  maanden 
o ……….  jaren 
 
29. Hoe lang duurt een clusterperiode maximaal? (graag 1 antwoord geven) 
o  ………. weken  
o  ………. maanden 
o  ………. jaren 
 
30. Hoe lang duurt een aanvalsvrije periode (plaatje 3) gemiddeld (dus de periode tussen twee 
clusters in)? (graag 1 antwoord geven) 
o  ………. weken 
o  ………. maanden 
o  ………. jaren 
 
31. Hoe lang duurt een aanvalsvrije periode minimaal? (graag 1 antwoord geven) 
o  ………. weken 
o  ………. maanden 
o  ………. jaren 
 
32. Hoe lang duurt een aanvalsvrije periode maximaal? (graag 1 antwoord geven) 
o ……….  weken 
o  ………. maanden 
o  ………. jaren 
 
33. Hoe vaak hebt u een clusterperiode? (graag 1 antwoord geven) 
o ……….  keer per jaar 
o eens in de ………. jaar 
 
Ga verder met de vragen 39 t/m 68 op bladzijde Z. 
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Vraag 34 t/m 36 zijn bedoeld voor mensen die geen aanvalsvrije perioden hebben. 
 
34. Hoe vaak hebt u gemiddeld aanvallen? (graag 1 antwoord geven) 
o  ………. keer per dag 
o  ………. keer per week 
o  ………. keer per maand 
o  ………. keer per jaar 
 
35. Hoe vaak hebt u minimaal aanvallen? (graag 1 antwoord geven) 
o  ………. keer per dag 
o ……….  keer per week 
o  ………. keer per maand 
o ……….  keer per jaar 
 
36. Hoe vaak hebt u maximaal aanvallen? (graag 1 antwoord geven) 
o  ………. keer per dag 
o  ………. keer per week 
o  ………. keer per maand 
o  ………. keer per jaar 
 
Vraag 37 en 38  zijn bedoeld voor mensen die geen aanvalsvrije perioden meer hebben.  
 
 
37. Hoe oud was u toen er geen aanvalsvrije perioden meer optraden? 
 ……….  jaar 
 























Vraag 39 t/m 68 zijn bedoeld voor iedereen, dus zowel mensen met als mensen zonder 
aanvalsvrije periode.  
 
39. Hoe ernstig is de pijn?  (kruis 1 van de onderstaande opties aan) 
o Matig, er wordt geen of enige hinder ondervonden van de hoofdpijn  
o Hevig, de dagelijkse activiteiten kunnen met moeite gedaan worden  
o Ondraaglijk, onmogelijk om met de dagelijkse activiteiten door te gaan 
 
40. Waar zit de pijn? ………………………….. 
 
41. Heeft u pijn altijd aan 1 zijde van het hoofd? ………………… 
a. Zo ja, welke zijde? ……………………….. 
 
42. Heeft u pijn in/achter de ogen, bij de slapen of tanden?……………… 
 
43. Als u hoofdpijn heeft, heeft u dan ook 
a. Roodheid van het oog aan de kant van de hoofdpijn?  Ja/Nee 
b. Tranen van het oog aan de kant van de hoofdpijn?   Ja/Nee 
c. Een dichtzittende neus aan de kant van de hoofdpijn?  Ja/Nee 
d. Een loopneus aan de kant van de hoofdpijn?   Ja/Nee 
e. Hangend ooglid aan de kant van de hoofdpijn?  Ja/Nee 
f. Nauwere pupil aan de kant van de hoofdpijn?  Ja/Nee 
g. Misselijkheid en/of braken?      Ja/Nee 
h. Last van fel licht en/of hard geluid?     Ja/Nee 
i. Bewegingsdrang?      Ja/Nee 
 
44. Wat merkt u voorafgaand aan de clusterhoofdpijnaanval? 
……………………………………………………………………………… 
 
45. Zoekt u tijdens een aanval wel eens de koude op?  
Ja/Nee (indien nee ga verder naar vraag 48) 
 
46. Op welke manier zoekt u de koude op? ……………………… 
 
47. Hoeveel heeft de koude de pijn doen verbeteren?  
Helemaal/veel/weinig/niets  
 
48. Heeft u de hoofdpijn op vaste tijdstippen op de dag?………………………… 
 
49. Heeft u ook ’s nachts hoofdpijn? 
Ja/Nee (indien nee ga verder met vraag 51)  
 
50. Als u ’s nachts hoofdpijn heeft wat doet u dan? …………………………… 
 
51. Heeft u ooit zuurstof gebruikt bij een aanval van clusterhoofdpijn?  
Ja/Nee (indien nee ga naar vraag 60) 
 
52. Hoe oud was u toen u voor het eerst zuurstof gebruikte? ……………… 
 





54. Hoeveel minuten na het begin van de hoofdpijn begon u met zuurstof? ……………… 
 
55. Hoeveel verlichting van de pijn kreeg u door de zuurstof? 
Helemaal/veel/weinig/niets 
 
56. Na hoeveel tijd aan de zuurstof voelde u verlichting? ………………….. 
 
57. Na hoeveel tijd aan de zuurstof was de hoofdpijn over? ………………… 
 
58. Hoe vaak heeft u de zuurstof gebruikt met goed effect (veel of helemaal verbeterd) ? 
…………………………….…………………………. 
 
59. Indien de zuurstof na verloop van tijd minder effect heeft gekregen, na hoeveel weken/ 
maanden/ jaren was dat dan? ………………………….. 
 
60. Heeft u ooit triptanen zoals imigran/sumatriptan gebruikt tegen de hoofdpijn?  
Ja/Nee (indien nee ga verder met vraag 63) 
 
61. Was dit een injectie, neusspray, zetpil of tablet van 50 mg of 100 mg? ………………. 
 
62. Hoeveel heeft dit medicijn de pijn doen verbeteren?  
Helemaal/veel/weinig/niets  
 
63. Heeft u ooit verapamil (isoptin) gebruikt tegen de hoofdpijn?  
Ja/Nee (indien nee ga verder met vraag 65) 
 
64. Hoeveel heeft verapamil (isoptin) de pijn doen verbeteren?  
Helemaal/veel/weinig/niets  
 
65. Heeft u ooit andere medicijnen gebruikt tegen de hoofdpijn? Ja/Nee 
a. Zo ja, welke? ……………………………………….. 
 






 III. Beperking dagelijks functioneren:  
66. Wordt u door de hoofdpijn tijdens de clusterperiode (of tijdens een periode dat u veel 
aanvallen heeft als u geen duidelijke clusterperiode heeft) beperkt bij dagelijkse 
bezigheden? Zet een kruisje in het juiste vakje.  
 
                 helemaal niet beperkt  beetje beperkt    ernstig beperkt    
1. Forse inspanning zoals  
hardlopen, tillen van zware  
voorwerpen, deelnemen  
aan een veeleisende sport 
 
2. Matige inspanning zoals een  
tafel verplaatsen, stofzuigen,  
zwemmen of fietsen 
 
3. Boodschappen tillen/dragen 
 
4. Een trap oplopen 
 
5. Bukken, knielen of hurken 
 
6. Meer dan een kilometer lopen 
 
7. Uzelf wassen of aankleden 
 
 
67. In hoeverre hebben uw lichamelijke gezondheid of emotionele problemen tijdens de 
clusterperiode (of tijdens een periode waarin u aanvallen heeft) u gehinderd in uw normale 
omgang met familie, vrienden, buren of bij activiteiten in groepsverband? 
 
Helemaal niet/ enigszins/ nogal/ vrij veel/ ernstig  
 
68. In welke mate bent u tijdens de clusterperiode (of tijdens een periode waarin u 
aanvallen heeft) door pijn gehinderd in uw normale werk (zowel werk buitenshuis als 
huishoudelijk werk)? 
 




- Hartelijk dank voor het invullen van de vragenlijst –  






Vragenlijst 1: Zuurstoftherapie bij Clusterhoofdpijn 
Atrium Medisch Centrum Heerlen, Afdeling Neurologie 
 








In welk ziekenhuis bent u onder behandeling? ……………………………. 
 
 
Deze vragenlijst is opgedeeld in 3 delen. Het 1e deel bevat een aantal algemene vragen. Het 2e 
deel bevat vragen over de clusterhoofdpijn. Tussen de vragen door zult u wat uitleg vinden 
over clusterhoofdpijn zelf. Het 3e deel bevat vragen over eventuele beperkingen in het 
dagelijks leven.  
 
Er zijn drie soorten vragen. Bij de meerkeuze vragen kunt u één rondje (0) aankruisen met het 
juiste antwoord, zo nodig kunt u op de stippellijn uw antwoord nog aanvullen. Bij de vragen 
waar ‘Ja/Nee’ of ‘helemaal/veel/weinig/niets’ achter staat kunt u omcirkelen wat voor u van 
toepassing is. Bij de open vragen wordt u verzocht in uw eigen woorden een korte 
omschrijving te geven.  
 
Deel 1: Algemene gegevens 
 
1. Wat is uw leeftijd? …….. jaar 
 
2. Wat zijn uw lengte en gewicht? 
Lengte: ………….. cm  
Gewicht: ………… kg 
 
3. Welke opleiding(en) heeft u gedaan? 
…………………………………………………………………………………………... 
 
4. Wat is uw beroep? ………………………………………………………………………  
 
5. Rookt u?  
Ja/Nee (Indien nee ga verder naar vraag 9) 
 
6. Op welke leeftijd bent u begonnen met roken? ……..  
 
7. Hoe lang rookt u nu? …….. jaar 
 
8. Hoeveel sigaretten rookt u nu gemiddeld per dag? …………….  
 
9. Heeft u in het verleden gerookt? 
Ja/Nee (Indien nee ga verder naar vraag 13) 
 




11. Hoelang heeft u gerookt? ………… 
 
12. Hoeveel sigaretten heeft u in het verleden gemiddeld per dag gerookt? ….………….. 
 
13. Gebruikt u alcohol?  
Ja/Nee (Indien nee ga verder naar vraag 16) 
 
14. Hoeveel dagen per week drinkt u alcohol bevattende dranken? ……………….. 
 
15. Hoeveel glazen alcoholbevattende drank gebruikt u gemiddeld in één week? ……...…. 
 
16. Heeft u in het verleden alcohol gebruikt? 
Ja/Nee (indien nee ga verder naar vraag 18) 
 
17. Hoeveel glazen alcoholbevattende drank gebruikte u in het verleden gemiddeld per 
week? …………. 
 
18. Heeft u nu of in het verleden te maken gehad met onderstaande ziekten/aandoeningen?  
a. Slaapapneu syndroom?    Ja/Nee 
b. Andere vormen van hoofdpijn?  Ja/Nee  
Zo ja, wie heeft de diagnose gesteld?  Uzelf/ huisarts/ anders, namelijk……….. 
Had u deze hoofdpijn eerder dan de  
clusterhoofdpijn?    Ja/Nee 
c. Hersenschudding?     Ja/Nee 
 
19. Gebruikt u medicijnen voor andere ziekten/aandoeningen dan clusterhoofdpijn? Zo ja, 
welke medicijnen en voor welke aandoening? 
 
Medicijn     Aandoening 
………………………………..  ………………………….. 
………………………………..  ………………………….. 
………………………………..  ………………………….. 
 
20. Komt er bij u in de familie clusterhoofdpijn voor? Ja/Nee 
Zo ja, bij wie? .…………………………...……  
 
21. Komt er bij u in de familie migraine voor? Ja/Nee 
Zo ja, bij wie? ……………….……………….. 
 
Deel 2: Clusterhoofdpijn specifieke gegevens 
 
Tussen de vragen door zult u informatie vinden over en wat precies bedoeld wordt met een 
clusterhoofdpijnaanval, clusterperiode en piekfase. Later zult u dit terugvinden in de vragen.  
 
Clusterhoofdpijn 
Clusterhoofdpijn wordt gekenmerkt door aanvallen van hevige bonzende of stekende 
éénzijdige hoofdpijn rondom het oog of de slaap. Tijdens de hoofdpijnaanval kunnen andere 
klachten voorkomen, zoals bijvoorbeeld een rood, tranend oog, neusverstopping, een 








22. Hoe zou u de hoofdpijn tijdens een aanval omschrijven? (Graag één antwoord 
aankruisen, waarmee de aard van de hoofdpijn het best wordt omschreven) 
o Borend of kloppend 
o Stekend, alsof er messen in het hoofd worden gestoken  
o Het gevoel alsof het oog eruit gedrukt wordt 
o Anders, namelijk …………………………………………………………………….. 
 
23. Waar zit de pijn? (Graag één antwoord aankruisen, waarmee de lokatie van de hoofdpijn 
het best wordt omschreven) 
o In/achter de ogen 
o Bij de slapen 
o Bij de tanden 
o Anders, namelijk …………………………………………………………………….. 
 
24. Heeft u pijn altijd aan één zijde van het hoofd? Ja/Nee 
a. Zo ja, welke zijde? ………………………………………………………….. 
 
25. Als u hoofdpijn heeft, heeft u dan ook 
a.   Roodheid van het oog aan de kant van de hoofdpijn?  Ja/Nee 
b. Tranen van het oog aan de kant van de hoofdpijn?   Ja/Nee 
c. Een dichtzittende neus aan de kant van de hoofdpijn?  Ja/Nee 
d. Een loopneus aan de kant van de hoofdpijn?   Ja/Nee 
e. Een hangend ooglid aan de kant van de hoofdpijn?  Ja/Nee 
f. Een nauwere pupil aan de kant van de hoofdpijn?  Ja/Nee 
g. Misselijkheid en/of braken?      Ja/Nee 
h. Last van fel licht?      Ja/Nee 
i. Last van hard geluid?      Ja/Nee 
j. Bewegingsdrang (waaronder ook niet stil kunnen liggen)? Ja/Nee 
 
26. Op welke leeftijd had u voor de eerste keer een clusterhoofdpijnaanval? ………….  
 
27. Hoe ernstig is de pijn gemiddeld als u geen medicatie gebruikt? (kruis één van de 
onderstaande opties aan) 
o Matig, er wordt geen of enige hinder ondervonden van de hoofdpijn 
o Hevig, de dagelijkse activiteiten kunnen met moeite gedaan worden 
o Ondraaglijk, onmogelijk om met de dagelijkse activiteiten door te gaan 
 
28. Heeft u de hoofdpijn steeds op vaste tijdstippen op de dag? Ja/Nee  
 
29. Zoekt u tijdens een aanval wel eens de koude op?  
Ja/Nee (indien nee ga verder naar vraag 32) 
 
30. Op welke manier zoekt u de koude op? ……………………………………………………. 
 
31.  Hoeveel heeft de koude de pijn doen verbeteren?  
Helemaal/veel/weinig/niets  
 
32. Heeft u ook ’s nachts hoofdpijn? 




33. Als u ’s nachts hoofdpijn heeft wat doet u dan? …………………………………………… 
 
34. Heeft u ooit onderstaande medicijnen voor de hoofdpijn gebruikt? 
 
a. Triptanen zoals sumatriptan (imigran)? Ja/Nee 
 Was dit een injectie, neusspray, zetpil of tablet van 50 mg of 100 mg? ………………. 
Hoeveel heeft dit medicijn de pijn doen verbeteren? Helemaal/veel/weinig/niets 
 
b. Verapamil (isoptin)? Ja/Nee 
 Hoeveel heeft dit medicijn de pijn doen verbeteren? Helemaal/veel/weinig/niets 
 
c. Lithium? Ja/Nee 
Hoeveel heeft dit medicijn de pijn doen verbeteren? Helemaal/veel/weinig/niets 
 
d. Methysergide (deseril)? Ja/Nee 
Hoeveel heeft dit medicijn de pijn doen verbeteren? Helemaal/veel/weinig/niets 
 
e. Pizotifeen (sandomigran)? Ja/Nee 
Hoeveel heeft dit medicijn de pijn doen verbeteren? Helemaal/veel/weinig/niets 
 
f. Andere medicijnen zoals paracetamol, ibuprofen etc? Ja/Nee 
 Zo ja, welke? ………………………………………………………………………….. 
Hoeveel heeft dit medicijn de pijn doen verbeteren? Helemaal/veel/weinig/niets 
 
g. Heeft u ooit eerder zuurstoftherapie gebruikt? Ja/Nee 
 
h. Welke medicatie gebruikt u nu nog voor de hoofdpijn? 
……………………………………….……….. 
 
De clusterhoofdpijnaanval  
Clusterhoofdpijn komt voor in aanvallen. Een aanval wil zeggen dat de hoofdpijn vrij snel 
komt opzetten, toeneemt tot een hoogtepunt, enkele minuten, uren of dagen achtereen 
aanhoudt, en vervolgens weer duidelijk afneemt. De aanvallen zijn dus vrij scherp begrensd. 
Tussen de aanvallen in is er geen hoofdpijn (zie plaatje 1), of is de hoofdpijn duidelijk 










35. Bent u pijnvrij in de periode tussen de aanvallen (plaatje 1) of heeft u tussen de 
hoofdpijnaanvallen minder hoofdpijn (plaatje 2)?  
o Pijnvrij (plaatje 1) 
o Minder hoofdpijn (plaatje 2) 
 
36. Hoe lang duurt een aanval (plaatje 1-2) gemiddeld? (graag één antwoord geven) 
o Korter dan 15 minuten, namelijk…………………minuten 
o 15 minuten tot 3 uur, namelijk………………….minuten 
o Langer dan 3 uur, namelijk ………………....uur 
o Weet niet 
 
37. Hoe lang duurt een aanval minimaal?  
o Korter dan 15 minuten, namelijk…………………minuten 
o 15 minuten tot 3 uur, namelijk …………………minuten 
o Langer dan 3 uur, namelijk …………………uur 
o Weet niet 
 
38. Hoe lang duurt een aanval maximaal?  
o korter dan 15 minuten, namelijk…………………minuten 
o 15 minuten tot 3 uur, namelijk ………………...minuten 
o langer dan 3 uur, namelijk………………….uur 
o weet niet 
 
De clusterperiode  
Aanvallen van hoofdpijn kunnen in clusterperiodes voorkomen. Een clusterperiode is een 
periode van enige weken tot enkele maanden, waarin de aanvallen van hoofdpijn zeer 
frequent voorkomen (soms meerdere malen per dag). Tussen de clusterperiodes zit een 
aanvalsvrije periode van weken, maanden of zelfs jaren (zie plaatje 3: een verticale streep is 
een clusterhoofdpijnaanval, de groepen aanvallen is een clusterperiode). Als dit het geval is, 




Echter, in een klein percentage van de gevallen is er sprake van chronische clusterhoofdpijn. 
Hierbij treden de aanvallen vrijwel dagelijks of wekelijks op, zonder duidelijke, lange 









De piekfase van een clusterperiode  
De frequentie van aanvallen tijdens een clusterperiode kan verschillen (zie plaatje 5). In de 
aanloopfase zijn er meestal relatief weinig aanvallen. Vaak wordt de aanloopfase gevolgd 
door een periode met zeer frequente aanvallen (de piekfase). Deze aanvallen duren vaak 
langer dan de aanvallen in de aanloopfase. Aan het eind van een clusterperiode nemen de 




39. Is dit de 1e keer dat u clusterhoofdpijn heeft? 
o Ja  
Hoe lang duurt de periode van clusterhoofdpijn tot nu toe? …………………. 
Ga verder met de vragen 48 t/m 50     
o Nee 
 
40. Komen de aanvallen van hoofdpijn bij u voor in clusterperiodes met daartussen periodes 
van weken, maanden of jaren waarin u aanvalsvrij bent (zie plaatje 3)? 
o Ja Ga verder met de vragen 41 t/m 50     
o Nee (dit betekent dat u geen aanvalsvrije periodes hebt, zie plaatje 4). Ga verder met 
de vragen 51 t/m 53   
 
Vraag 41 t/m 50 zijn bedoeld voor mensen die wel aanvalsvrije periodes hebben. Als u 
geen clusterhoofdpijnvrije episodes heeft, ga dan naar vraag 51. 
 
41. Hoe lang duurt een clusterperiode (plaatje 3) gemiddeld? (graag één antwoord geven)  
o  ………. weken 
o  ………. maanden 
o  ………. jaren 
 
42. Hoe lang duurt een clusterperiode minimaal?  
o ……….  weken  
o ……….  maanden 








43. Hoe lang duurt een clusterperiode maximaal?  
o  ………. weken  
o  ………. maanden 
o  ………. jaren 
 
44. Hoe vaak heeft u een clusterperiode?  
o ……….  keer per jaar 
o Eens in de ………. jaar  
 
45. Hoelang duurt een aanvalsvrije periode (plaatje 3, dus de periode tussen twee clusters in) 
gemiddeld? (graag één antwoord geven) 
o  ………. weken 
o  ………. maanden 
o  ………. jaren 
 
46. Hoe lang duurt een aanvalsvrije periode minimaal?  
o  ………. weken 
o  ………. maanden 
o  ………. jaren 
 
47. Hoe lang duurt een aanvalsvrije periode maximaal?  
o ……….  weken 
o  ………. maanden 
o  ………. jaren 
  
48. Hoe vaak heeft u gemiddeld last van aanvallen van clusterhoofdpijn in de piekfase (zie 
plaatje 5)? (graag één antwoord geven) 
o ………. keer per dag  
o ………. keer per week 
 
49. Hoe vaak heeft u minimaal last van aanvallen van clusterhoofdpijn in de piekfase?  
o ………. keer per dag  
o ………. keer per week 
 
50. Hoe vaak heeft u maximaal last van aanvallen van clusterhoofdpijn in de piekfase? 
o  ………. keer per dag  
o  ………. keer per week 
Ga verder met de vragen 54 t/m 55  
 
Vraag 51 t/m 53 zijn bedoeld voor mensen die geen aanvalsvrije periodes hebben.  
 
51. Hoe vaak hebt u gemiddeld aanvallen? (graag één antwoord geven) 
o  ………. keer per dag 
o  ………. keer per week 
o  ………. keer per maand 
o  ………. keer per jaar 
 
52. Hoe vaak hebt u minimaal aanvallen? (graag één antwoord geven) 
o  ………. keer per dag 
o ……….  keer per week 
o  ………. keer per maand 




53. Hoe vaak hebt u maximaal aanvallen? (graag één antwoord geven) 
o  ………. keer per dag 
o  ………. keer per week 
o  ………. keer per maand 
o  ………. keer per jaar 
 
Deel 3: Beperkingen in het dagelijks leven 
 
54. In hoeverre hebben uw lichamelijke gezondheid of emotionele problemen u gehinderd in 
uw normale omgang met familie, vrienden, buren of bij activiteiten in groepsverband? 
 
Helemaal niet/ enigszins/ nogal/ vrij veel/ ernstig  
 
55. In welke mate bent u door clusterhoofdpijn gehinderd in uw normale werk (zowel werk 
buitenshuis als huishoudelijk werk)? 
 








Vragenlijst 2: Zuurstoftherapie bij Clusterhoofdpijn 
Atrium Medisch Centrum Heerlen, Afdeling Neurologie 
 










Net als in de vorige vragenlijst zijn er 3 soorten vragen. Bij de meerkeuze vragen kunt u één 
rondje (0) aankruisen met het juiste antwoord, zo nodig kunt u op de stippellijn uw antwoord 
nog aanvullen. Bij de vragen waar ‘Ja/Nee’ of ‘helemaal/veel/weinig/niets’ achter staat kunt u 
omcirkelen wat voor u van toepassing is. Bij de open vragen wordt u verzocht in uw eigen 




1. Hoe lang gebruikt u nu de zuurstoftherapie? ………………………………………………. 
 
2. Hoeveel dagen per week heeft u de zuurstof gemiddeld gebruikt? 
…………………………………………. 
 
3. Hoeveel keer per dag heeft u de zuurstof gemiddeld gebruikt? 
………………………………………….. 
 
4. Hoeveel liter zuurstof per minuut gebruikt u (ofwel op welke stand zet u de zuurstof)? 
………………… liter/minuut 
 
5. Hoeveel minuten na het begin van de hoofdpijnaanval begint u met zuurstof? …… minuten 
 
6. Gebruikte u tijdens de zuurstof ook andere medicatie tegen de hoofdpijn?  
 








C. Gebruikte u andere medicatie voor de hoofdpijn (bv. paracetamol, ibuprofen etc)? 
o Ja, namelijk (geneesmiddel + dosering): …………………………………………….. 
o Nee 
 
7. Hoeveel verlichting van de pijn kreeg u door de zuurstof (als u geen andere medicatie tegen 









8. Als u de hoofdpijn een cijfer zou moeten geven van 0 tot 10, waarbij 0 helemaal geen pijn 
is en 10 de ergste pijn is die u zich kan voorstellen, welk cijfer zou u de hoofdpijn vóór 
gebruik van de zuurstoftherapie geven en na gebruik van de zuurstof? Omcirkel het juiste 
cijfer. 
 
Cijfer vóór gebruik van de zuurstofbehandeling 1     2     3     4     5     6     7     8     9     10 
 
Cijfer na gebruik van de zuurstofbehandeling 1     2     3     4     5     6     7     8     9     10 
 
9. Hoelang gebruikte u gemiddeld de zuurstof tijdens een hoofdpijnaanval? ………..  minuten 
 
10. Na hoeveel tijd aan de zuurstof voelde u gemiddeld verlichting?  
o …….. minuten 
o …….. uur 
 
11. Na hoeveel tijd aan de zuurstof was de hoofdpijn over? 
o …….. minuten 
o …….. uur 
 
12. Werkte de zuurstoftherapie bij alle hoofdpijnaanvallen? 
o (Vrijwel) alle aanvallen 
o Bij meer dan de helft van de aanvallen 
o Bij minder dan de helft van de aanvallen 
o Bij (bijna) geen aanval 
 
13. Is de frequentie van hoofdpijnaanvallen (dus het aantal hoofdpijnaanvallen per dag of per 
week) verminderd of juist toegenomen met het gebruik van de zuurstoftherapie? 
o De frequentie is afgenomen 
o De frequentie is toegenomen 
o Er is geen verschil in frequentie van aanvallen 
 
14. Als u zou moeten kiezen: over het algemeen een goede of slechte reactie op zuurstof?  
 Goed/Slecht 
 
15. Indien u geen gebruikt maakt van de zuurstof, waarom niet?  
………………………………………………………………………………………………. 
 
16. Heeft u nog opmerkingen over de zuurstoftherapie? 
………………………………………………………………………………………………. 
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